{"title":"BEST SALE","description":"","products":[{"product_id":"tb-500-10mg","title":"( 💪 Speed up recovery) TB-500 (Thymosin Beta-4) Peptide (10mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003ch3\u003e🔧 Speed up recovery\u003cbr\u003e💪 Muscle repair\u003cbr\u003e🦴 Ligament\/tendon recovery\u003cbr\u003e🏃 Recovery from sports injuries\u003cbr\u003e🔥 Anti-inflammatory effects\u003cbr\u003e❤️ Tissue repair\u003c\/h3\u003e\n\u003ch3\u003eTB-500 (Thymosin Beta-4) Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eTB-500, or synthetic Thymosin Beta-4, also known as synthetic \u003cem\u003eTβ4\u003c\/em\u003e, is a synthetic analog of the endogenous Thymosin Beta-4 protein, which is considered to be ubiquitously present in cells. The peptide belongs to a widespread family of 16 related molecules observed to exhibit a high degree of sequence conservation and localization in most tissues and circulating cells. TB-500 was developed to sequester and block actin polymerization in eukaryotic cells.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e Thymosin Beta-4\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e212\u003c\/sub\u003eH\u003csub\u003e350\u003c\/sub\u003eN\u003csub\u003e56\u003c\/sub\u003eO\u003csub\u003e78\u003c\/sub\u003eS\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 4963 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-lle-GluLys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-LysThr-Glu-Thr-Gin-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-GluThy-lleGlu-Gin-Glu-Lys-Gin-Ala-Gly-Glu-Ser\u003c\/p\u003e\n\u003ch3\u003eTB-500 (Thymosin Beta-4) Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eTB-500 and Intracellular Mechanism of Action\u003c\/strong\u003e\u003cbr\u003eTB-500 is thought to contain a specific peptide sequence, LKKTETQ, located between the 16th and 24th amino acids. This sequence is hypothesized to play a role in mediating binding to actin. Actins are proteins that are considered integral to the cytoskeleton of cells. They appear to maintain the cell's structure and are believed to be critically involved in primary cellular functions such as motility.\u003cbr\u003e\u003cbr\u003eTB-500 interaction with actin might occur through the binding to globular actin (G-actin), the monomeric form of actin, before it polymerizes into filamentous actin (F-actin). The speculated interaction between thymosin beta-4 and G-actin is believed to inhibit the polymerization process, known as actin sequestration. This inhibition is likely to result in an increased availability of G-actin.\u003cbr\u003e\u003cbr\u003eThe potential suppression of F-actin polymerization by thymosin beta-4 might theoretically alter the structure of the cellular cytoskeleton. Such changes may affect the cell's capabilities in terms of movement and undergoing morphological transformations.\u003csup\u003e[1]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eTB-500 and Extracellular Mechanism of Action\u003c\/strong\u003e\u003cbr\u003eInitial research indicates that TB-500, beyond its intracellular potential with actin, may also have actions outside the cell that affect various cellular functions. These potential functions may also include cell motility and angiogenesis, the process through which new blood vessels form.\u003csup\u003e[2,3]\u003c\/sup\u003e\u003cbr\u003e\u003cbr\u003eIt is hypothesized that Thymosin beta-4, the naturally occurring version of TB-500, may facilitate these actions through its influence on ATP synthase enzymes. These enzymes, found on the surfaces of cells, appear to play an essential role in generating the energy required by cells to perform various functions. This hypothesis suggests a potential dual role for Thymosin beta-4 in both cellular structure maintenance and energy production.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eTB-500 and Vascular Tissues\u003c\/strong\u003e\u003cbr\u003eTB-500, or Thymosin Beta-4 expression appears to increase four-six fold during early angiogenesis. Research suggests it may promote the growth of new blood cells from existing vessels, potentially mediating faster tissue repair.\u003csup\u003e[4]\u003c\/sup\u003e Researchers point out, \"\u003cem\u003eDelineating the molecular pathways impacted by Tβ4 to promote vascular growth and remodeling may reveal novel targets for prevention … of vascular disease.”\u003c\/em\u003e The actin-binding domain is a short central sequence of amino acids. It appears to be involved in TB-500-mediated regulation of blood cell division, tissue repair processes, migration of endothelial cells and keratinocytes, and possibly higher production of extracellular matrix-degrading enzymes.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eTB-500 and Inflammation\u003c\/strong\u003e\u003cbr\u003eTB-500 research suggests the peptide’s potential anti-inflammatory characteristics.\u003csup\u003e[5]\u003c\/sup\u003e The research suggests, \u003cem\u003e“It acts by increasing angiogenesis and cell migration and is currently [studied in] wound repair.”\u003c\/em\u003e TB-500, unlike other naturally produced growth factors, may possibly support endothelial and keratinocyte migration. It also does not appear to bind to the extracellular matrix, and researchers suggest that its low molecular weight may help it travel comparatively long distances through tissues. Study findings typically hypothesize the action of the peptide may be to regulate the polymerization and function of actin.\u003cbr\u003e\u003cbr\u003eFurther research suggests that TB-500 may conceivably enhance the expression of microRNA-146a (miR-146a), which may act as an inhibitory regulator of certain cellular communication networks. These networks appear to be particularly involved with inflammation-related cytokines, such as interleukin-1 receptor-associated kinase 1 (IRAK1) and tumor necrosis factor receptor-associated factor 6 (TRAF6). Investigators in a recent study hypothesized this mechanism as a potential mode of action for TB-500, noting that inhibiting miR-146a appeared to have reversed the suppression of IRAK1 and TRAF6 by Tβ4, indicative of a likely anti-inflammatory mechanism.\u003csup\u003e[6]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eTB-500 and Tissue Wound Models\u003c\/strong\u003e\u003cbr\u003eIt has been suggested that TB-500 may influence cytokine production, potentially speeding up recovery in wound models.\u003csup\u003e[7]\u003c\/sup\u003e After an injury, preliminary data suggests that TB-500 might enhance the expression of interleukin-1β (IL-1β) and interleukin-6 (IL-6) mRNA in the corneal tissues of mice. Post-alkali injury, TB-500 exposure is believed to possibly reduce the levels of chemoattractants like macrophage inflammatory protein-2 (MIP-2) and keratinocyte chemoattractant (KC), which may lead to a reduction in polymorphonuclear neutrophils (PMNs) infiltration. It is also postulated that TB-500 may affect the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) signaling pathways in the cornea, potentially manifesting anti-inflammatory actions.\u003cbr\u003e\u003cbr\u003eAdditionally, TB-500 is thought to exhibit anti-apoptotic characteristics, observed in cellular models where overexpression of TB-500 appears to increase growth rates, reduce basal apoptosis, and enhance resistance to cell death inducers. TB-500 may inhibit apoptosis in corneal epithelial cells by obstructing caspases and limiting the release of the pro-apoptotic protein bcl-2 from mitochondria. The proposed anti-apoptotic mechanism might involve mitigating early cell death signals and activating the survival kinase Akt through interactions with particularly interesting new cysteine-histidine-rich protein (PINCH) and integrin-linked kinase. Consequently, all these potential mechanisms may contribute to TB-500 speeding up recovery in different tissue wound models.\u003c\/p\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eTB-500 and Cell Repair\u003c\/strong\u003e\u003cbr\u003eInitial studies tentatively suggest that TB-500 might enhance the restoration of heart cells in experimental models. It appears that cardiac fibroblasts, connective tissue cells in the heart, may transform into cells similar to cardiomyocytes—these are the muscle cells considered responsible for heart contractions.\u003csup\u003e[8]\u003c\/sup\u003e Additionally, laboratory research has hypothesized that TB-500, combined with cardiac reprogramming techniques, may cooperatively reduce heart cell damage and promote recovery. Researchers suggest this action may be done by stimulating endogenous cells within the heart region.\u003cbr\u003e\u003cbr\u003eFurther explorative studies in murine models involving ligation (the surgical blockage of coronary arteries) have hinted that TB-500 might elevate the levels of integrin-linked kinase (ILK) and protein kinase B (Akt). Both ILK and Akt are considered critical enzymes in cellular signaling pathways that may play crucial roles in the early survival and repair of cardiomyocytes, thus potentially enhancing the regeneration process of cardiac tissue.\u003csup\u003e[9]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e\u003cem\u003eDisclaimer: T Research chemicals are intended solely for laboratory experimentation and\/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and\/or qualified professionals. All information shared in this article is for educational purposes only.\u003c\/em\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eGurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008 May 15;453(7193):314-21. . PMID: 18480812.\u003c\/li\u003e\n\u003cli\u003eHuff, T., Müller, C. S., Otto, A. M., Netzker, R., \u0026amp; Hannappel, E. (2001). beta-Thymosins, small acidic peptides with multiple functions. \u003cem\u003eThe international journal of biochemistry \u0026amp; cell biology\u003c\/em\u003e, \u003cem\u003e33\u003c\/em\u003e(3), 205–220.\u003c\/li\u003e\n\u003cli\u003eFreeman, K. W., Bowman, B. R., \u0026amp; Zetter, B. R. (2011). Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling. \u003cem\u003eFASEB journal : official publication of the Federation of American Societies for Experimental Biology\u003c\/em\u003e, \u003cem\u003e25\u003c\/em\u003e(3), 907–915.\u003c\/li\u003e\n\u003cli\u003eDubé, K. N., \u0026amp; Smart, N. (2018). Thymosin β4 and the vasculature: multiple roles in development, repair and protection against disease. Expert opinion on biological therapy, 18(sup1), 131–139.\u003c\/li\u003e\n\u003cli\u003ePhilp, D., Goldstein, A. L., \u0026amp; Kleinman, H. K. (2004). Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mechanisms of ageing and development, 125(2), 113–115.\u003c\/li\u003e\n\u003cli\u003eSantra, M., Zhang, Z. G., Yang, J., Santra, S., Santra, S., Chopp, M., \u0026amp; Morris, D. C. (2014). Thymosin β4 up-regulation of microRNA-146a promotes oligodendrocyte differentiation and suppression of the Toll-like proinflammatory pathway. \u003cem\u003eThe Journal of biological chemistry\u003c\/em\u003e, \u003cem\u003e289\u003c\/em\u003e(28), 19508–19518.\u003c\/li\u003e\n\u003cli\u003eSosne, G., Qiu, P., \u0026amp; Kurpakus-Wheater, M. (2007). Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent. \u003cem\u003eClinical ophthalmology (Auckland, N.Z.)\u003c\/em\u003e, \u003cem\u003e1\u003c\/em\u003e(3), 201–207.\u003c\/li\u003e\n\u003cli\u003eSrivastava, D., Ieda, M., Fu, J., \u0026amp; Qian, L. (2012). Cardiac repair with thymosin β4 and cardiac reprogramming factors. \u003cem\u003eAnnals of the New York Academy of Sciences\u003c\/em\u003e, \u003cem\u003e1270\u003c\/em\u003e, 66–72.\u003c\/li\u003e\n\u003cli\u003eBock-Marquette, I., Saxena, A., White, M. D., Dimaio, J. M., \u0026amp; Srivastava, D. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. \u003cem\u003eNature\u003c\/em\u003e, \u003cem\u003e432\u003c\/em\u003e(7016), 466–472.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003cdiv\u003eAll orders ship same day if placed by 12 PST.\u003c\/div\u003e\n\u003cdiv class=\"vbni\"\u003e\u003cem\u003eOnly qualified and licensed professionals should handle these products. Any information found on Biotech Peptides is strictly for educational purposes only. Refer to our for more details.\u003c\/em\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786428154173,"sku":"sku2194756147549","price":280.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/TB-500-10MG-2-1.webp?v=1780466134"},{"product_id":"epithalon-25mg","title":"( 🌴Anti-aging ) Epithalon peptide (25mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is Epithalon?\u003c\/p\u003e\n\u003cp\u003eEpithalon is a tetrapeptide that was first associated with anti-aging research in Russia.\u003c\/p\u003e\n\u003cp\u003eKey areas of research include:\u003c\/p\u003e\n\u003cp\u003eTelomere length\u003cbr\u003ePineal gland function (melatonin-related)\u003cbr\u003eCircadian rhythm\u003cbr\u003eAntioxidation and cellular aging\u003cbr\u003e⏳ Core concept: Telomeres\u003c\/p\u003e\n\u003cp\u003eThe most well-known theory regarding Epithalon is:\u003c\/p\u003e\n\u003cp\u003e➡️ It may influence telomerase activity\u003c\/p\u003e\n\u003cp\u003eTelomeres can be understood as:\u003cbr\u003e🧬 “Protective caps” on chromosomes that shorten with age\u003c\/p\u003e\n\u003cp\u003eThe theoretical logic is:\u003cbr\u003e👉 Shorter telomeres → Older cells\u003cbr\u003e👉 Stable telomeres → Aging may slow down\u003c\/p\u003e\n\u003cp\u003e⚠️ But note:\u003cbr\u003eThis is a “research hypothesis,” not a definitive medical conclusion.\u003c\/p\u003e\n\u003cp\u003e😴 Potential Effects (Research \u0026amp; Rumors)\u003cbr\u003e🌙 1️⃣ Sleep and Melatonin\u003c\/p\u003e\n\u003cp\u003eEpithalon is believed to potentially:\u003c\/p\u003e\n\u003cp\u003eRegulate pineal gland function\u003cbr\u003eIncrease melatonin secretion\u003cbr\u003eImprove sleep rhythms\u003cbr\u003e🧠 2️⃣ Anti-aging effects\u003c\/p\u003e\n\u003cp\u003ePotential effects mentioned in studies:\u003c\/p\u003e\n\u003cp\u003eImprovement in biological age indicators\u003cbr\u003eAntioxidant effects\u003cbr\u003eStabilization of cellular function\u003cbr\u003e❤️ 3️⃣ Endocrine and immune regulation\u003c\/p\u003e\n\u003cp\u003ePossible effects on:\u003c\/p\u003e\n\u003cp\u003eHormone rhythms\u003cbr\u003eImmune system aging\u003cbr\u003eStress responses\u003c\/p\u003e\n\u003ch3\u003eEpithalon Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eEpithalon, or Epitalon, is a small synthetic peptide that appears to activate the telomerase enzyme and may promote the release of melatonin. Experimental research has suggested its potential to slow alterations in reproductive and immune systems and improve life spans in mice and rats.\u003csup\u003e[1]\u003c\/sup\u003e Apart from its potential in regulating cell aging, the peptide has also played an important role in research conducted on certain classes of cancer, infectious diseases, and DNA regulation.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e14\u003c\/sub\u003eH\u003csub\u003e22\u003c\/sub\u003eN\u003csub\u003e4\u003c\/sub\u003eO\u003csub\u003e9\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 390.34 g\/mol\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Ala-Glu-Asp-Gly\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e Epitalon, Epithalone, Epithalamin\u003c\/p\u003e\n\u003ch3\u003eEpithalon Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eEpithalon and Cell Aging\u003c\/strong\u003e\u003cbr\u003eEarly research on insect and murine models hypothesized that Epithalon may improve cell span to a significant extent.\u003csup\u003e[2] \u003c\/sup\u003eMore specifically, \u003cem\u003eepithalamin\u003c\/em\u003e, a related pineal peptide preparation containing Epithalon, has been suggested to potentially increase the mean lifespan of insect and murine models by 11–31%. Furthermore, the experiment in rats suggested a 52% decrease in mortality upon Epithalon exposure. It appears to have been impactful in mice models of cardiac disease, where the life expectancy was reported to be increased by 27% compared to control animals. The peptide has been observed to mediate action by eliminating free radicals (charged molecules that damage tissue). More specifically, this potential antioxidative action of the peptide may inhibit free radical processes in both murine and insect models, and it is suggested that these antioxidative properties may potentially lead to increased lifespan in other test models. Apart from studies focused on its antioxidant activity, Epithalon has also been studied for its potential to activate an enzyme called telomerase in cell culture assays. Telomerase is considered to preserve the ends of chromosomes, known as telomeres, which are deemed crucial for maintaining the integrity of DNA. Epithalon may potentially preserve the DNA from damage by activating the telomerase and decreasing the number of errors in the DNA strands. This dual potential of enhancing antioxidant defense and possibly boosting telomere integrity might explain some of the lifespan-extending actions hypothesized in epithalamin and Epithalon models.\u003cbr\u003e\u003cbr\u003eAnother study posited that Epithalon might reduce intracellular reactive oxygen species (ROS) in aged oocyte cells, suggesting antioxidative characteristics.\u003csup\u003e[3]\u003c\/sup\u003e Specifically, Epithalon appeared to decrease ROS accumulation significantly compared to higher concentrations, which did not yield the same protective action. This reduction in ROS might be crucial, as oxidative stress is considered a key factor in cellular aging. Epithalon also potentially preserves oocyte structural integrity. It was observed to decrease fragmentation rates in post-ovulatory aged oocytes and during parthenogenetic activation. Fragmentation, indicative of compromised cytoplasmic integrity, was notably reduced in the 0.1mM Epithalon group, implying a protective action on cellular morphology. Additionally, Epithalon appeared to maintain spindle integrity and proper cortical granule (CG) distribution. Spindle abnormalities, common in aged oocytes, appeared to have been mitigated by Epithalon, as was the mislocalization of CGs, which are essential for fertilization. These findings suggest that epithalons may help preserve the cytoskeletal and cortical structure of oocytes during aging. Mitochondrial function, a critical aspect of oocyte viability, appeared to be also positively affected by Epithalon. The study reported higher mitochondrial membrane potential and increased mtDNA copy numbers in Epithalon-exposed oocytes. Given that mitochondria are pivotal in ATP production and cellular energy metabolism, these findings propose that Epithalon may support mitochondrial integrity and functionality during oocyte aging. Furthermore, Epithalon experimentation seemed to reduce DNA damage and apoptosis in aged oocytes. The peptide decreased the fluorescence intensity of γH2AX signals, a marker of DNA damage, and appeared to have lowered apoptosis rates as indicated by Annexin-V staining. This implies that Epithalon might enhance oocyte survival by mitigating oxidative damage and preserving genomic stability.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eEpithalon and DNA Activation and Gene Expression\u003c\/strong\u003e\u003cbr\u003eEpithalon is being actively researched to explore the mechanisms by which this peptide may mediate longevity. One such potential pathway may be the regulation of certain gene expressions.\u003csup\u003e[4]\u003c\/sup\u003e Studies evaluating the effect of peptide exposure in cell cultures have noted that Epithalon appears to directly interact with promoter regions of certain genes such as Tram1, IL-2, CD5, and MMP2 and may also enhance their expression. CD5 and IL-2 are both involved in the functions of the immune system, while MMP2 is considered to play a role in the maintenance of extracellular matrix in tendons, skin, and other connective tissue. Epithalon appears to trigger interferon-gamma synthesis from aging lymphocytes in rats. Interferon-gamma is a relevant signaling molecule of the immune system and supports combating viral infections through T lymphocyte, macrophage, and natural killer cell activation.\u003cbr\u003e\u003cbr\u003eAnother study investigated the potential mechanisms of the Epithalon in influencing gene expression and protein synthesis in stem cells such as gingival mesenchymal stem cells (hGMSCs).\u003csup\u003e[5]\u003c\/sup\u003e The Epithalon peptide was suggested to induce neuronal cell differentiation in retinal and periodontal ligament stem cells (hPDLSCs). Epithalon peptide experimentation appeared to have led to an upregulation of neurogenic differentiation markers, including Nestin, GAP43, β Tubulin III, and Doublecortin, in hGMSCs. Specifically, mRNA expression of these markers increased by 1.6 to 1.8 times. This suggests a potential epigenetic mechanism where Epithalon peptide may regulate gene expression and protein synthesis related to neuronal differentiation. The study posits that the Epithalon peptide may interact specifically with histones, altering chromatin structure and thereby modulating gene expression. The Epithalon peptide's epigenetic regulation mechanism might involve competitive binding with histones at DNA interaction sites, increasing the likelihood of transcription for genes involved in neuronal differentiation. Molecular modeling indicated that Epithalon peptide may bind preferentially with histones H1\/6 and H1\/3 at specific sites, which may interact with DNA. This binding might facilitate increased transcription of neurogenic differentiation genes. The peptide-histone interaction might disrupt histone-DNA binding, potentially enhancing gene accessibility for transcription.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eEpithalon and Extracellular Matrix (Skin ECM)\u003c\/strong\u003e\u003cbr\u003eExperimental research suggests Epithalon’s potential to induce MMP2 expression. MMP2 is a protein found in connective tissue like skin. It may act as an enzyme with a potential role in the breakdown of extracellular matrix components, vital for tissue remodeling and repair. In the context of Epithalon, the induction of MMP2 expression might imply enhanced tissue regeneration and repair processes. Research in rodents indicates that apart from the activation of MMP2, the peptide might also activate fibroblasts, which produce and maintain MMP2 and other components of the extracellular matrix, such as collagen and elastin. Mice exposed to Epithalon exhibited 30-45% higher activation of fibroblasts than controls.\u003csup\u003e[6]\u003c\/sup\u003e This increase in fibroblast activity suggests a possible route through which Epithalon may exert its actions on tissue repair and regeneration. Epithalon also appears to inhibit the activity of Caspase-3, a key enzyme that is considered to promote apoptosis (programmed cell death).\u003csup\u003e[7]\u003c\/sup\u003e By inhibiting Caspase-3, Epithalon might contribute to cellular longevity and reduced apoptosis, which may complement its regenerative potential, yet this hypothesis demands more comprehensive research for validation.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eEpithalon and Tumor Growth\u003c\/strong\u003e\u003cbr\u003eDaily exposure to the peptide in rat models of cancerous tumors reported a reduction in tumor growth, with the burden diminishing the metastasis of the cells to distant tissues. Epithalon is currently under research for its interaction in Her-2\/neu positive breast cancer, testicular cancer, and certain types of leukemia. Scientific research associates the peptide with activating the PER1 protein produced in the hypothalamus.\u003csup\u003e[8]\u003c\/sup\u003e The gene is involved in regulating the circadian rhythm and is considered under-expressed in cancer instances. PER1 has been suggested to influence cancer progression once cancer has been established. It follows that control of PER1 expression may potentially be employed to reduce tumor growth. PER1 expression in cells appears to sensitize cancer cells to radiation. This is considered to exhibit a two-fold action. It may not only decrease tumor size and burden and decrease radiation, but it may also minimize the chances of secondary tumors from extensive radiation. Research is ongoing to further elucidate this hypothesis.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eEpithalon and Melatonin Secretion\u003c\/strong\u003e\u003cbr\u003eMelatonin is a hormone produced by the pineal gland that regulates sleep cycles. Studies on rats have suggested that Epithalon and similar peptides may potentially regulate the synthesis and secretion of melatonin by influencing the expression of two proteins: arylalkylamine-N-acetyltransferase (AANAT) and pCREB transcription protein.\u003csup\u003e[9]\u003c\/sup\u003e These genes are believed to be involved in melatonin production and the circadian (day\/night) control of hormone release. Research in monkeys observed that Epithalon may potentially restore normal physiological levels of melatonin.\u003c\/p\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eEpithalon and Vision\u003c\/strong\u003e\u003cbr\u003eEpithalon has been studied in rat models of retinitis pigmentosa.\u003csup\u003e[10]\u003c\/sup\u003e These studies reported that the peptide appeared to improve the outcome in 90% of the cohort. Generally, research in Epithalon has suggested its potential to preserve the overall structure of the eye and boost the retina's bioelectric function, which is deemed important for fully functional vision.\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eKhavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12374906.\u003c\/li\u003e\n\u003cli\u003eAnisimov VN, Mylnikov SV, Khavinson VK. Pineal peptide preparation epithalamin increases the lifespan of fruit flies, mice and rats. Mech Ageing Dev. 1998 Jun 15;103(2):123-32. . PMID: 9701766.\u003c\/li\u003e\n\u003cli\u003eYue X, Liu SL, Guo JN, Meng TG, Zhang XR, Li HX, Song CY, Wang ZB, Schatten H, Sun QY, Guo XP. Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro. Aging (Albany NY). 2022 Apr 12;14(7):3191-3202. . Epub 2022 Apr 12. PMID: 35413689; PMCID: PMC9037278.\u003c\/li\u003e\n\u003cli\u003eKhavinson, V. K.h, Tarnovskaya, S. I., Linkova, N. S., Pronyaeva, V. E., Shataeva, L. K., \u0026amp; Yakutseni, P. P. (2013). Short cell-penetrating peptides: a model of interactions with gene promoter sites. \u003cem\u003eBulletin of experimental biology and medicine\u003c\/em\u003e, \u003cem\u003e154\u003c\/em\u003e(3), 403–410.\u003c\/li\u003e\n\u003cli\u003eKhavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 2020 Jan 30;25(3):609. . PMID: 32019204; PMCID: PMC7037223.\u003c\/li\u003e\n\u003cli\u003eChalisova, N. I., Lin'kova, N. S., Zhekalov, A. N., Orlova, A. O., Ryzhak, G. A., \u0026amp; Khavinson, V. K.h (2014). \u003cem\u003eAdvances in gerontology = Uspekhi gerontologii\u003c\/em\u003e, \u003cem\u003e27\u003c\/em\u003e(4), 699–703.\u003c\/li\u003e\n\u003cli\u003eLin'kova, N. S., Drobintseva, A. O., Orlova, O. A., Kuznetsova, E. P., Polyakova, V. O., Kvetnoy, I. M., \u0026amp; Khavinson, V. K.h (2016). Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. \u003cem\u003eBulletin of experimental biology and medicine\u003c\/em\u003e, \u003cem\u003e161\u003c\/em\u003e(1), 175–178.\u003c\/li\u003e\n\u003cli\u003eGery, S., Komatsu, N., Baldjyan, L., Yu, A., Koo, D., \u0026amp; Koeffler, H. P. (2006). The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. \u003cem\u003eMolecular cell\u003c\/em\u003e, \u003cem\u003e22\u003c\/em\u003e(3), 375–382.\u003c\/li\u003e\n\u003cli\u003eKorkushko, O. V., Lapin, B. A., Goncharova, N. D., Khavinson, V. K.h, Shatilo, V. B., Vengerin, A. A., Antoniuk-Shcheglova, I. A., \u0026amp; Magdich, L. V. (2007). \u003cem\u003eAdvances in gerontology = Uspekhi gerontologii\u003c\/em\u003e, \u003cem\u003e20\u003c\/em\u003e(1), 74–85.\u003c\/li\u003e\n\u003cli\u003eKhavinson, V., Razumovsky, M., Trofimova, S., Grigorian, R., \u0026amp; Razumovskaya, A. (2002). Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. \u003cem\u003eNeuro endocrinology letters\u003c\/em\u003e, \u003cem\u003e23\u003c\/em\u003e(4), 365–368.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786428186941,"sku":"sku2194756129039","price":170.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/Epithalon-25mg-2-1.webp?v=1780466135"},{"product_id":"oxytocin-10mg","title":"(❤️ “Love Hormone”) Oxytocin Peptide - 10mg - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003eIt is best known as:\u003cbr\u003e❤️ “Love Hormone”\u003cbr\u003eor\u003cbr\u003e🤱 “Bonding Hormone”\u003c\/p\u003e\n\u003cp\u003eBecause it is associated with:\u003c\/p\u003e\n\u003cp\u003eIntimate relationships\u003cbr\u003eSocial connections\u003cbr\u003eTrust\u003cbr\u003eChildbirth\u003cbr\u003eBreastfeeding\u003c\/p\u003e\n\u003cp\u003eIn conventional medicine, Pitocin is a synthetic form of oxytocin, commonly used for:\u003c\/p\u003e\n\u003cp\u003eInducing labor\u003cbr\u003eInducing delivery\u003cbr\u003ePostpartum hemorrhage control\u003cbr\u003e🧬 The Effects of Oxytocin\u003c\/p\u003e\n\u003cp\u003eOxytocin is not just the “love hormone.”\u003c\/p\u003e\n\u003cp\u003eIt actually influences:\u003c\/p\u003e\n\u003cp\u003eEmotions\u003cbr\u003eSocial behavior\u003cbr\u003eStress response\u003cbr\u003eThe reproductive system\u003cbr\u003eUterine contractions\u003cbr\u003eThe lactation reflex\u003cbr\u003e❤️ Why It’s Called the “Love Hormone”\u003c\/p\u003e\n\u003cp\u003eBecause research has found that:\u003c\/p\u003e\n\u003cp\u003eIn humans:\u003c\/p\u003e\n\u003cp\u003eHugging 🤗\u003cbr\u003ePhysical intimacy\u003cbr\u003eSexual activity\u003cbr\u003eMother-infant interaction\u003c\/p\u003e\n\u003cp\u003eOxytocin levels rise.\u003c\/p\u003e\n\u003cp\u003eTherefore, many people believe it is associated with:\u003c\/p\u003e\n\u003cp\u003eTrust\u003cbr\u003eEmotional connection\u003cbr\u003eSocial comfort\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eOxytocin Peptide\u003c\/h3\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back-d\"\u003eOxytocin is a small peptide comprising only nine amino acids, naturally produced in the hypothalamus and secreted by the posterior pituitary gland cells. It has also been isolated from placenta, ovaries, testes, adrenal glands, thymus, retina, and pancreas tissues. The active hormone is obtained by proteolytic cleavage of a larger precursor protein. It is no longer considered merely a neurohypophyseal hormone as its actions are considered to be far-reaching and include interaction with additional peptides. Oxytocin appears to be a protein with two independent natural functions. First, it appears to act as a neuropeptide produced by the hypothalamus to regulate bonding, reproduction, and birth. Oxytocin appears to be bloodborne and secreted by the placenta of pregnant animals to influence birth, milk production, and bonding with their young. Small amounts of the protein produced from testes may promote mating behavior and pair bonding.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e Endopituitrina, Pitocin\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e43\u003c\/sub\u003eH\u003csub\u003e66\u003c\/sub\u003eN\u003csub\u003e12\u003c\/sub\u003eO\u003csub\u003e12\u003c\/sub\u003eS\u003csub\u003e2\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 1007.19 g\/mol\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Cys-Tyr-lle-Gln-Asn-Cys-Pro-Leu-Gly\u003c\/p\u003e\n\u003ch3\u003eOxytocin Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eOxytocin and Wound Recovery\u003c\/strong\u003e\u003cbr\u003eOxytocin appears to regulate inflammation through inflammatory cytokines. Increased social interaction in one research study was observed to trigger Oxytocin (Pitocin) levels, which researchers speculated may have led to faster tissue repair and wound recovery. Similarly, studies in hostile equations between animals appear to suppress oxytocin production and delay wound recovery, potentially by up to 40%.\u003csup\u003e[1]\u003c\/sup\u003e The researchers conclude, \"\u003cem\u003eThese data confirm and extend prior evidence implicating oxytocin and vasopressin in positive and negative communication behaviors, and also provide further evidence of their role in an important [variable].”\u003c\/em\u003e These hostile couples also exhibited reduced IL-6, tumor necrosis factor-alpha, and IL-1beta at the wound site.\u003csup\u003e[2]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eOxytocin and Cardiovascular Risk\u003c\/strong\u003e\u003cbr\u003eThe hormone has been speculated to protect cardiac and vascular systems. It may act to dissipate and burn off fat cell accumulation, influence blood pressure and glucose intolerance, and potentially block or mitigate the secretion of stress hormones.\u003csup\u003e[3]\u003c\/sup\u003e These factors may influence cardiovascular disease (CVD); thus, Oxytocin (Pitocin) may be a potential compound in the study of CVD. Reduced Oxytocin receptors may cause atherosclerosis.\u003csup\u003e[4]\u003c\/sup\u003e The primary scientist in the cited study reports that \u003cem\u003e“The major pathophysiological basis of CAD is atherosclerosis in association with varieties of immunometabolic disorders that can suppress oxytocin (OT) receptor (OTR) signaling in the cardiovascular system (CVS).”\u003c\/em\u003e Oxytocin exposure appears to overcome the drawback of reduced receptor density and helps maintain cardiac integrity. Exposure of the peptide in rodent hearts during a heart attack appeared to assist in preventing the cellular death of cardiomyocytes. Jankoski et. al. suggested that chronic Oxytocin (Endopituitrina) exposure may address late-term development of dilated cardiomyopathy.\u003cbr\u003e\u003cbr\u003eIt also appears to help to prime the cardiac stem cells for “\u003cem\u003etissue regeneration through direct differentiation, secretion of protective and cardiomyogenic factors, and\/or their fusion with injured cardiomyocytes\u003c\/em\u003e.” It further appears to mitigate cases of cardiac damage due to diabetes in mice. The fat accumulation in these mice was reported to be reduced by 19%, and the fasting glucose levels by about 23%. Oxytocin (Endopituitrina) appears to increase insulin resistance in the animals, possibly establishing proper systolic and diastolic functions over control animals, leading to decreased cardiomyocyte hypertrophy, fibrosis, and apoptosis.\u003csup\u003e[5]\u003c\/sup\u003e It also appears to protect against ischemic injuries in other tissues as well, outside of the heart. Studies in rat models of priapism indicate the potential action of Oxycotin (Pitocin) against ischemia-reperfusion injury by reducing nitric oxide levels.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eOxytocin and Diabetes\u003c\/strong\u003e\u003cbr\u003eThe peptide appears to improve skeletal muscles' glucose uptake by boosting insulin sensitivity. It may further support lipid utilization, dyslipidemia, and fat mass reduction. Oxytocin deficiency has also been suggested to correlate to body mass, irrespective of external factors, suggesting its role in energy homeostasis.\u003csup\u003e[6]\u003c\/sup\u003e Oxytocin appears to affect insulin, glucose, and body composition in obese mice but not lean mice. Research observations suggest that the peptide might be impactful only in certain conditions; for instance, the backdrop of diabetes appears to trigger different actions in diabetes models compared to controls. As per Barengolts, “\u003cem\u003ecirculating oxytocin is lower in type 2 diabetes versus normoglycemic subjects and negatively correlated with glycosylated hemoglobin A1C and insulin resistance.\u003c\/em\u003e“\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eOxytocin and Cognitive Performance\u003c\/strong\u003e\u003cbr\u003eMaternal deprivation may induce irreversible cognitive and behavioral functioning changes. Studies in murine models suggest Oxytocin changes due to decreased parental bonding may be a prominent cause. Oxytocin exposure in maternally deprived mice appeared to increase hormone levels for neuronal development in the prefrontal cortex. Overall behavior appeared to remain constant, but the cognitive ability was observed to be improved in the cohort exposed to Oxytocin.\u003csup\u003e[7]\u003c\/sup\u003e The researchers therefore felt they had grounds to speculate that Oxytocin may improve learning in mice under stress.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eOxytocin Peptide Research and Anxiety\u003c\/strong\u003e\u003cbr\u003eThe hormone has been studied for its potential to minimize anxiety and depression. The genetic polymorphisms in the Oxytocin (Endopituitrina) receptor gene related to anxiety disorder and problems with attachment. Animals exhibiting chronic anxious behavior have also displayed epigenetic changes in the Oxytocin receptor.\u003csup\u003e[8]\u003c\/sup\u003e This indicates a possible compensatory pathway for pathologically suppressed Oxytocin levels. This indicates that anxiety may be partially induced by diminished Oxytocin signaling.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eOxytocin and Hunger\u003c\/strong\u003e\u003cbr\u003eResearch on a condition marked by uncontrolled appetite has suggested that at least part of the pathology may result from increased suppression of Oxytocin (pitocin) signaling.[9] Therefore, Oxytocin (Endopituitrina) has been suggested to potentially regulate the state of hunger in the organism and its feeding behavior.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eOxytocin and Old Muscle\u003c\/strong\u003e\u003cbr\u003eOxytocin also appears to regulate muscle maintenance. Age-associated reduction in molecule levels appears to lead to muscle wasting (sarcopenia). The research carried out at Berkeley suggests that both blood levels of the peptide and its receptors on muscle stem cells decrease over time. Exogenous exposure to Oxytocin appears to allow muscles to recover much of their potential. According to Elabd, one of the authors of the study, \u003cem\u003e“repair of muscle in the old mice was at about 80%”\u003c\/em\u003e compared to younger mice after Oxytocin was presented.\u003csup\u003e[10]\u003c\/sup\u003e Thus, it can potentially be studied in relation to organ degeneration further, as it may slow down dysfunction.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eOxytocin and Neurotransmitter Regulation\u003c\/strong\u003e\u003cbr\u003eOxytocin is posited to engage with G-protein coupled receptors, which may increase intracellular calcium levels and, therefore, might regulate neurotransmission and excitation.\u003csup\u003e[11]\u003c\/sup\u003e Further, Oxytocin's potential influence on the brain may extend to neurogenesis and synaptic plasticity, which may impact the intricate formation and function of neural circuits. The presence of Oxytocin receptors across various neural cell types hints at the peptide's broad potential impact, possibly modulating the behavior of neural progenitor cells and influencing the fate of these cells. Oxytocin might also affect newly formed neural circuits by modulating neurotransmitter dynamics, including those of glutamate and gamma-aminobutyric acid (GABA), which serve as the brain's primary excitatory and inhibitory signals.\u003cbr\u003e\u003cbr\u003eAt the synaptic level, Oxytocin's actions appear to diverge, potentially enhancing neurotransmitter release in some contexts while diminishing it in others. This dual action may reflect Oxytocin's potential to modulate the balance between excitation and inhibition within the neural circuits, a balance considered crucial for maintaining the functional integrity of the brain. Such modulation may manifest through alterations in the release of neurotransmitters or changes in membranes, indirectly influencing neuronal excitability and the flow of neural information. The interactions of Oxytocin with glial cells, such as astrocytes, further complicate its role in neurotransmitter dynamics, suggesting a broader regulatory influence that extends beyond the neurons to the supportive environment that nurtures and maintains synaptic connections. This interaction may influence the synaptic plasticity and overall function of neural circuits, offering a glimpse into the complex regulatory roles Oxytocin might play in the neural ecosystem.\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"grey-back-d\"\u003e\u003cstrong\u003eOxytocin and Sexual Behavior\u003c\/strong\u003e\u003cbr\u003eOxytocin is hypothesized to potentially influence sexual behavior by modulating dopamine activity in central nervous system regions believed integral to the reward system, specifically the ventral tegmental area (VTA) and the nucleus accumbens.\u003csup\u003e[12]\u003c\/sup\u003e More specifically, the peptide may enhance dopamine release or increase the responsiveness of dopamine-releasing neurons. Such alterations in dopaminergic activity may conceivably elevate sexual drive and support the perception of reward, thereby playing a role in the anticipatory behaviors associated with mating and copulation.\u003cbr\u003e\u003cbr\u003eThe interaction between Oxytocin and these neurons may trigger a cascade of biological events leading to a significant release of dopamine in the nucleus accumbens. One component of this cascade might involve nitric oxide production within the VTA, suggesting a complex interaction between Oxytocin, dopamine, and nitric oxide in this context.\u003cbr\u003e\u003cbr\u003eFurthermore, Oxytocin might also exert indirect action on dopamine levels in other brain regions, such as the hippocampus and amygdala, thus contributing to its multifaceted role in modulating behavior. These indirect actions might regulate the activities of neurons that release glutamate or GABA, neurotransmitters that may then influence the activity of dopaminergic neurons in the VTA and nucleus accumbens. Such a mechanism underscores the intricate and potentially widespread influence of Oxytocin on brain functions related to sexual behavior.\u003cb\u003e\u003cem\u003e\u003c\/em\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv style=\"margin-bottom: 30px;\" class=\"white-back-d\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eGouin JP, Carter CS, Pournajafi-Nazarloo H, Glaser R, Malarkey WB, Loving TJ, Stowell J, Kiecolt-Glaser JK. Marital behavior, oxytocin, vasopressin, and wound healing. Psychoneuroendocrinology. 2010 Aug;35(7):1082-90. . Epub 2010 Feb 9. PMID: 20144509; PMCID: PMC2888874.\u003c\/li\u003e\n\u003cli\u003eKiecolt-Glaser JK, Loving TJ, Stowell JR, Malarkey WB, Lemeshow S, Dickinson SL, Glaser R. Hostile marital interactions, proinflammatory cytokine production, and wound healing. Arch Gen Psychiatry. 2005 Dec;62(12):1377-84. . PMID: 16330726.\u003c\/li\u003e\n\u003cli\u003eReiss AB, Glass DS, Lam E, Glass AD, De Leon J, Kasselman LJ. Oxytocin: Potential to mitigate cardiovascular risk. Peptides. 2019 Jul;117:170089. . Epub 2019 May 18. PMID: 31112739.\u003c\/li\u003e\n\u003cli\u003eWang P, Wang SC, Yang H, Lv C, Jia S, Liu X, Wang X, Meng D, Qin D, Zhu H, Wang YF. Therapeutic Potential of Oxytocin in Atherosclerotic Cardiovascular Disease: Mechanisms and Signaling Pathways. Front Neurosci. 2019 May 21;13:454. . PMID: 31178679; PMCID: PMC6537480.\u003c\/li\u003e\n\u003cli\u003ePlante E, Menaouar A, Danalache BA, Yip D, Broderick TL, Chiasson JL, Jankowski M, Gutkowska J. Oxytocin treatment prevents the cardiomyopathy observed in obese diabetic male db\/db mice. Endocrinology. 2015 Apr;156(4):1416-28. . Epub 2015 Jan 6. PMID: 25562615.\u003c\/li\u003e\n\u003cli\u003eDing C, Leow MK, Magkos F. Oxytocin in metabolic homeostasis: implications for obesity and diabetes management. Obes Rev. 2019 Jan;20(1):22-40. . Epub 2018 Sep 25. PMID: 30253045; PMCID: PMC7888317.\u003c\/li\u003e\n\u003cli\u003eDayi A, Kiray M, Sisman A, Ozbal S, Baykara B, Aksu I, Uysal N. Dose dependent effects of oxytocin on cognitive defects and anxiety disorders in adult rats following acute infantile maternal deprivation stress. Biotech Histochem. 2019 Oct;94(7):469-480. . Epub 2019 May 20. PMID: 31104534.\u003c\/li\u003e\n\u003cli\u003eZiegler C, Dannlowski U, Bräuer D, Stevens S, Laeger I, Wittmann H, Kugel H, Dobel C, Hurlemann R, Reif A, Lesch KP, Heindel W, Kirschbaum C, Arolt V, Gerlach AL, Hoyer J, Deckert J, Zwanzger P, Domschke K. Oxytocin receptor gene methylation: converging multilevel evidence for a role in social anxiety. Neuropsychopharmacology. 2015 May;40(6):1528-38. . Epub 2015 Jan 7. PMID: 25563749; PMCID: PMC4397412.\u003c\/li\u003e\n\u003cli\u003eAtasoy D, Betley JN, Su HH, Sternson SM. Deconstruction of a neural circuit for hunger. Nature. 2012 Aug 9;488(7410):172-7. . PMID: 22801496; PMCID: PMC3416931.\u003c\/li\u003e\n\u003cli\u003eElabd C, Cousin W, Upadhyayula P, Chen RY, Chooljian MS, Li J, Kung S, Jiang KP, Conboy IM. Oxytocin is an age-specific circulating hormone that is necessary for muscle maintenance and regeneration. Nat Commun. 2014 Jun 10;5:4082. . PMID: 24915299; PMCID: PMC4512838.\u003c\/li\u003e\n\u003cli\u003eBakos, Jan et al. “Molecular Mechanisms of Oxytocin Signaling at the Synaptic Connection.” Neural plasticity vol. 2018 4864107. 2 Jul. 2018, \u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.1155\/2018\/4864107\" target=\"_blank\"\u003edoi: 10.1155\/2018\/4864107\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eMelis, Maria Rosaria, and Antonio Argiolas. “Oxytocin, Erectile Function and Sexual Behavior: Last Discoveries and Possible Advances.” International journal of molecular sciences vol. 22,19 10376. 26 Sep. 2021, \u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.3390\/ijms221910376\" target=\"_blank\"\u003edoi: 10.3390\/ijms221910376\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"vbni\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786428252477,"sku":"sku2194756143847","price":120.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/Oxytocin-10MG-2-1.webp?v=1780466136"},{"product_id":"ghrp-2-5mg","title":"(🔥  Boosts GH secretion) GHRP-2 Peptide Online - (5mg) -10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is GHRP-2?\u003c\/p\u003e\n\u003cp\u003eHow GHRP-2 works:\u003c\/p\u003e\n\u003cp\u003eActivates ghrelin receptors\u003cbr\u003eStimulates the pituitary gland to release GH\u003cbr\u003eIndirectly increases IGF-1\u003c\/p\u003e\n\u003cp\u003eIt can be understood as:\u003cbr\u003e👉 An “optimized version” of GHRP-6 (cleaner, more controllable)\u003c\/p\u003e\n\u003cp\u003e💪 Main Effects (Theory + Feedback)\u003cbr\u003e🔥 1️⃣ Boosts GH secretion\u003c\/p\u003e\n\u003cp\u003eKey characteristics of GHRP-2:\u003c\/p\u003e\n\u003cp\u003eStrong GH-stimulating ability\u003cbr\u003eMore stable than GHRP-6\u003cbr\u003eMore “potent” than Ipamorelin\u003c\/p\u003e\n\u003ch3\u003eGHRP-2 Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eGHRP-2, also known as \u003cem\u003ePralmorelin\u003c\/em\u003e is a synthetic growth hormone secretagogue that researchers consider may interact with the ghrelin\/growth hormone secretagogue receptor found on pituitary cells. It is a pentapeptide consisting of five amino acids and bears a resemblance to the endogenous neurotransmitter, met-enkephalin. It is proposed, albeit with uncertainty, that GHRP-2 may not function as a typical neurotransmitter. Rather, it is hypothesized to engage with ghrelin receptors. Ghrelin, identified as a hormone that regulates appetite, may be affected by interactions with GHRP-2. There is a conjecture that GHRP-2 might induce the secretion of growth hormone (GH) through potential interactions with ghrelin receptors on the pituitary gland, specifically the growth hormone secretagogue receptors (GHS-Rs). Yet, the nature of this interaction is still under investigation and not conclusively established. Extensive research has also been performed to evaluate its role in regulating various physiological processes, including muscle development, appetite, immune functions, and sleep cycles.\u003csup\u003e[1]\u003c\/sup\u003e\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e Pralmorelin\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e45\u003c\/sub\u003eH\u003csub\u003e55\u003c\/sub\u003eN\u003csub\u003e9\u003c\/sub\u003eO\u003csub\u003e6\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 817.9 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2\u003c\/p\u003e\n\u003ch3\u003eGHRP-2 Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-2 and Muscle Structure\u003c\/strong\u003e\u003cbr\u003eResearch in yaks noted that GHRP-2 peptide appeared to stimulate the growth of muscles in two ways: enhanced protein synthesis and accumulation, and reduced protein degradation.\u003csup\u003e[3]\u003c\/sup\u003e The study suggested that GHRP-2 may help to overcome natural growth limitation that occurs in yaks because of food deprivation, adverse environmental conditions, and disease. The researchers also posited that \u003cem\u003e“GHRP-2 enhanced muscle protein deposition mainly by up-regulating the protein synthesis pathways.”\u003c\/em\u003e The most significant observation has been the potential action of GHRP-2 in reducing muscle atrophy through repression of atrogin-1 and MuRF1- proteins, which are considered to regulate muscle degradation pathways.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-2 and the Heart\u003c\/strong\u003e\u003cbr\u003eStudies in fetal heart cell culture lines have theorized that GHRP-2 and its analogs (GHRP-1 and ) may help to protect cardiac cells by minimizing apoptosis or programmed cell death.\u003csup\u003e[4]\u003c\/sup\u003e The peptide appears to protect cardiac muscles from a reduced supply of blood and nutrients, which may in some cases induce a cardiac arrest. Studies on , a GHRP-2 analog, have posited that these peptides associate with a specific receptor. It is posited that the receptor CD36 may have a notable role in the binding of oxidized low-density lipoprotein (OxLDL). There appears to be a possible interaction between GHRP-2 and CD36 that may lead to a decrease in the cellular absorption of OxLDL, which is thought to be implicated in the onset of atherosclerosis characterized by diminished blood and nutrient flow. Preliminary findings indicate that GHRP-2 might lower interferon-gamma levels by approximately 66% in cultured aortic smooth muscle cells, a model used to study atherosclerosis action. Although GHRP-2 seemingly did not alter the degree of atherosclerotic plaque formation significantly, it is suggested that the peptide might reduce superoxide generation within vascular tissues. Furthermore, GHRP-2 is reported to have decreased the gene expression of 12\/15-lipoxygenase by nearly 92% and may also have reduced levels of both interferon-gamma and macrophage migration inhibitory factors. Experimental observations in cultured aortic smooth muscle cells propose that GHRP-2 may potentially inhibit OxLDL-induced peroxide production, mitigate the downregulation of the IGF-I receptor, and perhaps prevent apoptosis. In macrophages loaded with OxLDL, it has been conjectured that GHRP-2 might lessen lipid accumulation, thereby underscoring its anticipated antioxidative and protective actions in scenarios of compromised blood and nutrient supply.\u003csup\u003e[4]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-2 and the Immune System\u003c\/strong\u003e\u003cbr\u003eGHRP-2 peptide researchers suggest the peptide may enhance the functions of the thymus, an organ that helps protect and mature certain cells of the immune system, especially the T lymphocytes.\u003csup\u003e[5]\u003c\/sup\u003e T lymphocytes are crucial for adaptive immunity and the physiological capacity to combat complex infections. However, the efficacy of the thymus diminishes, which may induce tissue damage and diminished immunity. In such cases, GHRP-2 appears to have the potential to rejuvenate the thymus, possibly promoting the number and diversity of T-cells, thereby supporting general immunity.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-2 and Pain Perception\u003c\/strong\u003e\u003cbr\u003eResearchers initially hypothesized that GHRP-2 may decrease pain associated with osteoarthritis in animal models through the stimulation of growth hormone production and the repair of damaged tissues. However, it has been suggested since that GHRP-2 may induce pain relief prior to tissue repair, which may occur due to an action on opioid receptors. There are four known opioid receptors.\u003csup\u003e[6]\u003c\/sup\u003e Other compounds studied for their impact on opioid receptors appear to typically mediate a universal action on all four receptors. The generic mode of action may create challenges as the receptors may have differential and diverse functions. GHRP-2 appears to be a selective opioid receptor agonist, binding uniquely to the receptors implicated in pain perception, reward system linking, and sedation.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-2 and Sleep Cycles\u003c\/strong\u003e\u003cbr\u003eGHRP-2 has been suggested to influence sleep cycles. The peptide may increase the duration of stages 3 and 4 of the sleep cycles by up to 50%, as reported by researchers, and potentially improve the duration of REM sleep by approximately 20%.\u003csup\u003e[7]\u003c\/sup\u003e It may further diminish deviation in sleeping patterns from normal standards. Research is ongoing.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-2 and Pituitary Cells\u003c\/strong\u003e\u003cbr\u003eThe primary mechanism by which GHRP-2 appears to operate is via its binding with Growth Hormone Secretagogue Receptors (GHS-Rs), which are considered to be activated by ghrelin. These receptors are found throughout various regions of the nervous system and in other tissues, notably in the hypothalamus and pituitary gland. It is hypothesized that the binding of GHRP-2 to GHS-Rs may possibly provoke a structural alteration, potentially initiating a chain of intracellular signaling events, commonly mediated by G-proteins. Such an interaction might facilitate the release of Gαq\/11, a G-protein component, potentially instigating additional signaling activities. For example, Phospholipase C (PLC) may cleave phosphatidylinositol 4,5-bisphosphate (PIP2) into secondary messengers, IP3 and DAG (diacylglycerol). IP3 might then stimulate the release of calcium ions, while DAG might activate Protein Kinase C (PKC), possibly enhancing the signaling pathway and contributing to the secretion of growth hormone from the pituitary cells. This sequence of events may also involve the activation of cyclic AMP (cAMP), deemed essential for cellular signaling. An elevation in cAMP levels might potentially enhance the signaling cascade, possibly facilitating the production of growth hormone in the somatotroph cells of the anterior pituitary gland. Yet, it has been postulated that exposure to GHRP-2 might quickly lead to receptor desensitization, potentially decreasing their responsiveness for up to four hours before this action may be reversed.\u003csup\u003e[8]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-2 Peptide and Growth Factors\u003c\/strong\u003e\u003cbr\u003eIt has been proposed that GHRP-2 may induce a more substantial increase in GH levels in somatotroph cells compared to the natural increase triggered by growth hormone-releasing hormone (GHRH). Preliminary data also suggests that GHRP-2 may elevate ACTH and cortisol levels, which are also produced by pituitary cells. Additional research points to the potential for GHRP-2 exposure to significantly elevate peak GH levels and average pulsatile GH secretion from anterior pituitary gland cells. Moreover, it may also potentially augment the activity of mediators involved in the anabolic actions of GH, such as insulin-like growth factor-1 (IGF-1). In a particular study, GHRP-2 was implicated in inducing up to an 181-fold increase in GH production from anterior pituitary cells relative to baseline.\u003csup\u003e[9]\u003c\/sup\u003e Additionally, IGF-1 levels reportedly increased from an average of 100mcg\/l at baseline to approximately 180mcg\/l, as indicated by researchers in another study. Another group of researchers observed that the peptide seemed to \"\u003cem\u003estimulate pulsatile, rhythmic, and entropic GH secretion by more than threefold\" when compared to GHRH\u003c\/em\u003e.”\u003csup\u003e[10]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eGHRP-2 and Hunger Regulation\u003c\/strong\u003e\u003cbr\u003eIt is suggested that GHRP-2's activation of GHS-Rs in various parts of the nervous system may initiate a series of cellular processes that might support the production of hunger-stimulating neuropeptides, notably Neuropeptide Y (NPY) and Agouti-related peptide (AgRP). These peptides are considered to play a crucial role in energy balance and appetite regulation. Concurrently, there is a suggestion that GHRP-2 might also suppress the release of melanocyte-stimulating hormone (α-MSH), an appetite-suppressing hormone, potentially leading to increased hunger and higher food consumption. Additionally, GHRP-2 might affect the mesolimbic reward system, a key brain pathway that regulates food cravings, possibly through the activation of GHSR-1a receptors. This mechanism may theoretically heighten appetite, possibly through the activation of cyclic adenosine monophosphate (cAMP) pathways, further implicating GHRP-2 in the modulation of feeding behavior and reward-driven eating. Research has suggested that models exposed to GHRP-2 consumed about 36% more food than control models, with a reported increase in food intake relative to body weight. Specifically, the energy intake per kilogram of weight was higher in the GHRP-2 group, recorded as 136.0±13.0 kJ\/kg compared to 101.3±10.5 kJ\/kg in the control group. Additionally, increases in GH levels were observed in the GHRP-2 models compared to those given saline, with hormone levels measured as the area under the curve (AUC) reaching up to 5550±1090 μg\/L\/240 min versus 412±161 μg\/L\/240 min.\u003csup\u003e[11]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003ePhung LT, Inoue H, Nou V, Lee HG, Vega RA, Matsunaga N, Hidaka S, Kuwayama H, Hidari H. The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine. Domest Anim Endocrinol. 2000 Apr;18(3):279-91. . PMID: 10793268.\u003c\/li\u003e\n\u003cli\u003eLaferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005 Feb;90(2):611-4. . PMID: 15699539; PMCID: PMC2824650.\u003c\/li\u003e\n\u003cli\u003eHu R, Wang Z, Peng Q, Zou H, Wang H, Yu X, Jing X, Wang Y, Cao B, Bao S, Zhang W, Zhao S, Ji H, Kong X, Niu Q. Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation. PLoS One. 2016 Feb 19;11(2):e0149461. . PMID: 26894743; PMCID: PMC4760683.\u003c\/li\u003e\n\u003cli\u003eTitterington JS, Sukhanov S, Higashi Y, Vaughn C, Bowers C, Delafontaine P. Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE-\/- mice but does not reduce atherosclerosis. Endocrinology. 2009 Dec;150(12):5478-87. . Epub 2009 Oct 9. PMID: 19819949; PMCID: PMC2795722.]\u003c\/li\u003e\n\u003cli\u003eChao YN, Sun D, Peng YC, Wu YL. Growth Hormone Releasing Peptide-2 Attenuation of Protein Kinase C-Induced Inflammation in Human Ovarian Granulosa Cells. Int J Mol Sci. 2016 Aug 19;17(8):1359. . PMID: 27548147; PMCID: PMC5000754.\u003c\/li\u003e\n\u003cli\u003eZeng P, Li S, Zheng YH, Liu FY, Wang JL, Zhang DL, Wei J. Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice. Peptides. 2014 May;55:103-9. . Epub 2014 Mar 4. PMID: 24607724.\u003c\/li\u003e\n\u003cli\u003eSigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018 Jan;6(1):45-53. . Epub 2017 Apr 8. PMID: 28400207; PMCID: PMC5632578.\u003c\/li\u003e\n\u003cli\u003eSinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., \u0026amp; Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. \u003cem\u003eTranslational andrology and urology\u003c\/em\u003e, \u003cem\u003e9\u003c\/em\u003e(Suppl 2), S149–S159. \u003ca href=\"https:\/\/doi.org\/10.21037\/tau.2019.11.30\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.21037\/tau.2019.11.30\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eVeldhuis, J. D., Keenan, D. M., Bailey, J. N., Adeniji, A. M., Miles, J. M., \u0026amp; Bowers, C. Y. (2009). Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies in men during experimental hypogonadal clamp. \u003cem\u003eThe Journal of clinical endocrinology and metabolism\u003c\/em\u003e, \u003cem\u003e94\u003c\/em\u003e(6), 2137–2143. \u003ca href=\"https:\/\/doi.org\/10.1210\/jc.2009-0136\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1210\/jc.2009-0136\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eBowers, C. Y., Granda, R., Mohan, S., Kuipers, J., Baylink, D., \u0026amp; Veldhuis, J. D. (2004). Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. \u003cem\u003eThe Journal of clinical endocrinology and metabolism\u003c\/em\u003e, \u003cem\u003e89\u003c\/em\u003e(5), 2290–2300. \u003ca href=\"https:\/\/doi.org\/10.1210\/jc.2003-031799\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1210\/jc.2003-031799\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eLaferrère, Blandine et al. “Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.” The Journal of clinical endocrinology and metabolism vol. 90,2 (2005): 611-4. \u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2824650\/\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2824650\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"vbni\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786428285245,"sku":"sku2194756132741","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/GHRP-2-5MG-3.webp?v=1780466138"},{"product_id":"ghrp-6-10mg","title":"(💪  Recovery and Muscle-Building Support) GHRP-6 peptide - (10mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is GHRP-6?\u003c\/p\u003e\n\u003cp\u003eGHRP-6 acts on:\u003c\/p\u003e\n\u003cp\u003eGhrelin receptors\u003cbr\u003eThe pituitary GH secretion pathway\u003c\/p\u003e\n\u003cp\u003eIt is one of the earliest GH secretagogues.\u003c\/p\u003e\n\u003cp\u003e💪 Main Effects (Theory + User Feedback)\u003cbr\u003e🔥 1️⃣ Stimulates GH secretion\u003cbr\u003eIncreases pulsatile GH release\u003cbr\u003eIndirectly increases IGF-1\u003c\/p\u003e\n\u003cp\u003eBut in terms of potency:\u003cbr\u003e👉 Moderately strong (not as “potent” as Hexarelin)\u003c\/p\u003e\n\u003cp\u003e🍽️ 2️⃣ Significantly increases appetite (signature characteristic)\u003c\/p\u003e\n\u003cp\u003eThis is GHRP-6’s most famous effect:\u003c\/p\u003e\n\u003cp\u003eMarkedly increased hunger\u003cbr\u003eIncreased food intake\u003cbr\u003eParticularly suitable for “bulking”\u003c\/p\u003e\n\u003cp\u003eMany users say:\u003cbr\u003e👉 “It’s like having your appetite forced open”\u003c\/p\u003e\n\u003cp\u003e💪 3️⃣ Recovery and Muscle-Building Support\u003c\/p\u003e\n\u003cp\u003eCommon feedback from the fitness community:\u003c\/p\u003e\n\u003cp\u003eFaster recovery\u003cbr\u003eReduced post-workout soreness\u003cbr\u003eWeight gain (partly due to increased food intake)\u003cbr\u003e😴 4️⃣ Improved Sleep\u003c\/p\u003e\n\u003cp\u003eSome users report:\u003c\/p\u003e\n\u003cp\u003eDeeper sleep\u003cbr\u003eEnhanced sense of recovery during the night\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eGHRP-6 Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eGHRP-6 (Growth hormone-releasing peptide-6) has been studied for its potential as a stimulant to release endogenously produced growth hormone (hGH) from the anterior pituitary gland cells. It appears to achieve that by acting as a ghrelin receptor agonist. Ghrelin, also known as the hunger hormone, is naturally produced by the stomach when empty. This ghrelin receptor is also known as growth hormone secretagogue (GHS) receptor 1a (aka GHS-R1a) and is classified amongst the group of growth hormone secretagogues. It has been suggested to positively influence cardiac muscle cells, scar formation, and memory processing, though it has been involved in research in other areas.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e46\u003c\/sub\u003eH\u003csub\u003e56\u003c\/sub\u003eN\u003csub\u003e12\u003c\/sub\u003eO\u003csub\u003e6\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 873.032 g\/mol\u003c\/p\u003e\n\u003cp class=\"grey-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e His-D-Trp-Ala-Trp-D-Phe-Lys\u003c\/p\u003e\n\u003ch3\u003eGHRP-6 Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-6 and Growth Hormone Synthesis\u003c\/strong\u003e\u003cbr\u003eExperiments suggest that GHRP-6 may actively engage with the GHS receptors in the anterior pituitary gland cells and stimulate them to produce growth hormone (hGH). Researchers have compared the potential of the peptide to the natural trigger of hGH synthesis, which is the growth hormone-regulating hormone (GHRH). It may be important to note that GHRH appears to trigger hGH synthesis via another pathway - by triggering the GHRH receptors on the anterior pituitary cells. The scientists reported a mean hGH peak of 15.7 ng\/ml, and the total mean amount of hGH released during the first 90 minutes of the experiment was estimated to be 674 ng\/ml. These values were considerably higher when compared to the hGH peak of 6.8 ng\/ml and the 412 ng\/ml total hGH released after GHRH.\u003csup\u003e[1] \u003c\/sup\u003eAnother experiment also compared GHRP-6 to placebo, suggesting that the peptide was associated with the release of 15.4 ng\/ml hGH, while the control group measured at 5.5 ng\/ml.\u003csup\u003e[2]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-6 and Memory\u003c\/strong\u003e\u003cbr\u003eStudies on rodent models have highlighted how GHRP-6 may help to consolidate newly created memories and transform short-term memories into long-term storage. Significant scientific observations further posit the role of ghrelin\/GHRP-6 in spatial learning tasks. Growth hormone secretagogues such as ghrelin may bring about activity-induced cognitive improvements. Hence, the role of growth hormone may be possibly indirect and perhaps secondary to these peptides.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-6 and Brain Tissue\u003c\/strong\u003e\u003cbr\u003eIn scientific investigations, the peptide known as GHRP-6 has been tentatively linked to the protection and recovery of brain tissues. For example, the potential of the GHRP-6 peptide in the amelioration of stroke has been studied using animal models. The timely exposure of the peptide appears to protect the brain tissue from reduced blood supply (following a stroke) and may help in recovery from memory lapses due to stroke.\u003csup\u003e[3]\u003c\/sup\u003e At a molecular level, the peptide and its analogs may prevent apoptosis of neurons of the central nervous system, which might prevent genetic reprogramming and inflammation. Another study has examined the potential influence of GHRP-6 on brain tissue via its ability to upregulate hGH synthesis and elevate local insulin-like growth factor-1 (IGF-1) levels.\u003csup\u003e[4]\u003c\/sup\u003e IGF-1, a protein resembling insulin, may play a crucial role in growth and development. The preliminary results from this study suggested that GHRP-6 may increase the messenger RNA (mRNA) levels of IGF-1 in certain brain regions such as the hypothalamus, cerebellum, and hippocampus. Interestingly, this increase was not observed in the cerebral cortex. This pattern implies that GHRP-6 (via hGH) might potentially promote IGF-1 synthesis in selective parts of the brain. Additionally, the study assessed the expression of the IGF-1 receptor and insulin-like growth factor-binding protein 2 (IGFBP-2), which is deemed responsible for regulating IGF-1's availability by binding to it. There were no significant changes detected in their activities following the peptide's presentation. However, there was a noticeable phosphorylation of protein kinase B (Akt) and the Bcl-2-associated death promoter (BAD) in regions showing increased IGF-1 levels. This phosphorylation might suggest that hGH and GHRP-6 might trigger cell survival pathways in response to growth factors. BAD is part of the Bcl-2 family, which plays essential roles in the regulation of cell death, while Akt is involved in various cellular functions, including metabolism, apoptosis, growth, transcription, and cell migration. The study observed an uptick in the levels of Bcl-2, an antiapoptotic protein, in areas with elevated IGF-1, whereas the levels of the proapoptotic protein Bax remained unchanged. This finding suggests a potential shift towards cellular preservation rather than programmed cell death (apoptosis).\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-6 Peptide and Parkinson’s Disease\u003c\/strong\u003e\u003cbr\u003eA study conducted in 2018 highlighted the prevalence of ghrelin receptors in substantia nigra, a part of the brain considered to be affected in the course of Parkinson’s Disease.\u003csup\u003e[5]\u003c\/sup\u003e Organisms genetically predisposed to the disease exhibited an apparent significant reduction in ghrelin receptors in their substantia nigra. It was observed that genetically modulated rats also exhibited Parkinson’s symptoms when an antagonist was introduced. The researchers concluded, \u003cem\u003e\"These findings suggest that the down-regulation of GHSRs in SNc-DA neurons induced the initial dysfunction of DA neurons, leading to extrapyramidal disorder under PD.”\u003c\/em\u003e Scientists hypothesize that the peptide associated with receptors present in the substantia nigra may decrease neuronal apoptosis.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-6 Peptide and Cardiac Issues\u003c\/strong\u003e\u003cbr\u003eThe GHRP-6 peptide was suggested to inhibit free radical-mediated cytotoxicity of cardiac cells in porcine models.\u003csup\u003e[6]\u003c\/sup\u003e It may be employed in ongoing research into viable cardiac tissue damaged following a cardiac arrest. Research in this focus is preliminary.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-6 and Sexual Behavior\u003c\/strong\u003e\u003cbr\u003eStudies on male rats have suggested the role of ghrelin receptors in the central nervous system in modulating sexual behavior and motivation. Increased amounts of ghrelin have been suggested to stimulate sexual impulses. Research findings in GHRP-6 and its modified counterpart (which may antagonize the ghrelin receptor) have suggested that ghrelin receptors in specific brain areas may influence sexual and reward-seeking conduct. There is also data to suggest that ghrelin may influence mood. The peptide and its analogs appear to help improve brain function associated with lifting moods, diminishing the secretion of stress hormones, and overcoming depressive behavior in murine models.\u003csup\u003e[7]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-6 and CD36 receptors\u003c\/strong\u003e\u003cbr\u003eResearchers hypothesize that GHRP-6 might interact with receptor sites beyond those associated with ghrelin (GHS-R1a receptors). It is speculated that these additional receptor sites might include the CD36 receptors, which are implicated in various biological functions.\u003csup\u003e[8]\u003c\/sup\u003e CD36 receptors are belie ed to potentially facilitate lipid metabolism by serving as scavenger receptors that assist in the uptake and transport of lipids. They may also play a role in modulating immune responses, particularly in processes like phagocytosis and inflammation, and may be involved in the regulation of angiogenesis, the formation of new blood vessels.\u003cbr\u003e\u003cbr\u003eIn a particular preclinical study evaluating murine models, exposure to GHRP-6 hinted at the possibility that activation of CD36 receptors might lead to improved wound healing processes and reduced development of hypertrophic scars.\u003csup\u003e[9]\u003c\/sup\u003e This is thought to occur through a decrease in inflammation and the expression of fibrotic cytokines, which collectively suggest potential benefits in enhancing the appearance of wounds.\u003cbr\u003e\u003cbr\u003eAnother study explored the actions of stimulating ghrelin receptors in murine models that had experienced combined radiation and burn injuries.\u003csup\u003e[10]\u003c\/sup\u003e Preliminary findings indicated improvements in wound healing, potentially due to decreased levels of pro-inflammatory markers such as TNF-α, and modifications in the signaling pathways that govern inflammation and tissue regeneration.\u003cbr\u003e\u003cbr\u003eAdditionally, data from an experiment where rodents were exposed to GHRP-6 for 60 days showed a potential reduction in liver fibrosis.\u003csup\u003e[11]\u003c\/sup\u003e Observations included a decrease in the expression of fibrogenic factors like transforming growth factor-beta (TGF-β) and connective tissue growth factor (CTGF). In these instances, the extent of fibrotic areas and nodularity was reduced significantly by approximately 75% and over 60%, respectively. These findings propose that GHRP-6 might be capable of attenuating fibrosis and promoting recovery in experimental models.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-6 and Scarring\u003c\/strong\u003e\u003cbr\u003eGHRP-6 researchers hypothesize the peptide may aid in the survival of diverse cells by decreasing programmed cell death. The peptide has been associated with the CD36 receptor and may help to promote blood vessel growth, particularly in wounds. Experiments with GHRP-6 and rat models also suggest it may hold potential for faster wound closure in rats. It appears to help in rapid wound healing and the formation of extracellular matrix proteins such as collagen, promoting the overall correct organization of tissue around a scar and thus reducing the appearance of scar marks. Hypertrophic scars, like keloids, are considered to occur due to improper deposition of matrix proteins. Scientists suggest that GHRP-6 may block this aberrant wound-healing process.\u003csup\u003e[12]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eGHRP-6 and Muscle Tissue\u003c\/strong\u003e\u003cbr\u003eEmerging studies tentatively propose that the peptide GHRP-6 might exhibit anabolic potential, likely by ostensibly stimulating the secretion of growth hormone and IGF-1. These are considered to be critical components in muscle development and repair processes. In laboratory experiments utilizing cultured myoblast cells, which are precursors to muscle cells, it was observed that GHRP-6 may contribute to increased levels of myogenic marker proteins.\u003csup\u003e[13]\u003c\/sup\u003e These proteins are indicators of muscle cell differentiation and development. Additionally, the peptide was associated with elevated production of IGF-1 and collagen type I, a primary structural protein essential in connective tissue and skeletal muscle fortification. The observed enhancements in metabolic activity within the myoblasts further support these findings. Based on these observations, it has been hypothesized that GHRP-6 may potentially facilitate the improvement of muscle tissue by fostering the synthesis of collagen type I and other vital proteins essential for muscle function and structure.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eCordido F, Peñalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab. 1993 Apr;76(4):819-23. . PMID: 8473389.\u003c\/li\u003e\n\u003cli\u003eFrieboes RM, Murck H, Maier P, Schier T, Holsboer F, Steiger A. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology. 1995 May;61(5):584-9. . PMID: 7617137.\u003c\/li\u003e\n\u003cli\u003eSubirós N, Pérez-Saad HM, Berlanga JA, Aldana L, García-Illera G, Gibson CL, García-Del-Barco D. Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy. Neurol Res. 2016 Mar;38(3):187-95. . Epub 2016 Apr 19. PMID: 26311576.\u003c\/li\u003e\n\u003cli\u003eFrago LM, Pañeda C, Dickson SL, Hewson AK, Argente J, Chowen JA. Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection. Endocrinology. 2002 Oct;143(10):4113-22. doi: 10.1210\/en.2002-220261. PMID: 12239123.\u003c\/li\u003e\n\u003cli\u003eSuda Y, Kuzumaki N, Sone T, Narita M, Tanaka K, Hamada Y, Iwasawa C, Shibasaki M, Maekawa A, Matsuo M, Akamatsu W, Hattori N, Okano H, Narita M. Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson’s disease-like motor dysfunction. Mol Brain. 2018 Feb 20;11(1):6. . PMID: 29458391; PMCID: PMC5819262.\u003c\/li\u003e\n\u003cli\u003eBerlanga J, Cibrian D, Guevara L, Dominguez H, Alba JS, Seralena A, Guillén G, López-Mola E, López-Saura P, Rodriguez A, Perez B, Garcia D, Vispo NS. Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clin Sci (Lond). 2007 Feb;112(4):241-50. . PMID: 16989643.\u003c\/li\u003e\n\u003cli\u003eHuang HJ, Zhu XC, Han QQ, Wang YL, Yue N, Wang J, Yu R, Li B, Wu GC, Liu Q, Yu J. Ghrelin alleviates anxiety- and depression-like behaviors induced by chronic unpredictable mild stress in rodents. Behav Brain Res. 2017 May 30;326:33-43. . Epub 2017 Feb 27. PMID: 28245976.\u003c\/li\u003e\n\u003cli\u003eDemers, A., McNicoll, N., Febbraio, M., Servant, M., Marleau, S., Silverstein, R., \u0026amp; Ong, H. (2004). Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. \u003cem\u003eThe Biochemical journal\u003c\/em\u003e, \u003cem\u003e382\u003c\/em\u003e(Pt 2), 417–424.\u003c\/li\u003e\n\u003cli\u003eMendoza Marí, Y., Fernández Mayola, M., Aguilera Barreto, A., García Ojalvo, A., Bermúdez Alvarez, Y., Mir Benítez, A. J., \u0026amp; Berlanga Acosta, J. (2016). Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds. \u003cem\u003ePlastic surgery international\u003c\/em\u003e, \u003cem\u003e2016\u003c\/em\u003e, 4361702.\u003c\/li\u003e\n\u003cli\u003eLiu, C., Huang, J., Li, H., Yang, Z., Zeng, Y., Liu, J., Hao, Y., \u0026amp; Li, R. (2016). Ghrelin accelerates wound healing through GHS-R1a-mediated MAPK-NF-κB\/GR signaling pathways in combined radiation and burn injury in rats. \u003cem\u003eScientific reports\u003c\/em\u003e, \u003cem\u003e6\u003c\/em\u003e, 27499.\u003c\/li\u003e\n\u003cli\u003eBerlanga-Acosta, J., Vázquez-Blomquist, D., Cibrián, D., Mendoza, Y., Ochagavía, M. E., Miranda, J., ... \u0026amp; Guillén-Nieto, G. E. (2012). Growth Hormone Releasing Peptide 6 (GHRP6) reduces liver fibrosis in CCl4 chronically intoxicated rats. \u003cem\u003eBiotecnología Aplicada\u003c\/em\u003e, \u003cem\u003e29\u003c\/em\u003e(2), 60-72.\u003c\/li\u003e\n\u003cli\u003eBerlanga-Acosta J, Abreu-Cruz A, Herrera DGB, Mendoza-Marí Y, Rodríguez-Ulloa A, García-Ojalvo A, Falcón-Cama V, Hernández-Bernal F, Beichen Q, Guillén-Nieto G. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Clin Med Insights Cardiol. 2017 Mar 2;11:1179546817694558. . PMID: 28469491; PMCID: PMC5392015.\u003c\/li\u003e\n\u003cli\u003eLim, C. J., Jeon, J. E., Jeong, S. K., Yoon, S. J., Kwon, S. D., Lim, J., Park, K., Kim, D. Y., Ahn, J. K., \u0026amp; Kim, B. W. (2015). Growth hormone-releasing peptide-biotin conjugate stimulates myocytes differentiation through insulin-like growth factor-1 and collagen type I. \u003cem\u003eBMB reports\u003c\/em\u003e, \u003cem\u003e48\u003c\/em\u003e(9), 501–506. \u003ca href=\"https:\/\/doi.org\/10.5483\/bmbrep.2015.48.9.258\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.5483\/bmbrep.2015.48.9.258\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"vbni\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786428350781,"sku":"sku2194756133975","price":100.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/GHRP-6-10Mg-2-1.webp?v=1780466139"},{"product_id":"sermorelin-5mg","title":"(🧠 Anti-aging) Sermorelin Peptide (5mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003ch3\u003eAnti-aging\u003cbr\u003ePost-workout recovery\u003cbr\u003eSleep optimization\u003cbr\u003eBody composition management\u003cbr\u003ePeptide clinics\u003c\/h3\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eSermorelin Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eSermorelin is among the growth hormone-releasing hormone (GHRH) analogs. It is classified as a GHRH as researchers have suggested that the peptide acts to induce the endogenous production and release of growth hormone (hGH). Growth hormone has been associated with numerous physiological activities, making Sermorelin and other GHRH analogs, potentially relevant in growth hormone-related research. Examples of studies employing GHRH analogs include research in the context of tissue scarring following cardiac dysfunction, as well as those examining bone density, renal function, dementia and seizure activity.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e149\u003c\/sub\u003eH\u003csub\u003e246\u003c\/sub\u003eN\u003csub\u003e44\u003c\/sub\u003eO\u003csub\u003e42\u003c\/sub\u003eS\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 3357.9 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Tyr-Ala-Asp-Ala-lle-Phe-DL-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2\u003c\/p\u003e\n\u003ch3\u003eSermorelin Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eSermorelin and Mechanisms of Action\u003c\/strong\u003e\u003cbr\u003eSermorelin may represent the shortest sequence speculated to potentially activate the biological mechanisms associated with GHRH receptors.\u003csup\u003e[1]\u003c\/sup\u003e This peptide consists of the initial 29 amino acids of the typical 44 amino acids present in GHRH. It is suggested that Sermorelin may interact with GHRH receptors located on the pituitary gland, potentially triggering the release of growth hormone. This interaction is thought to mimic the primary activities of GHRH, potentially activating the receptors within the somatotroph cells of the anterior pituitary gland. This interaction might lead to intermittent growth hormone emissions despite Sermorelin's truncated amino acid structure.\u003csup\u003e[2]\u003c\/sup\u003e Upon engaging with these receptors, it is theorized that Sermorelin might initiate various intracellular signaling events. One suspected pathway is the adenylyl cyclase pathway, which may facilitate the transformation of ATP (adenosine triphosphate) to cAMP (cyclic adenosine monophosphate).\u003csup\u003e[3]\u003c\/sup\u003e An increase in cAMP levels might potentially activate protein kinase A (PKA), which in turn might phosphorylate several proteins, such as the voltage-dependent calcium channels in the cell membrane. It is speculated that the phosphorylation and possible subsequent opening of these calcium channels might allow calcium ions to enter the somatotropic cells. The resultant rise in intracellular calcium levels is thought to be critical for the subsequent steps in growth hormone release. It is further hypothesized that elevated calcium levels inside the cell might stimulate the secretory vesicles within the somatotroph cells, potentially leading to the release of growth hormone into the bloodstream. One significant theoretical impact of Sermorelin is its apparent specificity for GHRH receptors, which might prevent it from significantly altering the levels of other endocrine markers like prolactin, insulin, cortisol, glucose, or thyroid hormones. The selective increase in growth hormone production is believed to potentially enhance levels of insulin-like growth factor-1 (IGF-1), which is notably involved in the anabolic actions of growth hormone. The approximate half-life of Sermorelin is estimated to be between 11 and 12 minutes, suggesting a relatively rapid turnover in the organism.\u003csup\u003e[4]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eSermorelin and Cardiac Function\u003c\/strong\u003e\u003cbr\u003eHeart attacks may induce secondary cardiac failure, cardiac conduction abnormalities (arrhythmias), and decreased cardiac capacity. Many of these risks have been associated with cardiac remodeling due to damaged myocytes (heart muscle cells), and may impact surrounding tissues. In 2016, a study in pigs observed that Sermorelin exposure appeared to reduce the instances of cardiac remodeling exhibited following a cardiac attack. Researchers suggested as a result of these findings that the peptide may have acted to decrease cell death in cardiomyocytes, as well as improve production of extracellular matrix components and angiogenesis to damaged tissue. The peptide has also been studied for its potential to assist in diastolic function, decrease scar size, and increase capillary growth.\u003csup\u003e[5]\u003c\/sup\u003e \u003csup\u003e[6]\u003c\/sup\u003e The researchers note that \u003cem\u003e“[Exposure to] GHRH agonists appears to reduce the inflammatory responses post-MI and may consequently improve mechanisms of healing and cardiac remodeling by regulating pathways involved in fibrosis, apoptosis and cardiac repair.”\u003c\/em\u003e It is being explored for different cardiac diseases like cardiac failure and valve disorders.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eSermorelin and Epilepsy\u003c\/strong\u003e\u003cbr\u003eGamma-aminobutyric acid (GABA) is a central nervous system signaling molecule that researchers consider may decrease electrical activity in the spinal cord and reduce overall electrical excitability in the central nervous system. Many anti-seizure compounds act either to: enhance levels of GABA in the central nervous system; or mimic GABA by binding to GABA. In one study using a murine model of epilepsy, scientists introduced Sermorelin to study the impact on the models’ seizure activity. GHRH analogs were observed to activate GABA receptors and inhibit seizures.\u003csup\u003e[7]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eSermorelin and Sleep\u003c\/strong\u003e\u003cbr\u003eOrexin is considered to be a powerful neurochemical secreted in the brain. It has been hypothesized by neurologists and brain researchers to regulate sleep cycles. Growth hormone secretion, in parallel, is considered to occur maximally during sleep. Studies have suggested that a functional GHRH axis may be required for orexin production and function, and that exposure to Sermorelin and other GHRH agonists appears to enhance orexin secretion.\u003csup\u003e[8]\u003c\/sup\u003e Sermorelin is being .\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eSermorelin and Growth Hormone\u003c\/strong\u003e\u003cbr\u003eSermorelin is a growth hormone-releasing hormone derivative that was developed to mediate the activity of growth hormone, with limited ancillary actions. Sermorelin has been studied for its potential to increase hormone levels as the peptide appears to be regulated through physiological feedback mechanisms that prevent certain ancillary actions of excess growth hormone. Such actions may include instances of edema, joint pain, and dysregulation of normal physiology.\u003csup\u003e[9]\u003c\/sup\u003e Sermorelin researchers have posited that the peptide may not be subject to tachyphylaxis, the process by which the organism becomes acclimatized to a compound and thereby negates its action.\u003csup\u003e[10]\u003c\/sup\u003e Scientists conclude that \u003cem\u003e“that the short time course of resensitisation following acute octreotide withdrawal is suggestive of an effect(s) on receptor function or on the receptor signal transduction cascade at sites further downstream, rather than an immune-mediated phenomenon.”\u003c\/em\u003e Studies have suggested peptide-induced production of GHRH receptors, rather than a down-regulation of them. This action may prevent the onset of tachyphylaxis. Initial results from an ongoing study suggest that Sermorelin, a synthetic form of growth-hormone-releasing hormone (GHRH), might potentially increase average growth hormone levels by approximately 82%.\u003csup\u003e[11]\u003c\/sup\u003e In a specific 16-week investigation, researchers explored the potential of Sermorelin on several biological functions, including the production of growth hormone and insulin-like growth factor 1 (IGF-1), as well as the proliferation of skin cells and the growth of muscle tissue. This study proposed that Sermorelin might have an influence on the pathway involving growth hormone and IGF-1 as its levels correlate with growth hormone and is considered to mediate hGH’s anabolic potential. The research suggested that Sermorelin might cause a considerable, yet variable, increase in the release of growth hormone—ranging from 70% to 107%—over a 12-hour period from the somatotroph cells in the anterior part of the pituitary gland. These cells are considered responsible for producing growth hormone in response to signals from the brain. Additionally, the levels of IGF-1 were observed to potentially increase by about 28%, which may indicate an enhanced functionality of the axis connecting growth hormone and IGF-1, suggesting improvements in how these hormones interact and affect the organism.\u003csup\u003e[12]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eSermorelin and Lean Mass\u003c\/strong\u003e\u003cbr\u003eIn the aforementioned 16-week study, it was proposed that Sermorelin may enhance lean mass by approximately 2.78 pounds (1.26 kilograms). The study found no noticeable changes in fat mass concurrent with this increase. Therefore it was posited to be the result of an increase in muscle tissues and water retention. This action was hypothesized to stem from Sermorelin's capacity to potentially elevate levels of growth hormone, which in turn might boost IGF-1. The latter is believed to act as an anabolic mediator for growth hormone, facilitating the muscle-building actions of growth hormone. Additionally, researchers observed a significant increase in skin thickness, suggesting possible dermal modifications linked to the hormonal actions.\u003csup\u003e[12]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSermorelin and Potential Synergism with Other Peptides\u003c\/strong\u003e\u003cbr\u003eSermorelin is a GHRH analog which may exert potential synergism when combined with ghrelin mimetics. Ghrelin mimetics, also known as growth hormone secretagogues (GHSs) are posited to stimulate growth hormone release by activating the ghrelin receptors rather than the GHRH receptors of the anterior pituitary gland. Thus by activating different receptors, Sermorelin and GHSs may exert synergistic actions. Indeed, studies with Sermorelin and GHSs such as GHRP-6 have reported greater elevation of IGF-1 levels compared to either peptide alone. IGF-1 is the main anabolic mediator of hGH’s actions and its levels are beleived to correlate to mean growth hormone levels. For instance, one study reported an apparent increase in IGF-1 levels of over 65% after the combined introduction of GHRP-6 and the unmodified version of Mod GRF 1-29.\u003csup\u003e[13]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e\u003cem\u003e Research chemicals are intended solely for laboratory experimentation and\/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and\/or qualified professionals. All information shared in this article is for educational purposes only.\u003c\/em\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003ePrakash, A, and K L Goa. “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.” BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 12,2 (1999): 139-57.\u003c\/li\u003e\n\u003cli\u003eClark, R G, and I C Robinson. “Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats.” Nature vol. 314,6008 (1985): 281-3.\u003c\/li\u003e\n\u003cli\u003eSinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. . PMID: 32257855; PMCID: PMC7108996.\u003c\/li\u003e\n\u003cli\u003eIshida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S. D., \u0026amp; von Haehling, S. (2020). Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications, 3(1), 25-37.\u003c\/li\u003e\n\u003cli\u003eBagno LL, Kanashiro-Takeuchi RM, Suncion VY, et al. Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy. J Am Heart Assoc. 2015;4(4):e001464. Published 2015 Mar 31. .\u003c\/li\u003e\n\u003cli\u003eKanashiro-Takeuchi RM, Szalontay L, Schally AV, et al. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(12):9728-9739. .\u003c\/li\u003e\n\u003cli\u003eTang S, Luo Z, Qiu X, et al. Interactions between GHRH and GABAARs in the brains of patients with epilepsy and in animal models of epilepsy. Sci Rep. 2017;7(1):18110. Published 2017 Dec 22. .\u003c\/li\u003e\n\u003cli\u003eShepherd BS, Johnson JK, Silverstein JT, et al. Endocrine and orexigenic actions of growth hormone secretagogues in rainbow trout (Oncorhynchus mykiss). Comp Biochem Physiol A Mol Integr Physiol. 2007;146(3):390-399. .\u003c\/li\u003e\n\u003cli\u003eWalker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clin Interv Aging. 2006;1(4):307-308. .\u003c\/li\u003e\n\u003cli\u003eWahid ST, Marbach P, Stolz B, Miller M, James RA, Ball SG. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues. Eur J Endocrinol. 2002;146(3):295-302. .\u003c\/li\u003e\n\u003cli\u003eVittone, J., Blackman, M. R., Busby-Whitehead, J., Tsiao, C., Stewart, K. J., Tobin, J., Stevens, T., Bellantoni, M. F., Rogers, M. A., Baumann, G., Roth, J., Harman, S. M., \u0026amp; Spencer, R. G. (1997). Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism: clinical and experimental, 46(1), 89–96. \u003ca href=\"https:\/\/doi.org\/10.1016\/s0026-0495(97)90174-8\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1016\/s0026-0495(97)90174-8\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eKhorram, O., Laughlin, G. A., \u0026amp; Yen, S. S. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism, 82(5), 1472–1479. \u003ca href=\"https:\/\/doi.org\/10.1210\/jcem.82.5.3943\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1210\/jcem.82.5.3943\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eSigalos, J. T., Pastuszak, A. W., Allison, A., Ohlander, S. J., Herati, A., Lindgren, M. C., \u0026amp; Lipshultz, L. I. (2017). Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. American journal of men's health, 11(6), 1752–1757. \u003ca href=\"https:\/\/doi.org\/10.1177\/1557988317718662\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1177\/1557988317718662\u003c\/a\u003e.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"vbni\"\u003e\u003cem\u003eOnly qualified and licensed professionals should handle these products. Any information found on Biotech Peptides is strictly for educational purposes only. Refer to our \u003ca href=\"https:\/\/biotechpeptides.com\/terms-and-conditions\/\"\u003eterms and conditions\u003c\/a\u003e for more details.\u003c\/em\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786428514621,"sku":"sku2194756146315","price":120.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/Sermorelin-5MG-2-1.webp?v=1780466141"},{"product_id":"ghrp-2-10mg","title":"(💪 Boosts GH secretion) GHRP-2 Peptide - (10mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is GHRP-2?\u003c\/p\u003e\n\u003cp\u003eHow GHRP-2 works:\u003c\/p\u003e\n\u003cp\u003eActivates ghrelin receptors\u003cbr\u003eStimulates the pituitary gland to release GH\u003cbr\u003eIndirectly increases IGF-1\u003c\/p\u003e\n\u003cp\u003eIt can be understood as:\u003cbr\u003e👉 An “optimized version” of GHRP-6 (cleaner, more controllable)\u003c\/p\u003e\n\u003cp\u003e💪 Main Effects (Theory + Feedback)\u003cbr\u003e🔥 1️⃣ Boosts GH secretion\u003c\/p\u003e\n\u003cp\u003eKey characteristics of GHRP-2:\u003c\/p\u003e\n\u003cp\u003eStrong GH-stimulating ability\u003cbr\u003eMore stable than GHRP-6\u003cbr\u003eMore “potent” than Ipamorelin\u003c\/p\u003e\n\u003ch3\u003eGHRP-2 Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eGHRP-2, also known as Pralmorelin , is a synthetic growth hormone secretagogue that interacts with the ghrelin\/growth hormone secretagogue receptor. It is a research peptide studied to evaluate growth hormone deficiency and secondary adrenal failure. GHRP-2, a pentapeptide composed of five amino acids, is similar in structure to the naturally occurring neurotransmitter met-enkephalin. However, it seems that GHRP-2 does not exhibit properties typical of neurotransmitters. Instead, it is thought to potentially interact with ghrelin receptors. Ghrelin, classified as an appetite-regulating hormone, may potentially be influenced by GHRP-2. It is suggested that this peptide may stimulate the production of growth hormone (GH) by potentially engaging with ghrelin receptors located on the pituitary gland, known as growth hormone secretagogue receptors (GHS-Rs). This interaction, however, remains speculative. Extensive research has also evaluated its role in regulating muscle cell development, the immune system, and sleep cycles.\u003csup\u003e[1]\u003c\/sup\u003e\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e Thymosin Beta 4\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e45\u003c\/sub\u003eH\u003csub\u003e55\u003c\/sub\u003eN\u003csub\u003e9\u003c\/sub\u003eO\u003csub\u003e6\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 817.9 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2\u003c\/p\u003e\n\u003ch3\u003eGHRP-2 Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-2 and the Pituitary Gland\u003c\/strong\u003e\u003cbr\u003eThe primary action of GHRP-2 seems to be linked to its interaction with Growth Hormone Secretagogue Receptors (GHS-Rs), which are activated by ghrelin. These receptors are distributed in various parts of the nervous system and other tissues, including the hypothalamus and pituitary gland. It is suggested that when GHRP-2 binds to GHS-Rs, it might induce a structural change that initiates a series of intracellular signals, often mediated by G-proteins. This interaction may lead to the release of Gαq\/11, a G-protein component, which may trigger further signaling events. For instance, Phospholipase C (PLC) might cleave phosphatidylinositol 4,5-bisphosphate (PIP2) into secondary messengers, IP3 and DAG (diacylglycerol). IP3 is believed to stimulate the release of calcium ions, whereas DAG may activate Protein Kinase C (PKC), thereby enhancing the signaling pathway and aiding in the secretion of growth hormone from the pituitary cells. The process might also involve the activation of cyclic AMP (cAMP), which is considered crucial for cellular signaling. An increase in cAMP levels may amplify the signaling cascade, possibly promoting the synthesis of growth hormone in the somatotroph cells of the anterior pituitary gland. However, it is theorized that GHRP-2 may cause immediate desensitization at these receptors after exposure, potentially reducing their sensitivity for up to four hours before this action reverses.\u003csup\u003e[2]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-2 Peptide and Growth Hormone Synthesis\u003c\/strong\u003e\u003cbr\u003eResearchers have suggested that GHRP-2 may lead to a greater increase in GH levels when introduced to somatotroph cells than the increase physiologically triggered by growth hormone-releasing hormone (GHRH). There is also some indication that GHRP-2 might raise ACTH and cortisol levels, which may also be produced by pituitary cells. Further research indicates that in laboratory settings, GHRP-2 exposure might result in a notable enhancement in peak GH levels and mean pulsatile GH secretion from anterior pituitary gland cells. It could also potentially increase the activity of mediators involved in the anabolic actions of GH, such as insulin-like growth factor-1 (IGF-1). In one study, GHRP-2 was implicated in causing up to an 181-fold surge in GH production from anterior pituitary cells compared to baseline.\u003csup\u003e[3]\u003c\/sup\u003e Furthermore, IGF-1 levels reportedly rose from an average of 100mcg\/l at baseline to about 180mcg\/l, as reported by the scientists in another experiment. The second team of researchers also reported that this was an apparent consequence of the peptide, which was reported to have “\u003cem\u003estimulated pulsatile, rhythmic, and entropic GH secretion by more than 3-fold\u003c\/em\u003e” compared to GHRH.\u003csup\u003e[4]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-2 and Muscle Structure\u003c\/strong\u003e\u003cbr\u003eResearch in yaks noted that GHRP-2 peptide may have potentially stimulated the growth of muscles in two ways: enhanced protein synthesis and accumulation, and reduced protein degradation.\u003csup\u003e[5]\u003c\/sup\u003e The study suggested that GHRP-2 may help overcome natural growth limitations in yaks due to food deprivation, adverse environmental conditions, and disease. The researchers also posited that \u003cem\u003e“GHRP-2 enhanced muscle protein deposition mainly by up-regulating the protein synthesis pathways.”\u003c\/em\u003e The most significant observation has been the potential action of GHRP-2 in reducing muscle atrophy through repression of atrogin-1 and MuRF1- proteins, which regulate muscle degradation pathways.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-2 and the Heart\u003c\/strong\u003e\u003cbr\u003eStudies in fetal heart cell culture lines have theorized that GHRP-2 and its analogs (GHRP-1 and ) may help to protect cardiac cells by minimizing apoptosis or programmed cell death.\u003csup\u003e[6]\u003c\/sup\u003e The peptide appears to protect cardiac muscles from a reduced supply of blood and nutrients, which may induce cardiac arrest. Studies on , a GHRP-2 analog, have posited that these peptides associate with a specific receptor. More specifically, it is hypothesized that the receptor CD36 may play a significant role in capturing oxidized low-density lipoprotein (OxLDL). This potential interaction between GHRP-2 and CD36 might reduce the cellular uptake of OxLDL, which is believed to contribute to the development of reduced blood supply and nutrients due to atherosclerosis. The research suggests that GHRP-2 may reduce interferon-gamma levels by 66% in cultured aortic smooth muscle cells, a test model for reduced blood and nutrient levels. While the introduction of GHRP-2 did not appear to have significantly changed the extent of atherosclerotic plaque coverage, researchers suggested that it may have lowered superoxide production in the blood vessels. Moreover, GHRP-2 reportedly reduced the gene expression of 12\/15-lipoxygenase by approximately 92% and also decreased the expressions of interferon-gamma and macrophage migration inhibitory factors. Observations in cultured aortic smooth muscle cells suggest that GHRP-2 might inhibit the production of peroxides induced by OxLDL, prevent the suppression of the IGF-I receptor, and possibly block apoptosis. In macrophages exposed to OxLDL, GHRP-2 was speculated to diminish lipid accumulation, further highlighting its potential antioxidative and protective actions against a reduced supply of blood and nutrients.\u003csup\u003e[6]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-2 and the Immune System\u003c\/strong\u003e\u003cbr\u003eGHRP-2 peptide researchers suggest the peptide may enhance the functions of the thymus, an organ considered to protect and mature certain cells of the immune system, especially the T lymphocytes.\u003csup\u003e[7]\u003c\/sup\u003e T lymphocytes are considered crucial for adaptive immunity and the organism’s capacity to combat complex infections. However, the efficacy of the thymus diminishes over time, which may lead to tissue damage and diminished immunity. In such cases, GHRP-2 appears to have the potential to rejuvenate the thymus, possibly promoting the number and diversity of T-cells and also boosting general immunity.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-2 and Pain Perception\u003c\/strong\u003e\u003cbr\u003eResearchers initially hypothesized that GHRP-2 may decrease pain associated with osteoarthritis in animal models through the stimulation of growth hormone production and the repair of damaged tissues. It has been suggested that GHRP-2 may induce pain relief before tissue repair, which may occur due to an action on opioid receptors. There are four known opioid receptors.\u003csup\u003e[8]\u003c\/sup\u003e Other compounds studied for their impact on opioid receptors may typically mediate a universal action on all four receptors. This generic mode of action may create challenges as the receptors may have differential and diverse functions. GHRP-2 appears to be a selective opioid receptor agonist, binding uniquely to the receptors implicated in pain perception, reward system linking, and sedation.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-2 and Sleep Cycles\u003c\/strong\u003e\u003cbr\u003eGHRP-2 has been suggested to influence sleep cycles. The peptide may increase the duration of stages 3 and 4 of the sleep cycles by up to 50%, as reported by researchers, as well as potentially improve the duration of REM sleep by approximately 20%.\u003csup\u003e[9]\u003c\/sup\u003e It may further diminish deviation in sleeping patterns from “normal sleep.” Research is ongoing.\u003c\/p\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eGHRP-2 and Appetite\u003c\/strong\u003e\u003cbr\u003eIt appears that by activating GHS-Rs in various parts of the nervous system, GHRP-2 may initiate a cascade of cellular processes, which may enhance the production of hunger-stimulating neuropeptides, specifically Neuropeptide Y (NPY) and Agouti-related peptide (AgRP). These peptides are considered vital for managing energy balance and appetite control. Concurrently, it is suggested that GHRP-2 may also reduce the release of melanocyte-stimulating hormone (α-MSH), an appetite-suppressant hormone, potentially leading to increased hunger and greater food consumption. Additionally, GHRP-2 might influence the mesolimbic reward system, a brain pathway important for regulating food cravings, possibly through the activation of GHSR-1a receptors. This mechanism may theoretically amplify appetite, potentially via the activation of cyclic adenosine monophosphate (cAMP) pathways, further implicating GHRP-2 in controlling feeding behavior and reward-driven eating. Research indicates that models tested with GHRP-2 consumed about 36% more food than control models, with a reported increase in food intake relative to body weight. Specifically, the energy intake per kilogram of weight appeared to be higher in the GHRP-2 group, measuring 136.0±13.0 kJ\/kg compared to 101.3±10.5 kJ\/kg in the control group. Additionally, increases in GH levels were observed in the GHRP-2 models compared to those given saline, with hormone levels measured as the area under the curve (AUC) reaching up to 5550±1090 μg\/L\/240 min versus 412±161 μg\/L\/240 min.\u003csup\u003e[10]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003ePhung LT, Inoue H, Nou V, Lee HG, Vega RA, Matsunaga N, Hidaka S, Kuwayama H, Hidari H. The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine. Domest Anim Endocrinol. 2000 Apr;18(3):279-91. . PMID: 10793268.\u003c\/li\u003e\n\u003cli\u003eSinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., \u0026amp; Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. \u003cem\u003eTranslational andrology and urology\u003c\/em\u003e, \u003cem\u003e9\u003c\/em\u003e(Suppl 2), S149–S159.\u003c\/li\u003e\n\u003cli\u003eVeldhuis, J. D., Keenan, D. M., Bailey, J. N., Adeniji, A. M., Miles, J. M., \u0026amp; Bowers, C. Y. (2009). Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies in men during experimental hypogonadal clamp. \u003cem\u003eThe Journal of clinical endocrinology and metabolism\u003c\/em\u003e, \u003cem\u003e94\u003c\/em\u003e(6), 2137–2143.\u003c\/li\u003e\n\u003cli\u003eBowers, C. Y., Granda, R., Mohan, S., Kuipers, J., Baylink, D., \u0026amp; Veldhuis, J. D. (2004). Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. \u003cem\u003eThe Journal of clinical endocrinology and metabolism\u003c\/em\u003e, \u003cem\u003e89\u003c\/em\u003e(5), 2290–2300.\u003c\/li\u003e\n\u003cli\u003eHu R, Wang Z, Peng Q, Zou H, Wang H, Yu X, Jing X, Wang Y, Cao B, Bao S, Zhang W, Zhao S, Ji H, Kong X, Niu Q. Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation. PLoS One. 2016 Feb 19;11(2):e0149461. . PMID: 26894743; PMCID: PMC4760683.\u003c\/li\u003e\n\u003cli\u003eTitterington JS, Sukhanov S, Higashi Y, Vaughn C, Bowers C, Delafontaine P. Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE-\/- mice but does not reduce atherosclerosis. Endocrinology. 2009 Dec;150(12):5478-87. . Epub 2009 Oct 9. PMID: 19819949; PMCID: PMC2795722.]\u003c\/li\u003e\n\u003cli\u003eChao YN, Sun D, Peng YC, Wu YL. Growth Hormone Releasing Peptide-2 Attenuation of Protein Kinase C-Induced Inflammation in Human Ovarian Granulosa Cells. Int J Mol Sci. 2016 Aug 19;17(8):1359. . PMID: 27548147; PMCID: PMC5000754.\u003c\/li\u003e\n\u003cli\u003eZeng P, Li S, Zheng YH, Liu FY, Wang JL, Zhang DL, Wei J. Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice. Peptides. 2014 May;55:103-9. \u003ca href=\"https:\/\/doi.org\/10.1016\/j.peptides.2014.02.013\" rel=\"noopener\" target=\"_blank\"\u003edoi: 10.1016\/j.peptides.2014.02.013\u003c\/a\u003e. Epub 2014 Mar 4. PMID: 24607724.\u003c\/li\u003e\n\u003cli\u003eSigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018 Jan;6(1):45-53. \u003ca href=\"https:\/\/doi.org\/10.1016\/j.sxmr.2017.02.004\" rel=\"noopener\" target=\"_blank\"\u003edoi: 10.1016\/j.sxmr.2017.02.004\u003c\/a\u003e. Epub 2017 Apr 8. PMID: 28400207; PMCID: PMC5632578.\u003c\/li\u003e\n\u003cli\u003eLaferrère, Blandine et al. “Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.” The Journal of clinical endocrinology and metabolism vol. 90,2 (2005): 611-4. \u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2824650\/\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2824650\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"vbni\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786428580157,"sku":"sku2194756132741","price":130.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/GHRP-2-10MG-2-1.webp?v=1780466143"},{"product_id":"ipamorelin-5mg","title":"(🔥 Fat loss) Ipamorelin Peptide - 5mg - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is Ipamorelin?\u003c\/p\u003e\n\u003cp\u003eIpamorelin is a highly selective GHRP:\u003c\/p\u003e\n\u003cp\u003e👉 Acts on ghrelin receptors\u003cbr\u003e👉 Triggers the pituitary gland to release GH\u003cbr\u003e👉 Has minimal impact on other hormones (compared to older-generation GHRPs)\u003c\/p\u003e\n\u003cp\u003e💪 Why is it popular in the fitness community?\u003c\/p\u003e\n\u003cp\u003eMany consider it a “cleaner GH booster.” Common goals include:\u003c\/p\u003e\n\u003cp\u003e🔥 Fat loss\u003cbr\u003e💪 Muscle-building support\u003cbr\u003e😴 Improved sleep quality\u003cbr\u003e🩹 Faster recovery\u003cbr\u003e⚡ Enhanced training adaptation\u003c\/p\u003e\n\u003cp\u003eIt is often combined with:\u003c\/p\u003e\n\u003cp\u003eMod GRF 1-29 (CJC-1295 NO DAC)\u003c\/p\u003e\n\u003cp\u003e(a classic stack).\u003c\/p\u003e\n\u003cp\u003e🧠 How It Works (Simplified Version)\u003c\/p\u003e\n\u003cp\u003eIpamorelin → Mimics “hunger signals” → Stimulates the pituitary gland:\u003c\/p\u003e\n\u003cp\u003e➡️ Secretes GH (growth hormone)\u003cbr\u003e➡️ Increases IGF-1 (indirectly)\u003c\/p\u003e\n\u003cp\u003eBut its key features are:\u003cbr\u003e✔ Minimal impact on cortisol\u003cbr\u003e✔ Minimal impact on prolactin\u003cbr\u003e✔ Minimal impact on appetite (milder than GHRP-6)\u003c\/p\u003e\n\u003cp\u003eTherefore, it is considered “cleaner.”\u003c\/p\u003e\n\u003cp\u003e😴 Most Common User Feedback (Based on Experience)\u003c\/p\u003e\n\u003cp\u003eMany users report:\u003c\/p\u003e\n\u003cp\u003eDeeper sleep 😴\u003cbr\u003eFaster recovery 💪\u003cbr\u003eReduced post-workout soreness 🩹\u003cbr\u003eTighter physique 🔥\u003cbr\u003eEnhanced sense of recovery overnight\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eIpamorelin Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eIpamorelin is a small pentapeptide that binds to the receptor of ghrelin\/growth hormone secretagogue (GHS), and is speculated to trigger the release of growth hormone via pituitary cells. Research has suggested the peptide to be selective in its mode of action.\u003csup\u003e[1]\u003c\/sup\u003e Ipamorelin, researchers report, does not appear to induce non-specific release of hormones like prolactin, thyroid-stimulating hormone, ACTH, luteinizing hormone, follicle-stimulating hormone, or cortisol. The high specificity of the peptide makes it an ideal model for the study of selectivity in receptor binding. It appears to function through interaction with cognate receptors on the target cell surface and mediates a cellular response. Ipamorelin may induce secretions from the pituitary gland, promoting growth in animal study models.\u003csup\u003e[2]\u003c\/sup\u003e In addition, it may not only trigger the expression of insulin-like growth factor-1(IGF-1) but may also inhibit the secretion of somatostatin. IGF-1 is considered to be the main anabolic mediator of growth hormone.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e38\u003c\/sub\u003eH\u003csub\u003e49\u003c\/sub\u003eN\u003csub\u003e9\u003c\/sub\u003eO\u003csub\u003e5\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 711.86 g\/mol\u003c\/p\u003e\n\u003cp class=\"grey-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Aib-His-D-2Nal-D-Phe-Lys-NH2\u003c\/p\u003e\n\u003ch3\u003eIpamorelin Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eIpamorelin and The Growth Hormone Secretagogue Receptors\u003c\/strong\u003e\u003cbr\u003eIpamorelin may be a growth hormone secretagogue receptor agonist stimulating endogenous growth hormone (hGH) release. More specifically, Ipamorelin is classified as a growth hormone secretagogue receptor 1a (GHS-R1a), also the receptor for the endogenous hormone ghrelin. Ghrelin is known as the hunger hormone and appears to also regulate hGH release by activating the GHS-R1a in pituitary cells.\u003csup\u003e[3] \u003c\/sup\u003eIn vitro experiments indicate that Ipamorelin's interaction with the Growth Hormone Secretagogue Receptor type 1a (GHS-R1a) might influence the somatotroph cells located in the anterior segment of the pituitary gland.\u003csup\u003e[4]\u003c\/sup\u003e This potential influence is thought to initiate a cascade of cellular signaling mechanisms. A key component in this signaling cascade is phospholipase C (PLC), a crucial enzyme that, according to some scientific hypotheses, may facilitate the production of inositol triphosphate (IP3) and diacylglycerol (DAG). The emergence of these secondary messenger molecules, particularly IP3, may stimulate the release of calcium ions (Ca2+) from the cell’s internal reserves. Concurrently, DAG is believed to potentially activate protein kinase C (PKC), a family of enzymes believed to play significant roles in various cellular functions. The hypothesized increase in calcium ion concentration within the cells, along with the potential activation of PKC, might lead to the exocytosis of vesicles that contain growth hormones. Research in clinical settings has suggested that exposure to Ipamorelin may cause notable increases in hGH synthesis by these pituitary cells. Specifically, Ipamorelin was observed to elevate growth hormone concentrations up to approximately 80 milli-international units per liter (mIU\/l), which is about 26.6 nanograms per milliliter (ng\/ml). Comparatively, when these increases are quantified against a placebo baseline of 1.31 mIU\/l or 0.4 ng\/ml, there seems to be an enhancement that might exceed 60 times the baseline levels.\u003csup\u003e[5]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eIpamorelin and the Musculoskeletal System\u003c\/strong\u003e\u003cbr\u003eLessened bone density over prolonged periods may lead to fracture. Ipamorelin studies in rats have observed that the peptide may prevent bone loss following prolonged glucocorticoid exposure, and also may induce up to a four-fold increase in bone formation.\u003csup\u003e[6]\u003c\/sup\u003e The researchers also reported that \u003cem\u003e“the decrease in muscle strength and bone formation found in GC-rats was counteracted by simultaneous administration of the growth hormone secretagogue.”\u003c\/em\u003e The peptide may potentially improve the bone mineral density of both existing and new bones. Further research suggests that the peptide may potentially activate osteoblasts—cells crucial for bone formation—through mechanisms mediated by hGH, which might enhance their proliferation, growth, and differentiation. In specific research, mouse models were subjected to exposure with either Ipamorelin or a control.\u003csup\u003e[7]\u003c\/sup\u003e The actions of Ipamorelin on the bone mineral density of these mice were diligently observed using real-time dual X-ray absorptiometry (DEXA), focusing on critical areas such as the femur and the L6 vertebra. Following the trial, the femur samples underwent additional analysis with mid-diaphyseal peripheral quantitative computed tomography (pQCT) scans. Early results suggested that the peptide might have contributed to an increase in body mass and possibly raised the bone mineral content (BMC) in the tibia and vertebrae, as indicated by DEXA measurements, compared to the control group. Moreover, data from pQCT scans tentatively indicated that the noted increase in cortical BMC might be related to an increase in the cross-sectional area of the bone.\u003csup\u003e[7]\u003c\/sup\u003e Additionally, Ipamorelin may possibly mitigate or reverse ancillary impacts such as muscle wasting and fat deposition in visceral organs.\u003csup\u003e[6]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eIpamorelin and Diabetes\u003c\/strong\u003e\u003cbr\u003eStudies in murine models of diabetes have suggested an efficacy of Ipamorelin in promoting insulin release from islet cells of the pancreas.\u003csup\u003e[8]\u003c\/sup\u003e Studies suggest that the peptide may mediate the release of insulin through the indirect excitation of calcium channels found on the islet cells. The hypothesized mechanism of Ipamorelin action highlights the limitations of type 2 diabetes and further study may be of interest to researchers.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eIpamorelin and Muscle Cells\u003c\/strong\u003e\u003cbr\u003eGlucocorticoids are the kind of corticosteroids that are commonly considered to exert an anti-inflammatory response in diverse conditions ranging from cancer to autoimmune disease. Ancillary action has also been reported. Over long durations, a higher concentration of hormones may be required to overcome physiological ancillary impacts. Researchers studying the action of Ipamorelin have suggested the peptide’s potential to decrease certain unintended impacts associated with glucocorticoid exposure. More specifically, studies on Ipamorelin posit that it may help to reestablish the nitrogen balance and reduce nitrogen wasting in the liver of rats exposed to glucocorticoids.\u003csup\u003e[9]\u003c\/sup\u003e The observed actions might tentatively be attributed to Ipamorelin's potential in modulating hGH and subsequently IGF-1 production. The research primarily examined the liver’s ability to generate urea-N (CUNS), which indicates the liver's efficacy in nitrogen metabolism. The analysis included a detailed examination of the levels of messenger RNA (mRNA) for enzymes involved in the liver's urea cycle. Additionally, the study explored overall nitrogen homeostasis and proposed theoretical distributions of nitrogen among various body organs. The results tentatively indicate that Ipamorelin may lead to an approximate 20% decrease in CUNS when compared to conditions of artificially induced catabolism. Moreover, there is a potential reduction in the expression of enzymes responsible for the urea cycle, a possible re-establishment of nitrogen equilibrium, and a hypothetical modification or enhancement of nitrogen levels in different tissues.\u003csup\u003e[9]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eIpamorelin as Ghrelin Receptor Probe\u003c\/strong\u003e\u003cbr\u003eThe peptide appears to bind strongly to the ghrelin receptor and may act as a selective agonist. Interestingly, the ghrelin receptor has been observed to increase cardiac failure and certain types of cancer, including carcinomas. Researchers have proposed studying Ipamorelin as a probe in positron emission tomography (PET) scans to help diagnose research models. \u003csup\u003e[10]\u003c\/sup\u003e Further research is ongoing.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eIpamorelin and Food Intake\u003c\/strong\u003e\u003cbr\u003eIpamorelin has been studied in multiple proof-of-concept studies to determine its potential to reduce Post Operative Ilius (POI). It was found to shorten the time of uptake of the first meal by about 12 hours.\u003csup\u003e[11]\u003c\/sup\u003e The researchers concluded that \u003cem\u003e“Ipamorelin accelerates gastric emptying in a rodent model of postoperative ileus through the stimulation of gastric contractility by activating a ghrelin receptor-mediated mechanism involving cholinergic excitatory neurons.”\u003c\/em\u003e Some of the research observations in this and other studies suggest that residual radiolabeled food remaining in the stomach of rats with POI was less after the influence of Ipamorelin, even when compared to rats without POI. Thus it may be posited that Ipamorelin may speed up the passage of food through the digestive system, following food intake.\u003cbr\u003e\u003cbr\u003eOn top of that, some researchers suggest that Ipamorelin may also influence the total intake of food through its potential action via the ghrelin receptors in the nervous system.\u003csup\u003e[12] \u003c\/sup\u003eGhrelin receptors are known for their role in controlling appetite, and their activation may lead to heightened hunger cues, potentially resulting in increased body mass. It has been observed in some experimental setups that animal subjects exposed to Ipamorelin experienced an approximate 15% increase in body weight. In these studies, the augmented body weight might correlate with an increase in adipose tissue mass relative to overall body mass. Adipose tissue, or body fat, contributes to energy storage and hormone regulation. Dual-energy X-ray absorptiometry (DEXA) scans, which measure bone mineral density and body composition, might potentially exhibit an elevated body fat percentage as a result of Ipamorelin. Consequently the researchers posited that \"\u003cem\u003eGHSs increase body fat by GH-independent mechanisms that may include increased feeding.\u003c\/em\u003e”\u003csup\u003e[12]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"padding-bottom: 5px !important; margin-bottom: 25px !important;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eRaun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. . PMID: 9849822.\u003c\/li\u003e\n\u003cli\u003eJohansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106-13. . PMID: 10373343.\u003c\/li\u003e\n\u003cli\u003eSinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037\/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996\u003c\/li\u003e\n\u003cli\u003eJiménez-Reina, L., Cañete, R., de la Torre, M. J., \u0026amp; Bernal, G. (2002). Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 17(3), 707–714.\u003c\/li\u003e\n\u003cli\u003eGobburu, J.V.S., Agersø, H., Jusko, W.J. et al. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharm Res 16, 1412–1416 (1999).\u003c\/li\u003e\n\u003cli\u003eAndersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001 Oct;11(5):266-72. . PMID: 11735244.\u003c\/li\u003e\n\u003cli\u003eSvensson, J., Lall, S., Dickson, S. L., Bengtsson, B. A., Rømer, J., Ahnfelt-Rønne, I., Ohlsson, C., \u0026amp; Jansson, J. O. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. \u003cem\u003eThe Journal of endocrinology\u003c\/em\u003e, \u003cem\u003e165\u003c\/em\u003e(3), 569–577.\u003c\/li\u003e\n\u003cli\u003eAdeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinol Lett. 2004 Dec;25(6):403-6. PMID: 15665799.\u003c\/li\u003e\n\u003cli\u003eAagaard, N. K., Grøfte, T., Greisen, J., Malmlöf, K., Johansen, P. B., Grønbaek, H., Ørskov, H., Tygstrup, N., \u0026amp; Vilstrup, H. (2009). Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. \u003cem\u003eGrowth hormone \u0026amp; IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society\u003c\/em\u003e, \u003cem\u003e19\u003c\/em\u003e(5), 426–431.\u003c\/li\u003e\n\u003cli\u003eChilds MD, Luyt LG. A Decade’s Progress in the Development of Molecular Imaging Agents Targeting the Growth Hormone Secretagogue Receptor. Mol Imaging. 2020 Jan-Dec;19:1536012120952623. . PMID: 33104445; PMCID: PMC8865914.\u003c\/li\u003e\n\u003cli\u003eGreenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012 Oct 19;4:149-55. . PMID: 27186127; PMCID: PMC4863553.\u003c\/li\u003e\n\u003cli\u003eLall, S., Tung, L. Y., Ohlsson, C., Jansson, J. O., \u0026amp; Dickson, S. L. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and biophysical research communications, 280(1), 132–138.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786428612925,"sku":"sku2194756137677","price":150.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/IPAMORELIN-5MG-2-1.webp?v=1780466144"},{"product_id":"mod-grf-1-29-5mg-cjc-1295-no-dac","title":"(🔥 Fat loss+💪 Recovery) Mod GRF 1-29 (CJC-1295 NO DAC) (5mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003ch3\u003e🔥 Fat loss\u003cbr\u003e💪 Recovery\u003cbr\u003e😴 Improved sleep\u003cbr\u003e🩹 Post-workout recovery\u003cbr\u003e📈 Increased IGF-1\u003cbr\u003eDeeper sleep\u003cbr\u003eGreater sense of recovery\u003cbr\u003eBetter post-workout condition\u003cbr\u003eIncreased night sweats\u003cbr\u003eChanges in hunger\u003c\/h3\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eModified GRF (1-29) Peptide\u003c\/h3\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back-d\"\u003eModified GRF (1-29), or Mod GRF (1-29), is a synthetic peptide that is a modified fragment of the endogenously occurring growth hormone-releasing hormone (GHRH). It was first developed in the 1980s when studies indicated that the first 29 amino acids of GHRH may possess all of the biological potential associated with the full-length 44 GHRH molecule.\u003csup\u003e[1]\u003c\/sup\u003e\u003cbr\u003e\u003cbr\u003eThis discovery led to the development of a truncated version called GRF (1-29), also referred to as by researchers. Mod GRF (1-29) introduces specific modifications to support the peptide's stability and efficacy. Four amino acids in the sequence are substituted at positions 2, 8, 15, and 27.\u003csup\u003e[2]\u003c\/sup\u003e Here is what some researchers believe about these modifications:\u003cbr\u003e- Position 2: The amino acid alanine is replaced with its mirror image, D-alanine. This substitution aims to increase resistance to enzymatic degradation, thereby improving the peptide's stability.\u003cbr\u003e- Position 8: Asparagine is substituted with lysine, an amino acid with a positively charged side chain. This change may support the peptide's binding affinity to GHRH receptors, potentially increasing its biological activity.\u003cbr\u003e- Position 15: Histidine is replaced with D-phenylalanine, another D-amino acid. This modification is intended to protect the peptide from further enzymatic breakdown.\u003cbr\u003e- Position 27: Cysteine is substituted with N-methylglycine, also referred to as sarcosine. This alteration may extend the peptide's half-life by mitigating enzymatic cleavage.\u003cbr\u003e\u003cbr\u003eThese modifications collectively aim to produce a peptide with increased stability, a longer half-life, and better-supported interaction with GHRH receptors compared to the original GRF (1-29). Modified GRF (1-29) is structurally identical to CJC-1295 without DAC. The DAC in CJC-1295 serves to modify its pharmacokinetic properties.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 3367.95 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e152\u003c\/sub\u003eH\u003csub\u003e252\u003c\/sub\u003eN\u003csub\u003e44\u003c\/sub\u003eO\u003csub\u003e42\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back\"\u003e\u003cstrong\u003eSynonyms:\u003c\/strong\u003e Mod GRF (1-29)\u003c\/p\u003e\n\u003ch3\u003eMod GRF (1-29) Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eModified GRF 1-29 and Somatotroph Cells\u003c\/strong\u003e\u003cbr\u003eModified GRF (1-29) is believed to stimulate the release of growth hormone by binding to specific receptors referred to as growth hormone-releasing hormone (GHRH) receptors on somatotroph cells in the anterior pituitary gland. These somatotroph cells are posited to be responsible for producing and secreting growth hormone. Research suggests that when Modified GRF (1-29) attaches to these receptors, it may cause the receptors to change in shape, which initiates a series of intracellular signaling events.\u003csup\u003e[3]\u003c\/sup\u003e For example, this receptor activation may lead to the stimulation of G-proteins located on the inner surface of the cell membrane. Activated G-proteins may then promote the production of secondary messenger molecules within the cell, such as cyclic adenosine monophosphate (cAMP) and inositol triphosphate (IP3).\u003cbr\u003e\u003cbr\u003eAn increase in cAMP levels may activate protein kinases—enzymes that add phosphate groups to specific target proteins. These phosphorylated proteins may include transcription factors that move into the cell nucleus and influence the transcription of genes involved in the synthesis and secretion of growth hormone. Consequently, somatotroph cells accumulate vesicles containing growth hormone molecules. As a result of these molecular events, the vesicles containing growth hormone may fuse with the cell membrane of the somatotroph cells, which allows the release of the hormone.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eModified GRF 1-29 and Growth Hormone Synthesis\u003c\/strong\u003e\u003cbr\u003eScientific investigations have focused on partially modified versions of Mod GRF 1-29 and its potential magnitude of the influence on growth hormone synthesis. In one notable study, researchers observed a significant increase in growth hormone secretion by somatotroph cells within the anterior pituitary gland after exposure to the Mod GRF 1-29 analog. Specifically, there was an approximate 70% to 107% rise in the average amount of growth hormone released over 12 hours.\u003csup\u003e[4]\u003c\/sup\u003e This substantial support suggests that the modified peptides have a pronounced potential to stimulate growth hormone production.\u003cbr\u003e\u003cbr\u003eDespite these findings, it remains unclear whether the heightened levels of growth hormone are maintained over time or if they represent a transient spike. Additional research has provided data that Mod GRF 1-29 may elevate the total RNA content in the pituitary gland and increase the levels of growth hormone messenger RNA (mRNA).\u003csup\u003e[5]\u003c\/sup\u003e This suggests a possible proliferation of somatotroph cells. The researchers proposed that the peptide-induced an increase in both total pituitary RNA and growth hormone mRNA levels, implying that somatotroph cell numbers had expanded.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eModified GRF 1-29 and Anabolic Potential\u003c\/strong\u003e\u003cbr\u003eBy promoting potential growth hormone secretion, Mod GRF 1-29 may activate anabolic signaling pathways in experimental models. Studies have suggested that the exposure of research models to Mod GRF 1-29 in laboratory settings might lead to increased levels of insulin-like growth factor 1 (IGF-1), a critical mediator of growth hormone’s anabolic potential.\u003csup\u003e[4]\u003c\/sup\u003e IGF-1 is mainly produced in liver cells but is also synthesized in various other tissues under the influence of growth hormone. Research indicates that IGF-1 levels may rise by approximately 28% following administration of Mod GRF 1-29.\u003cbr\u003e\u003cbr\u003eThe elevation in IGF-1 is associated with increased thickness of dermal tissue, potentially due to the anabolic actions of growth hormone and IGF-1 on collagen-producing cells like fibroblasts. Additionally, some data supports scientists' observations of significant hypertrophy of muscular tissue in laboratory settings. Some of these trials resulted in an average gain of lean muscular tissue mass of about 2.77 lbs. These observations suggest that Mod GRF 1-29 may support anabolic processes in experimental settings.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eModified GRF 1-29 and Cardiac Function\u003c\/strong\u003e\u003cbr\u003eResearch in rodent models has suggested that GHRH analogs similar to Mod GRF 1-29 may support the capacity of the heart to pump blood, even following events that are typically believed to contribute to cardiac dysfunction.\u003csup\u003e[6]\u003c\/sup\u003e More specifically, the researchers comment that \u003cem\u003e“Various studies [suggest] that GHRH agonists promote repair of cardiac tissue, producing improvement of ejection fraction and reduction of infarct size in rats, reduction of infarct scar in swine, and attenuation of cardiac hypertrophy in mice.” \u003c\/em\u003eThese positive actions are believed to occur through activation of the GHRH receptor. As such, these actions may be inhibited by substances that block this receptor.\u003cbr\u003e\u003cbr\u003eThe protective mechanisms may involve the stimulation of intracellular signaling pathways, including the adenylyl cyclase\/cyclic AMP\/protein kinase A (PKA) pathway, as well as the activation of MAPK ERK1\/2 and phosphatidylinositol 3-kinase\/Akt pathways. Additionally, GHRH analogs may counteract artificially induced increases in pro-apoptotic signaling within these cells. Research also suggests that GHRH analogs may oppose experimentally induced hypertrophy of cardiomyocytes, whether they are adult heart cells or derived from induced pluripotent stem cells. Specifically, analogs may inhibit the expression of genes associated with hypertrophy and modulate related signaling pathways. This includes supporting signaling through Gαs\/cAMP\/PKA and promoting the phosphorylation of phospholamban at the serine 16 position\/ Researchers believe this action may have anti-hypertrophic potential.\u003cbr\u003e\u003cbr\u003eImportantly, the anti-hypertrophic properties of GHRH analogs involve blocking the expression of the exchange protein directly activated by cAMP1 (Epac1) induced by phenylephrine. This protein plays a significant role in the development of hypertrophy. Despite these findings, along with other GHRH analogs, it is currently unclear whether Mod GRF 1-29 shares this cardioprotective and anti-hypertrophic potential.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eModified GRF 1-29 and Thyroid, Growth Hormone\u003c\/strong\u003e\u003cbr\u003eMalfunctioning of the thyroid gland is often associated with concomitant issues in growth hormone release. Research studies have suggested that research models of hyperthyroidism under the influence of thyroid replacement hormone may indicate stronger reactions to GRF, providing a possible link between thyroid hormone and growth hormone.\u003csup\u003e[7]\u003c\/sup\u003e The scientists commented the following: \u003cem\u003e“These data indicate that thyroid hormone […] enhances the responsiveness of the somatotroph to GRF 1-29.”\u003c\/em\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"grey-back-d\"\u003e\u003cstrong\u003eModified GRF 1-29 and the Intestine\u003c\/strong\u003e\u003cbr\u003eResearch in monkeys suggested that Modified GRF 1-29 may bind with receptors to potentially support bowel motility. Better-supported bowel movement is considered to be crucial in inflammatory bowel diseases. The peptide appears to interact with VIPC1, present on the smooth muscle of the reproductive, gastrointestinal, and urinary systems.\u003csup\u003e[8][9]\u003c\/sup\u003e These conditions may potentially trigger a great deal of morbidity.\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv style=\"margin-bottom: 30px;\" class=\"white-back-d\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eCen, L. P., Ng, T. K., Chu, W. K., \u0026amp; Pang, C. P. (2022). Growth hormone-releasing hormone receptor signaling in experimental ocular inflammation and neuroprotection. Neural regeneration research, 17(12), 2643–2648.\u003c\/li\u003e\n\u003cli\u003eJetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., van Wyk, P., Pham, K., \u0026amp; Bridon, D. P. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052–3058.\u003c\/li\u003e\n\u003cli\u003eZhou, F., Zhang, H., Cong, Z., Zhao, L. H., Zhou, Q., Mao, C., Cheng, X., Shen, D. D., Cai, X., Ma, C., Wang, Y., Dai, A., Zhou, Y., Sun, W., Zhao, F., Zhao, S., Jiang, H., Jiang, Y., Yang, D., Eric Xu, H., … Wang, M. W. (2020). Structural basis for activation of the growth hormone-releasing hormone receptor. Nature communications, 11(1), 5205.\u003c\/li\u003e\n\u003cli\u003eKhorram, O., Laughlin, G. A., \u0026amp; Yen, S. S. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism, 82(5), 1472–1479.\u003c\/li\u003e\n\u003cli\u003eAlba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. . Epub 2006 Jul 5. PMID: 16822960.\u003c\/li\u003e\n\u003cli\u003eSchally, A. V., Zhang, X., Cai, R., Hare, J. M., Granata, R., \u0026amp; Bartoli, M. (2019). Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists. Endocrinology, 160(7), 1600–1612.\u003c\/li\u003e\n\u003cli\u003eValcavi, R., Jordan, V., Dieguez, C., John, R., Manicardi, E., Portioli, I., Rodriguez-Arnao, M. D., Gomez-Pan, A., Hall, R., \u0026amp; Scanlon, M. F. (1986). Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine. Clinical endocrinology, 24(6), 693–698.\u003c\/li\u003e\n\u003cli\u003eIto, T., Igarashi, H., Pradhan, T. K., Hou, W., Mantey, S. A., Taylor, J. E., Murphy, W. A., Coy, D. H., \u0026amp; Jensen, R. T. (2001). GI side-effects of a possible therapeutic GRF analog in monkeys are likely due to VIP receptor agonist activity. Peptides, 22(7), 1139–1151.\u003c\/li\u003e\n\u003cli\u003eWaelbroeck, M., Robberecht, P., Coy, D. H., Camus, J. C., De Neef, P., \u0026amp; Christophe, J. (1985). Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology, 116(6), 2643–2649. \u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.1210\/endo-116-6-2643\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1210\/endo-116-6-2643\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786428776765,"sku":"sku2194756141379","price":150.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/Mod-GRF-5MG-1.webp?v=1780466146"},{"product_id":"dsip-5mg","title":"(🧠 Improves sleep structure) DSIP (Delta Sleep-Inducing Peptide) (5mg) -10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🌙 1️⃣ Improves sleep structure\u003c\/p\u003e\n\u003cp\u003eSome studies and user reports suggest that DSIP may:\u003c\/p\u003e\n\u003cp\u003eIncrease deep sleep (delta wave sleep)\u003cbr\u003eReduce the time it takes to fall asleep\u003cbr\u003eEnhance the feeling of sleep recovery\u003cbr\u003e🧠 2️⃣ Anti-stress effects\u003c\/p\u003e\n\u003cp\u003eIn some animal studies:\u003c\/p\u003e\n\u003cp\u003eReduced stress response\u003cbr\u003eRegulation of the HPA axis\u003c\/p\u003e\n\u003cp\u003eIt is therefore classified as:\u003cbr\u003e👉 “Anti-stress peptide”\u003c\/p\u003e\n\u003cp\u003e⚡ 3️⃣ Neuroregulation\u003c\/p\u003e\n\u003cp\u003eMay affect:\u003c\/p\u003e\n\u003cp\u003eThe GABA system\u003cbr\u003eCircadian rhythms\u003cbr\u003eMelatonin-related pathways (speculated)\u003c\/p\u003e\n\u003ch2\u003eDSIP (Delta Sleep-Inducing Peptide)\u003c\/h2\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eDSIP is a naturally occurring neuropeptide made of 9 amino acids that may influence diverse endocrine and physiological pathways involved in the central nervous system. DSIP is of key interest as it was developed to help combat oxidative stress and normalize myocardial contractility. The peptide is considered a potential research candidate in studies of major depressive disorder. Delta sleep-inducing peptide (DSIP) is a naturally occurring peptide of short length. The molecule’s name came about due to researchers’ speculation of its potential to induce sleep in rabbits and because it was first isolated from the brains of rats during slow-wave sleep (in 1977).\u003csup\u003e[1]\u003c\/sup\u003e Slow Wave Sleep (SWS), often referred to as deep sleep, is considered a pivotal phase within the overall sleep architecture, which is composed of non-rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep. Sleep architecture itself exhibits a cyclical pattern, typically oscillating between NREM and REM phases multiple times throughout the duration of total sleep. Predominantly classified under the NREM sleep category, SWS is characterized by its distinctive low-frequency, high-amplitude delta brainwaves, as observed in electroencephalogram (EEG) recordings. The sleep cycle initiates with NREM sleep, which is further divided into three phases: N1, N2, and N3. The initial stages, N1 and N2, represent lighter sleep phases, whereas N3, equated with SWS, signifies the deepest phase of sleep. Upon completion of the deep sleep phase, the cycle transitions to REM sleep, marked by heightened brain activity and dreaming. Researchers have gradually explored its function in different endocrine and physiological roles. In addition to its potential influence on sleep patterns, DSIP appears to influence levels of corticotropin, inhibit the production of somatostatin, reduce stress hormone secretion, maintain normal blood pressure, alter sleep patterns and also may impact pain perception.\u003csup\u003e[2]\u003c\/sup\u003e\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eOther Known Titles: \u003c\/strong\u003eDelta Sleep-Inducing Peptide\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e35\u003c\/sub\u003eH\u003csub\u003e48\u003c\/sub\u003eN\u003csub\u003e10\u003c\/sub\u003eO\u003csub\u003e15\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 848.82 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu\u003c\/p\u003e\n\u003ch3\u003eDSIP Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eDSIP and Potential Mechanisms\u003c\/strong\u003e\u003cbr\u003eDSIP is purported to influence the structure and quality of sleep through its interactions with the central nervous system. It is speculated that DSIP may shorten the onset of sleep and enhance sleep quality by modulating the activity of several neurotransmitters in the brain. However, the precise mechanisms and pathways by which DSIP operates remain unclear.\u003cbr\u003e\u003cbr\u003eOne hypothesis suggests that DSIP targets specific receptors that play a pivotal role in its actions. These receptors include the N-methyl-D-aspartate (NMDA) receptors and gamma-aminobutyric acid (GABA) receptors. NMDA receptors are associated with glutamate, an essential excitatory neurotransmitter in the brain, while GABA receptors are linked to inhibitory neurotransmission, which is considered crucial for reducing neural activity and inducing a relaxed state. Experimental studies on murine models indicate that DSIP may enhance the inhibitory actions of GABA, thereby reducing neural excitability and facilitating the onset of sleep.\u003csup\u003e[3]\u003c\/sup\u003e These studies also suggest that DSIP could attenuate the excitatory actions of NMDA receptors, further contributing to its sleep-promoting properties.\u003csup\u003e[4]\u003c\/sup\u003e\u003cbr\u003e\u003cbr\u003eMoreover, research points to a possible interaction between DSIP and opioid receptors in the brain, which may play a role in the peptide’s ability to regulate sleep and mitigate withdrawal symptoms, underscoring its intricate role in neural signaling pathways.\u003csup\u003e[5,6]\u003c\/sup\u003e Additionally, the alpha 1-adrenergic receptor, located in the pineal gland, has emerged as a potential target in DSIP-related research. Preliminary findings suggest that DSIP’s modulation of this receptor may influence sleep patterns and possibly aid in stress management, given the receptor’s significant consideration in stress response processes. These insights emphasize the complex and varied potential ways in which DSIP might impact sleep and stress, though further investigation is essential to fully delineate its biological functions and research potential.\u003csup\u003e[7]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eDSIP and Stress\u003c\/strong\u003e\u003cbr\u003eIn one scientific investigation, the action of DSIP on murine models subjected to controlled stress scenarios has been explored.\u003csup\u003e[4]\u003c\/sup\u003e This inquiry largely examined the variations in levels of substance P, beta-endorphin, and corticosterone—key biomarkers relevant for decoding the stress response and the potential regulatory actions of DSIP. Preliminary results indicated that exposure to DSIP may lead to significant alterations in the concentrations of these indicators, which may imply a role in modulating stress. Specifically, an initial reduction followed by a substantial increase in beta-endorphin levels was observed, a pattern that suggests DSIP’s impact on the opioidergic system, potentially playing a role in stress alleviation or adaptation processes. Furthermore, a reduction in corticosterone levels was recorded soon after exposure to DSIP. These observations suggest that the actions of DSIP on substance P, beta-endorphin, and corticosterone are indicative of a wider array of biochemical modifications, proposing that DSIP may trigger a cascade of molecular events that may facilitate its stress-modulatory functions.\u003csup\u003e[4]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eDSIP and Sleep Activity\u003c\/strong\u003e\u003cbr\u003eExtensive research has been conducted to establish the connection between the peptide and sleep. Despite the initial findings in rabbits, it was tough to establish the pattern in which DSIP may affect sleep. In some findings, it did not appear to influence sleep at all.\u003csup\u003e[8]\u003c\/sup\u003e In some, the peptide favored Slow Wave (SWS) paradoxical sleep. Interestingly, there were other groups whose research noted that the molecule appeared to cause arousal in the first hour of sleep, followed by sedation in the second hour of sleep. In totality, it was observed that DSIP may help to bring about a normalized sleeping pattern and eliminate possible dysfunction in sleep cycles. Possibly, the most relevant work regarding the regulation of sleep by DSIP has been conducted in the backdrop of insomnia.\u003csup\u003e[9]\u003c\/sup\u003e The results have suggested that the peptide may potentially improve sleep patterns in animal research models. Other studies have further highlighted that it may improve sleep structure and decrease sleep latency in chronic insomnia. However, although polysomnographic studies have suggested that DSIP may induce statistically significant improvement in sleep, sufficient research material is still weak.\u003csup\u003e[10][11]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eDSIP and Depression\u003c\/strong\u003e\u003cbr\u003eScientists have investigated the role of DSIP in altering mitochondrial activity under hypoxic conditions. The peptide was observed to have the potential to prevent changes in monoamine oxidase type A (MAO-A) and serotonin levels. This finding suggests that the peptide may have an impact on the course of depression.\u003csup\u003e[12]\u003c\/sup\u003e DSIP abundance has been observed to be lower in cerebrospinal fluid of research models of depression compared to the same controls. Sleep and depression are considered to be closely related; a molecule that regulates sleep may likely have action in depressive behavior. However, there has been no scientific approach that aims to balance the DSIP level to date. It has, however, been linked to alterations in the hypothalamic-pituitary-adrenal axis.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eDSIP and Metabolism\u003c\/strong\u003e\u003cbr\u003eStudies on rat models have highlighted that Delta Sleep-Inducing Peptide may help change stress-related metabolic fluctuations,\u003csup\u003e[13]\u003c\/sup\u003e which may induce mitochondria to switch from oxygen-dependent to oxygen-independent respiration. The latter is considered less efficient and may bring about toxic metabolic byproduct formation. Delta Sleep-Inducing Peptide may promote oxidative phosphorylation even in hypoxic conditions and may thus be impactful in stroke or heart attack. It appears to assist normal metabolic function and thus may reverse the damage caused by oxygen deprivation, protecting tissues until blood flow is restored. Delta Sleep-Inducing Peptide research suggests that DSIP may host anti-oxidant characteristics, potentially preventing free radical formation.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eDSIP and Withdrawal, Addiction\u003c\/strong\u003e\u003cbr\u003eDSIP research noted improvement in animal research models of withdrawal during ethanol and opiate detoxification. Study findings resulted in 97% and 87% recovery rates for ethanol and opiate withdrawals, respectively. Opiate withdrawal may require DSIP exposure for a longer tenure, as this addiction is considered more resistant to alteration.\u003csup\u003e[6]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eDSIP and Cancer Cells\u003c\/strong\u003e\u003cbr\u003eResearchers have explored the possibility of mitigating the onset of cancer cell proliferation through exposure to DSIP. Initial research on DSIP has hypothesized that its potential impact on sleep may have downstream impacts as a cancer cell-mitigating agent. This is considered to be possible through sleep-boosted immunity, which may seek out and eliminate rogue cells before they metastasize. Studies have observed that female mice exposed to DSIP for 5 consecutive days of every month starting at the age of 3 months till their death exhibited a 2.6-fold reduction in the development of tumors compared to parallel control groups. There has also been a corresponding 22.6% reduction in the frequency of chromosomal defects in the bone marrow of the DSIP-exposed mice. Research in this area is preliminary, and is still ongoing.\u003csup\u003e[13]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eDSIP and Muscle Cells\u003c\/strong\u003e\u003cbr\u003eDelta Sleep-Inducing Peptide was first discovered in the brains of rabbits during slow-wave sleep and has since been involved with sleep research and central nervous system-mediated control of sleep-wake cycles. Not much is known about DSIP synthesis. High Levels of Delta Sleep-Inducing Peptide present in both CNS tissues and peripheral tissues suggest that the peptide may be produced outside CNS, and its primary function might not be the regulation of sleep. Delta Sleep-Inducing Peptide is also considered a hypothalamic hormone that may influence more than just sleep. In one study, DSIP was suggested to inhibit somatostatin, a protein produced in muscle cells that inhibits muscle growth.\u003csup\u003e[9]\u003c\/sup\u003e By inhibiting somatostatin, DSIP may potentially contribute to hypertrophy and hyperplasia in skeletal muscle. Such direct inhibitory action appears surprising for a peptide thought to be primarily involved in sleep promotion. This has triggered speculation that the peptide might have a larger and more universal role in influencing physiology.\u003cbr\u003e\u003cbr\u003eIn animal models, Delta Sleep-Inducing Peptide has been suggested to regulate blood pressure, heart rate, thermogenesis, and the lymphokine system. Some of these processes appear before any signs of sleep, indicating that Delta Sleep-Inducing Peptide may actually play a role in altering physiology to prepare the organism for sleep onset.\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\n\u003col\u003e\n\u003cli\u003eMonnier M, Dudler L, Gächter R, Maier PF, Tobler HJ, Schoenenberger GA. The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide. Experientia. 1977 Apr 15;33(4):548-52. . PMID: 862769.\u003c\/li\u003e\n\u003cli\u003eKoval’zon VM. DSIP: peptid sna ili neizvestnyĭ gormon gipotalamusa [DSIP: the sleep peptide or an unknown hypothalamic hormone?]. Zh Evol Biokhim Fiziol. 1994 Mar-Apr;30(2):310-9. Russian. PMID: 7817664.\u003c\/li\u003e\n\u003cli\u003eGrigor'ev VV, Ivanova TA, Kustova EA, Petrova LN, Serkova TP, Bachurin SO. Effects of delta sleep-inducing peptide on pre- and postsynaptic glutamate and postsynaptic GABA receptors in neurons of the cortex, hippocampus, and cerebellum in rats. Bull Exp Biol Med. 2006 Aug;142(2):186-8. English, Russian. doi: 10.1007\/s10517-006-0323-9. PMID: 17369935\u003c\/li\u003e\n\u003cli\u003eSudakov KV, Umriukhin PE, Rayevsky KS. Delta-sleep inducing peptide and neuronal activity after glutamate microiontophoresis: the role of NMDA-receptors. Pathophysiology. 2004 Oct;11(2):81-86.\u003c\/li\u003e\n\u003cli\u003eNakamura A, Nakashima M, Sakai K, Niwa M, Nozaki M, Shiomi H. Delta-sleep-inducing peptide (DSIP) stimulates the release of immunoreactive Met-enkephalin from rat lower brainstem slices in vitro. Brain Res. 1989 Feb 27;481(1):165-8. doi: 10.1016\/0006-8993(89)90498-8. PMID: 2706459.\u003c\/li\u003e\n\u003cli\u003eDick P, Grandjean ME, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology. 1983;10(4):205-8. doi: 10.1159\/000118012. PMID: 6328354.\u003c\/li\u003e\n\u003cli\u003eGraf MV, Schoenenberger GA. Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor. J Neurochem. 1987 Apr;48(4):1252-7. doi: 10.1111\/j.1471-4159.1987.tb05654.x. PMID: 3029331.\u003c\/li\u003e\n\u003cli\u003eNakagaki K, Ebihara S, Usui S, Honda Y, Takahashi Y, Kato N. [Effects of intraventricular injection of anti-DSIP serum on sleep in rats]. Yakubutsu Seishin Kodo. 1986 Jun;6(2):259-65. Japanese. PMID: 3776352.\u003c\/li\u003e\n\u003cli\u003eIyer KS, Marks GA, Kastin AJ, McCann SM. Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat. Proc Natl Acad Sci U S A. 1988 May;85(10):3653-6. . PMID: 3368469; PMCID: PMC280272.\u003c\/li\u003e\n\u003cli\u003eSchneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981 Aug;19(8):341-5. PMID: 6895513.\u003c\/li\u003e\n\u003cli\u003eLarbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984;23(5):372-85. . PMID: 6548970.\u003c\/li\u003e\n\u003cli\u003eLesch KP, Widerlöv E, Ekman R, Laux G, Schulte HM, Pfüller H, Beckmann H. Delta sleep-inducing peptide response to human corticotropin-releasing hormone (CRH) in major depressive disorder. Comparison with CRH-induced corticotropin and cortisol secretion. Biol Psychiatry. 1988 Jun;24(2):162-72. . PMID: 2839244.\u003c\/li\u003e\n\u003cli\u003eKhvatova EM, Samartzev VN, Zagoskin PP, Prudchenko IA, Mikhaleva II. Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia. Peptides. 2003 Feb;24(2):307-11. . PMID: 12668217.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786428907837,"sku":"sku2194756130273","price":100.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/DSIP-5MG-1-1.webp?v=1780466147"},{"product_id":"receptor-grade-igf-1-lr3-100mcg","title":"(💪 Rapid muscle gain) Receptor Grade IGF-1 LR3 (100mcg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is IGF-1 LR3?\u003c\/p\u003e\n\u003cp\u003eIGF-1 LR3 (Long R3 IGF-1) is a modified version of IGF-1:\u003c\/p\u003e\n\u003cp\u003eIts characteristics include:\u003c\/p\u003e\n\u003cp\u003eExtended half-life (longer than natural IGF-1)\u003cbr\u003eStronger receptor binding affinity\u003cbr\u003eHigher biological activity\u003c\/p\u003e\n\u003cp\u003e“Receptor Grade” is typically a marketing term meaning:\u003cbr\u003e👉 “High-purity \/ strong receptor-binding version” (though not an official medical classification)\u003c\/p\u003e\n\u003cp\u003e💪 Why Does the Fitness Community Consider It “Powerful”?\u003c\/p\u003e\n\u003cp\u003eIts core mechanism of action is:\u003c\/p\u003e\n\u003cp\u003e➡️ Enhances cellular uptake of glucose and amino acids\u003cbr\u003e➡️ Promotes protein synthesis\u003cbr\u003e➡️ Accelerates muscle recovery\u003c\/p\u003e\n\u003cp\u003eTherefore, it is marketed for:\u003c\/p\u003e\n\u003cp\u003e🔥 Rapid muscle gain\u003cbr\u003e💪 Powerful recovery capabilities\u003cbr\u003e📈 Improved nutrient utilization efficiency\u003cbr\u003e🩹 Accelerated post-workout repair\u003cbr\u003e🧠 Its relationship with GH (Growth Hormone)\u003c\/p\u003e\n\u003cp\u003eMany people misunderstand:\u003c\/p\u003e\n\u003cp\u003eHGH    IGF-1 LR3\u003cbr\u003eUpstream hormone    Downstream signaling factor\u003cbr\u003eStimulates the liver to produce IGF-1    Acts directly on tissues\u003cbr\u003eIndirect action    More direct cellular action\u003c\/p\u003e\n\u003cp\u003e👉 Simply put:\u003cbr\u003eGH is the “conductor,” and IGF-1 is the “performer.”\u003c\/p\u003e\n\u003cp\u003e⚡ What makes “LR3” special?\u003c\/p\u003e\n\u003cp\u003eAfter modification, LR3:\u003c\/p\u003e\n\u003cp\u003eHas a longer half-life (around 20+ hours)\u003cbr\u003eIs less susceptible to inhibition by IGF-binding protein\u003cbr\u003ePenetrates tissues more easily to exert its effects\u003c\/p\u003e\n\u003cp\u003eTherefore, it is more “potent” than natural IGF-1.\u003c\/p\u003e\n\u003cp\u003e💪 Common User Feedback (from forums)\u003c\/p\u003e\n\u003cp\u003eCommon observations in the fitness community:\u003c\/p\u003e\n\u003cp\u003eEnhanced muscle “fullness”\u003cbr\u003eFaster recovery\u003cbr\u003eStronger post-workout pump\u003cbr\u003eRapid weight gain (water\/glycogen)\u003cbr\u003eImproved nutrient utilization\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eReceptor Grade IGF-1 LR3 Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eReceptor Grade IGF-1 LR3 peptide is a research reagent examined in studies on cellular growth, IGF receptors, and IGF binding proteins. It contains an extended N-terminal structure of 13 amino acids and a replacement of the glutamic acid at residue 3. Additionally, the addition of arginine in the original sequence of recombinant IGF-1 (rhIGF-1), which ultimately leads to the formation of an 83 amino acid peptide. Hence, it is named IGF-1 Long R3.\u003csup\u003e[1,2]\u003c\/sup\u003e It appears to be potentially more influential on cellular activities than rhIGF-1 due to an apparent significant improvement in its biological activity. This is since it exhibits a stronger affinity for the IGF receptor and lower affinity towards other proteins that may inactivate it. Moreover, the classification of \u003cem\u003eReceptor Grade\u003c\/em\u003e refers to the purity of the material, which is considered higher than the standard Media Grade IGF-1 LR3. Media grate IGF-1 LR3 is routinely studied in cell cultures and as a research reagent, at an economical cost, for studies where biological potency is not crucial. Receptor Grade IGF-1 LR3 is considered the reagent of choice to achieve optimum results when performing any animal study and cell-based assays. Growth of mammalian cells in the presence of low concentrations of Long R3 IGF-1 appears to result in better productivity than standard concentrations of insulin and\/or standard IGF-1.\u003csup\u003e[1]\u003c\/sup\u003e Researchers report that the peptide exhibited \u003cem\u003e“equivalent or better performance using two recombinant CHO cell lines.”\u003c\/em\u003e IGF-1 LR3 may be more capable of inducing the type 1 IGF receptor, potentially promoting an elevated level of intracellular signaling, cellular proliferation, and apoptosis inhibition.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e400\u003c\/sub\u003eH\u003csub\u003e625\u003c\/sub\u003eN\u003csub\u003e111\u003c\/sub\u003eO\u003csub\u003e115\u003c\/sub\u003eS\u003csub\u003e9\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 9117.5 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e MFPAMPLSSL FVNGPRTLCG AELVDALQFV CGDRGFYFNK PTGYGSSSRR APQTGIVDEC CFRSCDLRRL EMYCAPLKPA KSA\u003c\/p\u003e\n\u003ch3\u003eReceptor Grade IGF-1 LR3 Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eReceptor Grade IGF-1 LR3 and Biological Activity\u003c\/strong\u003e\u003cbr\u003eThe peptide appears to bring about a more pronounced but short-lived impact than IGF-1 through a potential resistance in the association of inactivating proteins such as IGF binding proteins (IGFBPs).\u003csup\u003e[2]\u003c\/sup\u003e Insulin-like Growth Factor Binding Proteins (IGFBPs) are a category of proteins that may regulate the availability of Insulin-like Growth Factors (IGFs) within the bloodstream, possibly influencing their interactions with various tissues. It is conceivable that a decrease in the binding affinity of IGF-1 LR3 for IGFBPs might affect its bioavailability, potentially reducing its duration of action. Additionally, this weakened binding might alter how IGF-1 LR3 engages with targeted tissues in experimental settings. These changes could potentially enhance the potency of IGF-1 LR3, although possibly shortening its active duration. This suggests that the interactions between IGF-1 LR3 and IGFBPs might determine the functional outcomes of IGF-1 LR3 in specific experimental contexts. Consequently, this may result in IGF-1 LR3 being more potent but with a shorter duration of action compared to recombinant Insulin-like Growth Factor 1 (rhIGF-1). Studies in murine models indicate that IGF-1 LR3 may be cleared from the plasma faster, to be destributed more quickly into various tissue models as compared to IGF-1.\u003csup\u003e[3]\u003c\/sup\u003e The investigation into the tissue distribution patterns of IGF-1 LR3 suggested it might localize differently from IGF-1. Notably, elevated levels of IGF-1 LR3 were observed in specific tissues, including the kidneys, ovaries, and adrenal glands in murine models.\u003csup\u003e [1]\u003c\/sup\u003e This distinct localization pattern implies that organs primarily involved in metabolic and reproductive functions might have different abilities to absorb or retain IGF-1 LR3 compared to IGF-1. It is speculated that these observed differences might be due to IGF-1 LR3's reduced tendency to bind with IGF-binding proteins (IGFBPs). This reduced binding may affect its bioavailability and interactions with target tissues in experimental models. However, there is a hypothesis that a peptide with similar modifications, specifically the R3 modification found in IGF-1 LR3, may possess greater anabolic potential than regular IGF-1 despite a shorter duration of action. Further research is necessary to understand these mechanisms and their implications fully.\u003csup\u003e[4]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eReceptor Grade IGF-1 LR3 and Insulin-Like Growth Factor Receptor Interactions\u003c\/strong\u003e\u003cbr\u003eNaturally produced IGF-1 hormones interact with at least two cell surface receptors: the IGF-1 receptor (IGF-1R) and the insulin receptor.\u003csup\u003e[5]\u003c\/sup\u003e The researchers also note that \u003cem\u003e“IR and IGF1R act as identical portals to the regulation of gene expression, with differences between insulin and IGF-1 effects due to a modulation of the amplitude of the signal created by the specific ligand-receptor interaction.”\u003c\/em\u003e The IGF-1R is referred to as the “physiologic” receptor due to its potential higher affinity (approximately 100 times higher) for IGF-1 as compared to the insulin receptor. The association of IGF-1 and IGF-1R apparently leads to changes in metabolism, prevention of cell death (apoptosis), promotion of cell growth (hypertrophy), differentiation and cell division (hyperplasia), normal development, and even malignant growth. IGF-1R has been researched for its involvement in diverse types of cancer, such as prostate, breast, and lung cancer.\u003csup\u003e[6]\u003c\/sup\u003e IGF-1 also appears to stimulate insulin receptors and activate them, thereby promoting glucose uptake from the bloodstream by cells. IGF-1 displays a three-fold influence on muscle cells.\u003c\/p\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eReceptor Grade IGF-1 LR3 and Muscle Cells \u003c\/strong\u003e\u003cbr\u003ePreliminary research utilizing murine models suggests that IGF-1 LR3 might have significant anabolic (muscle-building) actions. Specifically, a study examined its impact on both normal mice and those experiencing catabolic (muscle-wasting) conditions induced by dexamethasone, a synthetic steroid.\u003csup\u003e[7]\u003c\/sup\u003e The researchers noted that IGF-1 LR3 appeared to be roughly 2.5 times more potent than regular IGF-1 in producing anabolic actions. These observed actions included weight gain, an increase in the weight of internal organs (visceral organs), and possibly improved efficiency in converting feed into body mass. These findings were noted when the murine models were subjected to continuous exposure to IGF-1 LR3. Unfortunately, there are no studies investigating the direct potential of IGF-1 LR3 on muscle cells. Considering the similaritied between the two peptides, IGF-1 LR3 is expected to have similar actions on muscle cells as IGF-1.\u003cbr\u003e\u003cbr\u003eBased on research, studies posit that IGF-1 may promote an increase in the number of muscle cells, also known as hyperplasia. Secondly, IGF-1 appears to influence the lifespan of satellite cells of the skeletal muscles.\u003csup\u003e[8]\u003c\/sup\u003e Satellite cells appear to provide nutritional support to muscle cells, helping them to operate efficiently. IGF-1 may help to build muscle tissue by improving the lifespan of these cells. Finally, IGF-1 appears to promote the differentiation of myoblasts.\u003csup\u003e[9]\u003c\/sup\u003e In other words, it may encourage the commitment of stem cell progeny from non-specific pluripotent stem cells to dedicated muscle tissue. To conclude, IGF-1 may improve muscle development by enhancing the rate at which generic stem cells are transformed into muscle cells.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eThomas, James N., and Victor Fung. “Comparison of long R3 IGF-1 with insulin in the support of cell growth and recombinant protein expression in CHO cells.” Animal Cell Technology. Butterworth-Heinemann, 1994. 91-95.\u003c\/li\u003e\n\u003cli\u003eAssefa, Biruhalem, et al. “Insulin-like growth factor (IGF) binding protein-2, independently of IGF-1, induces GLUT-4 translocation and glucose uptake in 3T3-L1 adipocytes.” Oxidative Medicine and Cellular Longevity 2017 (2017).\u003c\/li\u003e\n\u003cli\u003eBastian SE, Walton PE, Wallace JC, Ballard FJ. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I) and an analogue LR3IGF-I in pregnant rats. J Endocrinol. 1993 Aug;138(2):327-36. . PMID: 7693845.\u003c\/li\u003e\n\u003cli\u003eElis S, Wu Y, Courtland HW, Cannata D, Sun H, Beth-On M, Liu C, Jasper H, Domené H, Karabatas L, Guida C, Basta-Pljakic J, Cardoso L, Rosen CJ, Frystyk J, Yakar S. Unbound (bioavailable) IGF1 enhances somatic growth. Dis Model Mech. 2011 Sep;4(5):649-58. . Epub 2011 May 31. PMID: 21628395; PMCID: PMC3180229.\u003c\/li\u003e\n\u003cli\u003eBoucher J, Tseng YH, Kahn CR. Insulin and insulin-like growth factor-1 receptors act as ligand-specific amplitude modulators of a common pathway regulating gene transcription. J Biol Chem. 2010 May 28;285(22):17235-45. . Epub 2010 Apr 1. PMID: 20360006; PMCID: PMC2878077.\u003c\/li\u003e\n\u003cli\u003eShanmugalingam T, Bosco C, Ridley AJ, Van Hemelrijck M. Is there a role for IGF-1 in the development of second primary cancers? Cancer Med. 2016 Nov;5(11):3353-3367. . Epub 2016 Oct 13. PMID: 27734632; PMCID: PMC5119990.\u003c\/li\u003e\n\u003cli\u003eTomas, F. M., Knowles, S. E., Owens, P. C., Chandler, C. S., Francis, G. L., Read, L. C., \u0026amp; Ballard, F. J. (1992). Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. The Biochemical journal, 282 ( Pt 1)(Pt 1), 91–97.\u003c\/li\u003e\n\u003cli\u003eYoshida T, Delafontaine P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells. 2020 Aug 26;9(9):1970. . PMID: 32858949; PMCID: PMC7564605.\u003c\/li\u003e\n\u003cli\u003eAboalola D, Han VKM. Different Effects of Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor-2 on Myogenic Differentiation of Human Mesenchymal Stem Cells. Stem Cells Int. 2017;2017:8286248. . Epub 2017 Dec 14. PMID: 29387091; PMCID: PMC5745708.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786428940605,"sku":"sku2194756137677","price":120.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/IGF-1-LR3-100MCG-1.webp?v=1780466148"},{"product_id":"receptor-grade-igf-1-lr3-1mg","title":"(💪 Rapid muscle gain)Receptor Grade IGF-1 LR3 (1mg) - Buy Online - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is IGF-1 LR3?\u003c\/p\u003e\n\u003cp\u003eIGF-1 LR3 (Long R3 IGF-1) is a modified version of IGF-1:\u003c\/p\u003e\n\u003cp\u003eIts characteristics include:\u003c\/p\u003e\n\u003cp\u003eExtended half-life (longer than natural IGF-1)\u003cbr\u003eStronger receptor binding affinity\u003cbr\u003eHigher biological activity\u003c\/p\u003e\n\u003cp\u003e“Receptor Grade” is typically a marketing term meaning:\u003cbr\u003e👉 “High-purity \/ strong receptor-binding version” (though not an official medical classification)\u003c\/p\u003e\n\u003cp\u003e💪 Why Does the Fitness Community Consider It “Powerful”?\u003c\/p\u003e\n\u003cp\u003eIts core mechanism of action is:\u003c\/p\u003e\n\u003cp\u003e➡️ Enhances cellular uptake of glucose and amino acids\u003cbr\u003e➡️ Promotes protein synthesis\u003cbr\u003e➡️ Accelerates muscle recovery\u003c\/p\u003e\n\u003cp\u003eTherefore, it is marketed for:\u003c\/p\u003e\n\u003cp\u003e🔥 Rapid muscle gain\u003cbr\u003e💪 Powerful recovery capabilities\u003cbr\u003e📈 Improved nutrient utilization efficiency\u003cbr\u003e🩹 Accelerated post-workout repair\u003cbr\u003e🧠 Its relationship with GH (Growth Hormone)\u003c\/p\u003e\n\u003cp\u003eMany people misunderstand:\u003c\/p\u003e\n\u003cp\u003eHGH    IGF-1 LR3\u003cbr\u003eUpstream hormone    Downstream signaling factor\u003cbr\u003eStimulates the liver to produce IGF-1    Acts directly on tissues\u003cbr\u003eIndirect action    More direct cellular action\u003c\/p\u003e\n\u003cp\u003e👉 Simply put:\u003cbr\u003eGH is the “conductor,” and IGF-1 is the “performer.”\u003c\/p\u003e\n\u003cp\u003e⚡ What makes “LR3” special?\u003c\/p\u003e\n\u003cp\u003eAfter modification, LR3:\u003c\/p\u003e\n\u003cp\u003eHas a longer half-life (around 20+ hours)\u003cbr\u003eIs less susceptible to inhibition by IGF-binding protein\u003cbr\u003ePenetrates tissues more easily to exert its effects\u003c\/p\u003e\n\u003cp\u003eTherefore, it is more “potent” than natural IGF-1.\u003c\/p\u003e\n\u003cp\u003e💪 Common User Feedback (from forums)\u003c\/p\u003e\n\u003cp\u003eCommon observations in the fitness community:\u003c\/p\u003e\n\u003cp\u003eEnhanced muscle “fullness”\u003cbr\u003eFaster recovery\u003cbr\u003eStronger post-workout pump\u003cbr\u003eRapid weight gain (water\/glycogen)\u003cbr\u003eImproved nutrient utilization\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eReceptor Grade IGF-1 LR3 Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eReceptor Grade IGF-1 LR3 is an altered variant of insulin-like growth factor-1; the complete name of the peptide is insulin-like growth factor-1 long arginine 3. IGF-1 derivatives have played important roles in research studies on cell proliferation, cell division, and cell-to-cell communication. Despite research reporting physiological potential similar to the parent protein, Receptor Grade IGF-1 LR3 does not appear to interact with IGF binding proteins (IGFBPs) as strongly as IGF-1. IGFBPs are a group of proteins that modulate the accessibility of Insulin-like Growth Factors (IGFs) within the bloodstream. This modulation potentially alters how IGFs engage with diverse bodily tissues. A reduction in the binding affinity of Insulin-like Growth Factor 1 Long Arg3 (IGF-1 LR3) for IGFBPs might potentially influence its bioavailability. Furthermore, this reduced binding might also affect the manner in which IGF-1 LR3 interacts with targeted tissues within experimental frameworks. Such alterations may lead to an enhanced potential of IGF-1 LR3, albeit possibly with a diminished duration of its active presence. This scenario suggests that the dynamics between IGF-1 LR3 and IGFBPs might be critical in determining the functional outcomes of IGF-1 LR3 in specific experimental contexts. The structural modifications in IGF-1 LR3 may have also contributed to the increased affinity of the peptide towards the IGF-1 receptors. The peptide is created by the inclusion of 13 amino acids to the N-terminus of native IGF-1 and by replacing the glutamic acid at position 3 with arginine, which ultimately leads to the formation of an 83 amino acid peptide.\u003csup\u003e[1]\u003c\/sup\u003e The designation of Receptor Grade addresses the purity of the reference product, which is considered higher than Media Grade IGF-1 LR3.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e400\u003c\/sub\u003eH\u003csub\u003e625\u003c\/sub\u003eN\u003csub\u003e111\u003c\/sub\u003eO\u003csub\u003e115\u003c\/sub\u003eS\u003csub\u003e9\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 9117.5 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e MFPAMPLSSL FVNGPRTLCG AELVDALQFV CGDRGFYFNK PTGYGSSSRR APQTGIVDEC CFRSCDLRRL EMYCAPLKPA KSA\u003c\/p\u003e\n\u003ch3\u003eReceptor Grade IGF-1 LR3 Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eReceptor Grade IGF-1 LR3 and Cell Division\u003c\/strong\u003e\u003cbr\u003eLike IGF-1, research suggests that Receptor Grade IGF-1 LR3 may act as a stimulus for cell division and proliferation, primarily affecting connective tissues of the muscle and bone and cell division in the liver, kidney, skin, lung, nerve, and blood tissues. IGF-1 is best considered to be a maturation hormone because of its apparent influence in cell proliferation, differentiation, and maturation, helping them to carry out their specialized functions. The higher potency of Receptor Grade IGF-1 LR3 towards the IGF-1 receptors may make it the preferred molecule for studies involving cell division. Receptor Grade IGF-1 LR3 appears to provide almost three times as much cellular activation compared to similar IGF-1.\u003csup\u003e[2]\u003c\/sup\u003e Notably, the researchers commented that analogs, including “\u003cem\u003eLR3 IGF-1, were approx. 2.5-fold more potent than IGF-1\u003c\/em\u003e” in enhancing anabolic activities in various experimental models. These activities included increased body mass, growth of visceral organs, and possibly improved feed utilization efficiency when models were continuously exposed to the agent. The implication is that IGF-1 LR3 might exhibit increased efficacy in studies focused on cellular proliferation compared to its unmodified counterpart, IGF-1. This research employed murine models subjected to catabolic stressors. The team noted a significant reduction in the excretion of Nτ-methylhistidine, an indicator of muscle protein breakdown. The decrease in this biomarker was more substantial with IGF-1 LR3, potentially up to threefold compared to IGF-1. This suggests that under certain experimental conditions, IGF-1 LR3 might exhibit more pronounced anabolic actions, though these were not consistently observed across all the variables measured. Given these findings, it might be suggested that Receptor Grade IGF-I LR3, specifically engineered for enhanced receptor affinity, might show even greater anabolic activity than IGF-1.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eReceptor Grade IGF-1 LR3 and Myostatin\u003c\/strong\u003e\u003cbr\u003eMyostatin (also known as growth differentiation factor 8) is a muscle protein that is considered to surpress the growth and differentiation of muscle cells. Myostatin may thus be deemed crucial in protection from unregulated hypertrophy. However, some situations demand inhibition of myosin. Blocking of myosin may be impactful in Duchenne Muscular Dystrophy (DMD) research, or in research related to muscle loss due to prolonged immobility. In such cases, blocking the natural enzyme might slow down muscle breakdown. Studies conducted in mouse models of DMD have suggested that Receptor Grade IGF-1 LR3 and other IGF-1 derivatives may overcome the adverse impacts of Myostatin to protect muscle cells and prevent apoptosis.\u003csup\u003e[3]\u003c\/sup\u003e The scientists note that \u003cem\u003e“results together suggest that myostatin suppresses both basal and IGF-1-stimulated proliferation of both WAT and BAT preadipocytes, actions that are again similar to those in muscle satellite cells.”\u003c\/em\u003e Receptor Grade IGF-1 LR3, due to its speculated stability, may potentially counteract Myostatin by activating MyoD, a muscle protein normally triggered through prolonged physical strain.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eReceptor Grade IGF-1 LR3 and Metabolism\u003c\/strong\u003e\u003cbr\u003eResearchers suggest that Receptor Grade IGF-1 LR3 may indirectly boost fat cell dissolution through association with the IGF-1R receptor and the insulin receptor. These interactions may improve glucose uptake from the blood by muscle, nerve, and liver cells. It is possible that the observed actions occurred through a complex signaling mechanism that involves the PI3K (Phosphoinositide 3-kinases) and AMPK (AMP-activated protein kinase) pathways. In this context, PI3K and AMPK are considered critical molecular pathways in cells, regulating various functions, including metabolism and growth. Specifically, it might be speculated that the interaction of IGF-1 analogs with their specific receptors might initiate a series of biochemical reactions via the PI3K pathway, posited as essential for cell proliferation and survival. This activation of the PI3K pathway could trigger Protein Kinase B (Akt), a potential enzyme within this pathway that may influence the movement of glucose transporters to the plasma membrane, potentially increasing the uptake of glucose by cells. Simultaneously, the AMPK pathway, which may play a significant role in maintaining energy homeostasis, might be indirectly affected by IGF-1 analogs such as IGF-1 LR3. The influence of these analogs may potentially alter AMPK activity, stimulating the cellular intake of glucose. Further, such activation may feasibly facilitate the movement of GLUT4 (Glucose Transporter Type 4), a predominant glucose transporter, to the cell surface, potentially promoting the entry of glucose into the cells. Overall, this potential may result in an overall reduction in blood sugar levels, which then triggers adipose tissue and the liver to initiate catabolism of glycogen and triglycerides. Overall, this may lead to decreased adipose tissue and net energy consumption (i.e. net catabolism). Given its potential in controlling blood sugar levels, Receptor Grade IGF-1 LR3 may reduce insulin levels and the need for exogenous insulin in diabetes.\u003csup\u003e[4]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eReceptor Grade IGF-1 LR3 and Longevity Research\u003c\/strong\u003e\u003cbr\u003eStudies observe that Receptor Grade IGF-1 LR3 may promote tissue repair and cell survival, making it a potentially protective molecule against cellular damage. Research in cows and pigs indicates that Receptor Grade IGF-1 LR3 exposure may overcome the impacts related to cell turnover. Ongoing research in mice has focused on the potential of Receptor Grade IGF-1 LR3 in possibly mitigating the progression of a wide range of conditions such as muscle atrophy, dementia, and kidney disease.\u003csup\u003e[5]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eAssefa B, Mahmoud AM, Pfeiffer AFH, Birkenfeld AL, Spranger J, Arafat AM. Insulin-Like Growth Factor (IGF) Binding Protein-2, Independently of IGF-1, Induces GLUT-4 Translocation and Glucose Uptake in 3T3-L1 Adipocytes. Oxid Med Cell Longev. 2017;2017:3035184. . Epub 2017 Dec 20. PMID: 29422987; PMCID: PMC5750484.\u003c\/li\u003e\n\u003cli\u003eTomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC, Ballard FJ. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J. 1992 Feb 15;282 ( Pt 1)(Pt 1):91-7. . PMID: 1371669; PMCID: PMC1130894.\u003c\/li\u003e\n\u003cli\u003eLi N, Yang Q, Walker RG, Thompson TB, Du M, Rodgers BD. Myostatin Attenuation In Vivo Reduces Adiposity, but Activates Adipogenesis. Endocrinology. 2016 Jan;157(1):282-91. . Epub 2015 Nov 18. PMID: 26580671; PMCID: PMC4701895.\u003c\/li\u003e\n\u003cli\u003eBailes J, Soloviev M. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports. Biomolecules. 2021 Feb 4;11(2):217. . PMID: 33557137; PMCID: PMC7913862.\u003c\/li\u003e\n\u003cli\u003eAsghariHanjani N, Vafa M. The role of IGF-1 in obesity, cardiovascular disease, and cancer. Med J Islam Repub Iran. 2019 Jun 17;33:56. . PMID: 31456980; PMCID: PMC6708115.\u003c\/li\u003e\n\u003cli\u003ePhilippou A, Barton ER. Optimizing IGF-I for skeletal muscle therapeutics. Growth Horm IGF Res. 2014 Oct;24(5):157-63. . Epub 2014 Jun 19. PMID: 25002025; PMCID: PMC4665094.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786428973373,"sku":"sku2194756136443","price":280.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/IGF-1-LR3-1MG-3-2.webp?v=1780466150"},{"product_id":"ghrp-6-5mg","title":"(💪 Recovery and Muscle-Building Support)GHRP-6 (5mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is GHRP-6?\u003c\/p\u003e\n\u003cp\u003eGHRP-6 acts on:\u003c\/p\u003e\n\u003cp\u003eGhrelin receptors\u003cbr\u003eThe pituitary GH secretion pathway\u003c\/p\u003e\n\u003cp\u003eIt is one of the earliest GH secretagogues.\u003c\/p\u003e\n\u003cp\u003e💪 Main Effects (Theory + User Feedback)\u003cbr\u003e🔥 1️⃣ Stimulates GH secretion\u003cbr\u003eIncreases pulsatile GH release\u003cbr\u003eIndirectly increases IGF-1\u003c\/p\u003e\n\u003cp\u003eBut in terms of potency:\u003cbr\u003e👉 Moderately strong (not as “potent” as Hexarelin)\u003c\/p\u003e\n\u003cp\u003e🍽️ 2️⃣ Significantly increases appetite (signature characteristic)\u003c\/p\u003e\n\u003cp\u003eThis is GHRP-6’s most famous effect:\u003c\/p\u003e\n\u003cp\u003eMarkedly increased hunger\u003cbr\u003eIncreased food intake\u003cbr\u003eParticularly suitable for “bulking”\u003c\/p\u003e\n\u003cp\u003eMany users say:\u003cbr\u003e👉 “It’s like having your appetite forced open”\u003c\/p\u003e\n\u003cp\u003e💪 3️⃣ Recovery and Muscle-Building Support\u003c\/p\u003e\n\u003cp\u003eCommon feedback from the fitness community:\u003c\/p\u003e\n\u003cp\u003eFaster recovery\u003cbr\u003eReduced post-workout soreness\u003cbr\u003eWeight gain (partly due to increased food intake)\u003cbr\u003e😴 4️⃣ Improved Sleep\u003c\/p\u003e\n\u003cp\u003eSome users report:\u003c\/p\u003e\n\u003cp\u003eDeeper sleep\u003cbr\u003eEnhanced sense of recovery during the night\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eGHRP-6 Peptide\u003c\/h3\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-6 peptide \u003c\/strong\u003eis a hexapeptide made of six amino acids and is classified amongst researchers as a growth hormone secretagogue (GHS), the classification of which is speculated to facilitate growth hormone (GH) release from the anterior pituitary gland cells. It may achieve this action by potentially acting as a ghrelin receptor agonist and is amongst the ghrelin analogs developed in recent decades. Researchers have suggested that the ghrelin receptor is found in anterior pituitary gland cells. Since their activation appears to result in the synthesis of growth hormone, the receptors are also termed “\u003cem\u003egrowth hormone secretagogue receptors\u003c\/em\u003e” (GHS-Rs). Since ghrelin is posited to impact hunger hormone stimulation, GHRP-6 is also posited to exert similar actions and stimulate food intake. In addition, it has been suggested that it positively influences cardiac muscle cells even in fibrosis cases, and may deliver possible positive neurological impacts in experimental settings.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e46\u003c\/sub\u003eH\u003csub\u003e56\u003c\/sub\u003eN\u003csub\u003e12\u003c\/sub\u003eO\u003csub\u003e6\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 873.032 g\/mol\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e His-D-Trp-Ala-Trp-D-Phe-Lys\u003c\/p\u003e\n\u003ch3\u003eGHRP-6 Peptide Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-6 and the GHS receptors\u003c\/strong\u003e\u003cbr\u003eUpon binding to the GHS receptors, GHRP-6 likely triggers a cascade of intracellular signaling processes deemed crucial for GH secretion.\u003csup\u003e[1]\u003c\/sup\u003e One of the primary pathways activated by GHRP-6 may involve the stimulation of Gq protein subtypes. This stimulation is theorized to lead to the activation of phospholipase C (PLC). Upon activation, PLC facilitates the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into two-second messengers: \u003cem\u003einositol triphosphate\u003c\/em\u003e (IP3) and \u003cem\u003ediacylglycerol \u003c\/em\u003e(DAG). The release of IP3 into the cytoplasm may be pivotal in increasing intracellular calcium levels. IP3 appears to achieve this by binding to its receptors located on the endoplasmic reticulum (ER), prompting the release of calcium ions (Ca2+) from these intracellular stores. The surge in cytosolic calcium is believed to be a critical signal that promotes the fusion of GH-containing vesicles with the plasma membrane, leading to the secretion of growth hormone via exocytosis. Simultaneously, DAG appears to activate protein kinase C (PKC), a key signaling molecule in numerous cellular processes, including the secretion of hormones. The activation of PKC further supports the process of vesicle fusion and GH release.\u003cbr\u003e\u003cbr\u003eResearchers have observed a potential rise in growth hormone (GH) concentrations subsequent to exposure to GHRP-6. The data indicates that the average peak level of GH attained was approximately 15.7 nanograms per milliliter (ng\/ml). Furthermore, the cumulative average quantity of GH secreted over the initial 90-minute period of the study was recorded at 674 ng\/ml. \u003csup\u003e[2] \u003c\/sup\u003eIn a separate study, GHRP-6's actions were evaluated in comparison to a control compound. This analysis tentatively suggests that the influence of GHRP-6 correlated with a release of 15.4 ng\/ml of GH, in contrast to the control group, which exhibited a level of 5.5 ng\/ml. These observations imply a potential link between GHRP-6 exposure and increased GH levels.\u003csup\u003e[3]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-6 and the CD36 receptors\u003c\/strong\u003e\u003cbr\u003eIt is posited that GHRP-6, a growth hormone-releasing peptide, may potentially interact with receptor sites other than those specifically related to ghrelin, known as GHS-Rs. There is a possibility that these additional receptors might encompass CD36 receptors.\u003csup\u003e[4]\u003c\/sup\u003e CD36 receptors, involved in an array of biological processes, are hypothesized to contribute to lipid metabolism. This function is thought to be mediated through their role as scavenger receptors, which help in the absorption and conveyance of lipids throughout the organism. Furthermore, CD36 receptors may exhibit some role in influencing immune responses. This might be particularly relevant in activities such as phagocytosis, where cells ingest harmful particles, and inflammation, a critical response of the immune system to infection and injury. Additionally, CD36 receptors have been associated with angiogenesis, a complex process involving the growth of new blood vessels from pre-existing ones, which is deemed crucial for tissue recovery and development.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-6 and Neurological Dysfunction\u003c\/strong\u003e\u003cbr\u003eA study conducted in 2018 highlighted the prevalence of ghrelin receptors in substantia nigra, a part of the brain considered to be impacted by the pathology of Parkinson’s Disease.\u003csup\u003e[1]\u003c\/sup\u003e Further, the scientists noted that they \u003cem\u003e“found a dramatic decrease in the expression of GHSR in PD-specific induced pluripotent stem cell (iPSC)-derived dopaminergic (DAnergic) neurons generated from [research models] carrying parkin gene (PARK2) mutations.”\u003c\/em\u003e Genetically predisposed cases are posited to exhibit a significant reduction in ghrelin receptors in their substantia nigra. It was observed that genetically modulated rats may exhibit Parkinson’s symptoms when an antagonist is present. Scientists hypothesize that the peptide associated with receptors present in the substantia nigra may potentially decrease neuronal apoptosis and thus may subside or ameliorate the onset of this disease.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-6 Peptide and Brain Cell Death\u003c\/strong\u003e\u003cbr\u003eThe role of the GHRP-6 peptide in ameliorating stroke has been evaluated in animal model research. Exposure to GHRP-6 may potentially mitigate the reduction of blood supply to brain tissues following a stroke and may participate in memory recall functions, which may be imperiled during a stroke.\u003csup\u003e[2]\u003c\/sup\u003e At a molecular level, the peptide and its analogs may prevent apoptosis of neurons of the central nervous system, preventing genetic reprogramming and inflammation.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-6 and Cognitive Function\u003c\/strong\u003e\u003cbr\u003eScientists have been investigating the role of mild muscular stress in cognitive functions encompassing learning and memory formation. It has been hypothesized that muscular action may support such functions. However, the precise mechanism has remained elusive. Initially, researchers suggested that physical activity facilitated improved blood circulation in the brain and thereby may have increased growth hormone production. Studies on rodent models have posited that GHRP-6 may support the transfer of short-term memories into long-term storage.\u003csup\u003e[3]\u003c\/sup\u003e Significant scientific observations further posit the active role of ghrelin\/GHRP-6 in spatial learning tasks.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-6 and Cardiac Tissues\u003c\/strong\u003e\u003cbr\u003eThe GHRP-6 peptide was suggested to potentially inhibit free radical-mediated cytotoxicity of cardiac cells in porcine models.\u003csup\u003e[4]\u003c\/sup\u003e The researchers commented, \"\u003cem\u003elevels of oxidative stress markers suggested that GHRP6 prevented myocardial injury via a decrease in reactive oxygen species and by the preservation of antioxidant defense systems.”\u003c\/em\u003e Research is ongoing in this area.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-6 and Reproduction\u003c\/strong\u003e\u003cbr\u003eStudies on male rats have hypothesized the positive correlation of ghrelin receptors in the central nervous system in modulating arousal and mating impulses. GHRP-6 peptide and its modified counterpart (suggested to antagonize the ghrelin receptor) may influence brain areas that facilitate reward-seeking behavior.\u003csup\u003e[5]\u003c\/sup\u003e There is also data to suggest that ghrelin may influence mood. The peptide and its analogs appear to impact brain function associated with mood, stress hormone secretion, and reward behavior in murine models.\u003csup\u003e[6]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHRP-6 and Fibrosis\u003c\/strong\u003e\u003cbr\u003eGHRP-6 researchers hypothesize the peptide may contribute to cell survival by decreasing programmed cell death (apoptosis). The peptide has been associated with the CD36 receptor, and researchers suggest that it may stimulate blood vessel growth, particularly in damaged tissue. Experiments with GHRP-6 peptide and rat models suggest it may hasten natural repair processes. It appears to support the formation of extracellular matrix proteins such as collagen, and the overall correct organization of tissue around a scar, thus reducing fibrosis. Hypertrophic scars, like keloids, may occur due to improper deposition of matrix proteins, and the process may potentially be ameliorated by GHRP-6.\u003csup\u003e[7]\u003c\/sup\u003e\u003cbr\u003e\u003cbr\u003eScientists suggest that GHRP-6 may block this aberrant process.\u003csup\u003e[8]\u003c\/sup\u003e In a recent experimental study involving rodents, it was observed that exposure to GHRP-6 over a period of 60 days may have potentially lessened the severity of liver fibrosis.\u003csup\u003e[13]\u003c\/sup\u003e This study noted a decline in the levels of several fibrogenic markers, including transforming growth factor-beta (TGF-β) and connective tissue growth factor (CTGF). Both factors appear to play a critical role in the development and progression of fibrotic tissue. Specifically, the research indicated that the fibrotic areas and the nodularity within the liver were decreased by an estimated 75% and more than 60%, respectively. Such preliminary data suggest that GHRP-6 may help mitigate fibrosis and assist in the healing processes within experimental settings.\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back-d\"\u003e\u003cstrong\u003eGHRP-6 and Cellular Apoptosis\u003c\/strong\u003e\u003cbr\u003eResearch has investigated the possible action of GHRP-6 on neuronal cells, specifically through its role in enhancing GH production and subsequently increasing levels of insulin-like growth factor-1 (IGF-1) in targeted areas. IGF-1, structurally similar to insulin, serves as GH's principal anabolic mechanism, facilitating hypertrophy and potentially supporting cell division and development. Initial observations suggest that GHRP-6 might elevate the messenger RNA (mRNA) expression of IGF-1 within specific brain regions, including the hypothalamus, cerebellum, and hippocampus. However, such an increase was notably absent in the cerebral cortex. This selective enhancement indicates that GHRP-6, via GH, may encourage IGF-1 synthesis in distinct neural areas. Moreover, the research evaluated the expression of the IGF-1 receptor and insulin-like growth factor-binding protein 2 (IGFBP-2). IGFBP-2 regulates the bioavailability of IGF-1 by binding to it, although the study did not record significant changes in their expression post-exposure to the peptide. However, there was observed phosphorylation of protein kinase B (Akt) and the Bcl-2-associated death promoter (BAD) in regions with heightened IGF-1 mRNA, potentially indicating that GH and GHRP-6 may activate cellular survival pathways in response to these growth factors. BAD, a member of the Bcl-2 protein family, is crucial in controlling cellular survival and death. In contrast, Akt participates in a spectrum of cellular processes, including metabolism, apoptosis, growth, transcription, and cell migration. Additionally, an increase in Bcl-2, an antiapoptotic protein, was noted in the same areas, suggesting a possible inclination toward cell survival rather than programmed cell death. In contrast, the levels of the proapoptotic protein Bax did not show a change. These findings tentatively propose that GHRP-6 might influence certain neuroprotective mechanisms in the brain.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv style=\"padding-bottom: 5px !important; margin-bottom: 25px !important;\" class=\"white-back-d\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eMousseaux D, Le Gallic L, Ryan J, Oiry C, Gagne D, Fehrentz JA, Galleyrand JC, Martinez J. Regulation of ERK1\/2 activity by ghrelin-activated growth hormone secretagogue receptor 1A involves a PLC\/PKCvarepsilon pathway. Br J Pharmacol. 2006 Jun;148(3):350-65. . PMID: 16582936; PMCID: PMC1751558.\u003c\/li\u003e\n\u003cli\u003eCordido F, Peñalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab. 1993 Apr;76(4):819-23. . PMID: 8473389.\u003c\/li\u003e\n\u003cli\u003eFrieboes RM, Murck H, Maier P, Schier T, Holsboer F, Steiger A. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology. 1995 May;61(5):584-9. . PMID: 7617137.\u003c\/li\u003e\n\u003cli\u003eDemers, A., McNicoll, N., Febbraio, M., Servant, M., Marleau, S., Silverstein, R., \u0026amp; Ong, H. (2004). Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. The Biochemical journal, 382(Pt 2), 417–424.\u003c\/li\u003e\n\u003cli\u003eSuda, Y., Kuzumaki, N., Sone, T., Narita, M., Tanaka, K., Hamada, Y., Iwasawa, C., Shibasaki, M., Maekawa, A., Matsuo, M., Akamatsu, W., Hattori, N., Okano, H., \u0026amp; Narita, M. (2018). Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson’s disease-like motor dysfunction. Molecular brain, 11(1), 6.\u003c\/li\u003e\n\u003cli\u003eSubirós, N., Pérez-Saad, H. M., Berlanga, J. A., Aldana, L., García-Illera, G., Gibson, C. L., \u0026amp; García-Del-Barco, D. (2016). Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy. Neurological research, 38(3), 187–195.\u003c\/li\u003e\n\u003cli\u003eHuang, C. C., Chou, D., Yeh, C. M., \u0026amp; Hsu, K. S. (2016). Acute food deprivation enhances fear extinction but inhibits long-term depression in the lateral amygdala via ghrelin signaling. Neuropharmacology, 101, 36–45.\u003c\/li\u003e\n\u003cli\u003eBerlanga, J., Cibrian, D., Guevara, L., Dominguez, H., Alba, J. S., Seralena, A., Guillén, G., López-Mola, E., López-Saura, P., Rodriguez, A., Perez, B., Garcia, D., \u0026amp; Vispo, N. S. (2007). Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clinical science (London, England : 1979), 112(4), 241–250.\u003c\/li\u003e\n\u003cli\u003eHyland, L., Rosenbaum, S., Edwards, A., Palacios, D., Graham, M. D., Pfaus, J. G., Woodside, B., \u0026amp; Abizaid, A. (2018). Central ghrelin receptor stimulation modulates sex motivation in male rats in a site dependent manner. Hormones and behavior, 97, 56–66.\u003c\/li\u003e\n\u003cli\u003eHuang, H. J., Chen, X. R., Han, Q. Q., Wang, J., Pilot, A., Yu, R., Liu, Q., Li, B., Wu, G. C., Wang, Y. Q., \u0026amp; Yu, J. (2019). The protective effects of Ghrelin\/GHSR on hippocampal neurogenesis in CUMS mice. Neuropharmacology, 155, 31–43.\u003c\/li\u003e\n\u003cli\u003eMendoza Marí, Y., Fernández Mayola, M., Aguilera Barreto, A., García Ojalvo, A., Bermúdez Alvarez, Y., Mir Benítez, A. J., \u0026amp; Berlanga Acosta, J. (2016). Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds. Plastic surgery international, 2016, 4361702. \u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.1155\/2016\/4361702\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1155\/2016\/4361702\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eFernández-Mayola, M., Betancourt, L., Molina-Kautzman, A., Palomares, S., Mendoza-Marí, Y., Ugarte-Moreno, D., Aguilera-Barreto, A., Bermúdez-Álvarez, Y., Besada, V., González, L. J., García-Ojalvo, A., Mir-Benítez, A. J., Urquiza-Rodríguez, A., \u0026amp; Berlanga-Acosta, J. (2018). Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study. International wound journal, 15(4), 538–546. \u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.1111\/iwj.12895\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1111\/iwj.12895\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eBerlanga-Acosta, J., Vázquez-Blomquist, D., Cibrián, D., Mendoza, Y., Ochagavía, M. E., Miranda, J., ... \u0026amp; Guillén-Nieto, G. E. (2012). Growth Hormone Releasing Peptide 6 (GHRP6) reduces liver fibrosis in CCl4 chronically intoxicated rats. Biotecnología Aplicada, 29(2), 60-72.\u003c\/li\u003e\n\u003cli\u003eFrago LM, Pañeda C, Dickson SL, Hewson AK, Argente J, Chowen JA. Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection. Endocrinology. 2002 Oct;143(10):4113-22. \u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.1210\/en.2002-220261\" target=\"_blank\"\u003edoi: 10.1210\/en.2002-220261\u003c\/a\u003e. PMID: 12239123.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786429006141,"sku":"sku2194756135209","price":90.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/GHRP-6-5MG-2-1.webp?v=1780466152"},{"product_id":"cjc-1295-dac-5mg","title":"(🌴Anti-aging) CJC-1295 DAC (5mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003eCJC-1295 with DAC is a classic growth hormone-releasing hormone (GHRH) analog classified as a “long-acting GH stimulator” in the anti-aging, fitness, and peptide communities.\u003c\/p\u003e\n\u003cp\u003eIn a nutshell:\u003cbr\u003e➡️ It provides prolonged, sustained stimulation of the body’s secretion of growth hormone (GH) and IGF-1\u003c\/p\u003e\n\u003cp\u003e🧬 What is CJC-1295 DAC?\u003c\/p\u003e\n\u003cp\u003eCJC-1295 is a modified version of GHRH (growth hormone-releasing hormone).\u003c\/p\u003e\n\u003cp\u003eDAC stands for:\u003cbr\u003e👉 Drug Affinity Complex\u003c\/p\u003e\n\u003cp\u003eThis structure allows it to:\u003c\/p\u003e\n\u003cp\u003eBind to albumin\u003cbr\u003eExtend its half-life (significantly)\u003c\/p\u003e\n\u003cp\u003e👉 Result: A single injection provides sustained effects for several days\u003c\/p\u003e\n\u003ch3\u003eCJC-1295 DAC Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eCJC-1295 DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) that has the potential to enhance plasma levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).\u003csup\u003e[1]\u003c\/sup\u003e Drug affinity complex (DAC) is an additive component that is considered to prolong the half-life of CJC-1295. Researchers have created several synthetic modifications of growth hormone-releasing hormone (GHRH), which appear to retain certain selective traits of the hormone while eliminating others. CJC-1295 is one such synthetic analog, comprising the first 29 amino acids of GHRH. This is believed to lend secretagogue characteristics with greater solubility, which may be easier to synthesize in larger volumes.\u003cbr\u003e\u003cbr\u003eCJC-1295 DAC shares similarities with other GHRH analogs like, as both are derivatives of the first 29 amino acids of GHRH. CJC-1295 is structurally identical to . In particular, CJC-1295 DAC and Mod GRF (1-29) exhibit four alterations within their 29 amino acid sequence, specifically at the 2nd, 8th, 15th, and 27th positions. These modifications are hypothesized to enhance the peptides' resistance to enzymatic breakdown, particularly by dipeptidyl peptidase-4 (DPP-4). For instance, the replacement of L-alanine with D-alanine at the 2nd position may contribute to increased resistance to molecular degradation. Substituting asparagine with glutamine at the 8th position may conceivably reduce the likelihood of asparagine rearrangement and amide hydrolysis. The substitution of glycine with alanine at the 15th position is suggested to enhance bioactivity. Finally, the alteration from methionine to leucine at the 27th position is thought to aid in mitigating the risk of methionine oxidation. The primary differential between the two peptides, CJC-1295 DAC and Mod GRF (1-29), is the addition of DAC to the CJC-1295 molecule. DAC is attached to CJC-1295 through a lysine linker to extend the peptide's pharmacokinetics. DAC appears to facilitate the association of peptides with blood proteins such as albumin. This appears to enhance their half-life, as compared to similar peptides such as GRF (1-29).\u003csup\u003e[2] \u003c\/sup\u003eThis occurrence may be attributed to the purported ability of DAC to interact with plasma proteins. Specifically, it seems that the DAC element involves the association of a lysine derivative, N-epsilon-3-maleimidopropionamide, with the C-terminus of CJC-1295 DAC. The incorporation of this altered amino acid sequence into the DAC configuration may plausibly improve the pharmacokinetics of CJC-1295 DAC, potentially prolonging its half-life to around eight days.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e CJC-1295 with DAC\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e152\u003c\/sub\u003eH\u003csub\u003e252\u003c\/sub\u003eN\u003csub\u003e44\u003c\/sub\u003eO\u003csub\u003e42\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 3367.954 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Mal)-NH2\u003c\/p\u003e\n\u003ch3\u003eCJC-1295 DAC Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eCJC-1295 DAC and Pituitary Cell Receptors\u003c\/strong\u003e\u003cbr\u003eStudies indicate that the peptide may enhance peak growth hormone levels up to seven and a half times in the models examined.\u003csup\u003e[3]\u003c\/sup\u003e CJC-1295 DAC may interact with specific binding sites on the growth hormone-releasing hormone (GHRH) receptor. Such interactions might alter the receptor's configuration, potentially initiating a cascade of molecular events. This binding is thought to activate particular intracellular signaling proteins, commonly known as G-proteins.\u003csup\u003e[4]\u003c\/sup\u003e When these proteins are activated, they may facilitate the production of secondary messengers like cyclic adenosine monophosphate (cAMP) or inositol trisphosphate (IP3), which are considered to play essential roles in cellular signaling pathways.\u003csup\u003e[5]\u003c\/sup\u003e These secondary messengers are believed to activate protein kinases, enzymes that alter specific proteins. These kinases may modify cellular functions by phosphorylating transcription regulators, which are proteins that control gene expression. Upon phosphorylation, these transcription regulators are hypothesized to enter the nucleus of somatotroph cells, potentially affecting the genes that govern growth hormone production. This sequence of events underscores the potential of CJC-1295 DAC to influence growth hormone levels through a detailed network of molecular interactions.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eCJC-1295 DAC and Growth Hormone Release\u003c\/strong\u003e\u003cbr\u003eThe peptide was initially developed to trigger growth hormone release and is a synthetic analog of the naturally occurring GHRH. Murine model experiments have reported that a single exposure to the peptide may induce almost 2-10 times higher production of growth hormone as compared to control models.\u003csup\u003e[6]\u003c\/sup\u003e GH expression appears to reach a maximum level after 2 hours of peptide introduction, and the action appears to be maintained up to six days later. The peptide appears to maintain the natural physiological level of growth hormone, unlike other secretagogues. In other words, CJC-1295 DAC may have the potential to perform as a physiological GHRH and maintain the natural biological high and low expression pattern in growth hormone levels. CJC-1295 DAC appears to maintain the physiological level of the hormone while enhancing its release in the blood. CJC-1295 DAC has been studied in relation to the physiological regulation of growth hormone in the course of protein synthesis, fat metabolism, blood sugar, hypertrophy, bone density, hyperplasia, and myocardial function. The production of growth hormone may interact with receptors on liver cells, potentially initiating a series of intracellular signaling events. This interaction may activate the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. Following activation, STAT proteins may possibly translocate to the nucleus and bind to specific DNA sequences known as response elements, which might facilitate the transcription of the IGF-I gene. It has been posited that CJC-1295 DAC may lead to increases in average IGF-I levels, ranging from 1.5- to 3-fold over approximately 9–11 days, with indications that these elevated levels might persist for at least two weeks in experimental settings. After repeated exposure to CJC-1295 DAC, average IGF-I levels seem to sustain an elevation above the initial baseline for up to 28 days. Importantly, data suggests a cumulative action with repeated exposures to the compound.\u003csup\u003e[6]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eCJC-1295 DAC and Infertility\u003c\/strong\u003e\u003cbr\u003eStudies from the early 1990s suggest that CJC-1295 DAC and other GRF analogs may exert stimulatory action in female infertility studies. Murine models of superovulation have suggested that growth hormone and IGF-1 levels increase in blood around the time of ovulation.\u003csup\u003e[7]\u003c\/sup\u003e Thus, exposure to CJC-1295 DAC and GRF analogs may promote ovulation in female animals, possibly through the IGF-1 and growth hormone expression cycle. The exposure of growth hormone secretagogues like CJC-1295 DAC may be sufficient to promote ovulation. Scientists have further suggested these analogs may improve sperm production, though research is inconclusive.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eCJC-1295 DAC and Growth\u003c\/strong\u003e\u003cbr\u003eResearch has suggested that CJC-1295 may restore the physiological release of growth hormone in murine models lacking normal growth hormone physiology.\u003csup\u003e[8]\u003c\/sup\u003e Jette et al. notes that \u003cem\u003e“CJC-1295, showed a 4-fold increase in GH area under the curve over a 2-h period.”\u003c\/em\u003e The peptide may potentially be researched in the context of growth anomalies in different mammalian species. Maintenance of the circadian cycle of growth hormone release appears crucial to producing downstream hormones, such as insulin-like growth factor-1 (IGF-1). Further investigations have also indicated that exposure to CJC-1295 DAC in murine models may potentially stabilize growth patterns. These studies propose that CJC-1295 DAC may influence body composition, possibly by promoting muscle hypertrophy without affecting (perhaps even decreasing), fat tissue levels. Specifically, the murine models examined exhibited a genetic deletion of the GHRH gene (referred to as GHRHKO); findings imply that CJC-1295 DAC may enhance growth hormone production, resulting in favorable changes in body composition. In these GHRHKO murine models, exposure to CJC-1295 DAC seemed to maintain standard levels of lean mass, in contrast to models not exposed, which displayed lower than optimal lean mass. Moreover, the quantity of subcutaneous fat mass remained similar to that observed in the control groups associated with peptide exposure, while GHRHKO models not exposed to CJC-1295 DAC showed signs of increased fat mass. This suggests that CJC-1295 DAC may beneficially influence muscle and bone structure without contributing to fat gain. The study also observed a potential elevation in pituitary RNA and GH mRNA levels following exposure to CJC-1295 DAC, indicating a probable increase in the population of somatotroph cells—cells believed to synthesize growth hormone within the pituitary gland. The researchers posited that \"\u003cem\u003eCJC-1295 caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred, as confirmed by immunohistochemistry images.\u003c\/em\u003e”\u003csup\u003e[1]\u003c\/sup\u003e\u003cb\u003e\u003cem\u003e\u003c\/em\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eAlba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. . Epub 2006 Jul 5. PMID: 16822960.\u003c\/li\u003e\n\u003cli\u003eGautam D, Jeon J, Starost MF, Han SJ, Hamdan FF, Cui Y, Parlow AF, Gavrilova O, Szalayova I, Mezey E, Wess J. Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth. Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6398-403. . Epub 2009 Mar 30. PMID: 19332789; PMCID: PMC2662962.\u003c\/li\u003e\n\u003cli\u003eIonescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210\/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654.\u003c\/li\u003e\n\u003cli\u003eMartin, B., Lopez de Maturana, R., Brenneman, R., Walent, T., Mattson, M. P., \u0026amp; Maudsley, S. (2005). Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromolecular medicine, 7(1-2), 3–36.\u003c\/li\u003e\n\u003cli\u003eNewton, A. C., Bootman, M. D., \u0026amp; Scott, J. D. (2016). Second Messengers. Cold Spring Harbor perspectives in biology, 8(8), a005926.\u003c\/li\u003e\n\u003cli\u003eTeichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. . Epub 2005 Dec 13. PMID: 16352683.\u003c\/li\u003e\n\u003cli\u003eGuo S, Li Z, Yan L, Sun Y, Feng Y. GnRH agonist improves pregnancy outcome in mice with induced adenomyosis by restoring endometrial receptivity. Drug Des Devel Ther. 2018 Jun 7;12:1621-1631. . PMID: 29922037; PMCID: PMC5995291.\u003c\/li\u003e\n\u003cli\u003eJetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8. . Epub 2005 Apr 7. PMID: 15817669.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"vbni\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786429038909,"sku":"sku2194756130273","price":180.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/CJC-1295-DAC-5MG-1-1.webp?v=1780466153"},{"product_id":"ll-37-5mg","title":"(💪Antibacterial) LL-37 (5mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is LL-37?\u003c\/p\u003e\n\u003cp\u003eLL-37 is a peptide naturally produced by the human body, primarily by:\u003c\/p\u003e\n\u003cp\u003eSkin cells\u003cbr\u003eNeutrophils (white blood cells)\u003cbr\u003eEpithelial tissue\u003c\/p\u003e\n\u003cp\u003eIts core functions are:\u003cbr\u003e🛡️ Antimicrobial + Immune Modulation + Tissue Repair\u003c\/p\u003e\n\u003cp\u003e🔥 Primary Biological Effects\u003cbr\u003e🦠 1️⃣ Antibacterial (Core Function)\u003c\/p\u003e\n\u003cp\u003eLL-37 can directly eliminate:\u003c\/p\u003e\n\u003cp\u003eBacteria 🦠\u003cbr\u003eViruses 🧬\u003cbr\u003eFungi 🍄\u003c\/p\u003e\n\u003cp\u003eBy:\u003cbr\u003e➡️ Destroying the cell membranes of pathogens\u003c\/p\u003e\n\u003cp\u003eIt is classified as a “broad-spectrum natural antibiotic.”\u003c\/p\u003e\n\u003cp\u003e🧠 2️⃣ Immune Modulation\u003c\/p\u003e\n\u003cp\u003eLL-37 does more than just “kill pathogens”; it also modulates the immune system:\u003c\/p\u003e\n\u003cp\u003eRegulates inflammatory responses\u003cbr\u003eAttracts immune cells\u003cbr\u003eControls immune balance\u003c\/p\u003e\n\u003cp\u003eTherefore, it can:\u003cbr\u003e🔥 Act as an anti-inflammatory, or in certain cases, promote inflammatory responses (bidirectional regulation)\u003c\/p\u003e\n\u003cp\u003e🩹 3️⃣ Wound Healing\u003c\/p\u003e\n\u003cp\u003eLL-37 is being studied for:\u003c\/p\u003e\n\u003cp\u003ePromoting skin repair\u003cbr\u003eAccelerating wound healing\u003cbr\u003eStimulating tissue regeneration\u003cbr\u003ePromoting angiogenesis\u003cbr\u003e🧴 Potential in Medicine\/Research\u003c\/p\u003e\n\u003cp\u003eResearch areas include:\u003c\/p\u003e\n\u003cp\u003eChronic wounds (diabetic foot)\u003cbr\u003eSkin infections\u003cbr\u003eEczema \/ Psoriasis\u003cbr\u003eAntibacterial alternatives to antibiotics\u003cbr\u003eRegulation of immune disorders\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eLL-37 Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eLL-37 is a Cathelicidin, a protein family of unique and diverse functions. These peptides, produced by macrophages and polymorphonuclear leukocytes (both types of white blood cells), have been suggested to exhibit bactericidal action. The entire group is classified as antimicrobial peptides (AMPs). The peptide, in particular, has been researched in relation to autoimmune disease, cancer, and wound recovery.\u003csup\u003e[1]\u003c\/sup\u003e For example, researchers note that \u003cem\u003e“Corneal and conjunctival epithelia express LL-37 as part of mucosal innate immunity to protect against bacterial and viral ocular infections.”\u003c\/em\u003e\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e CAP-18\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e205\u003c\/sub\u003eH\u003csub\u003e340\u003c\/sub\u003eN\u003csub\u003e50\u003c\/sub\u003eO\u003csub\u003e53\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 4493.34 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-GluLys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-ArgThr-Glu-Ser\u003c\/p\u003e\n\u003ch3\u003eLL-37 Peptide Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eLL-37 and Inflammatory Disease Models\u003c\/strong\u003e\u003cbr\u003eLL-37, although essentially researched as an antimicrobial peptide, has also been examined in research related to different inflammatory diseases such as lupus, rheumatoid arthritis, psoriasis, and atherosclerosis. LL-37 researchers suggest the peptide’s diverse immune system modulating behaviors based on the type of cells involved and the local inflammatory environment. It has been suggested to reduce apoptotic death of keratinocytes, improve IFN-alpha synthesis, suppress signaling through toll-like receptor 4 (TLR4), modify chemotaxis of neutrophils and eosinophils,\u003csup\u003e[2] \u003c\/sup\u003etrigger IL-18 production, and potentially reduce levels of atherosclerotic plaques. Interestingly, LL-37 (aka CAP-18) appears to stimulate the immune system in a different manner depending on the trigger. Cell culture studies have observed the importance of the inflammatory environment in determining the immune response to LL-37. T-cells appear to improve inflammatory action via LL-37 when not activated but minimize the inflammatory action when activated.\u003cbr\u003e\u003cbr\u003eThe peptide appears to mediate homeostasis of immunological response, thus controlling it from being hyperactive in instances of infection. There appears to be a strong correlation between the peptide levels and the extent of the disease. Initially, CAP-18 was thought to promote autoimmune disorders, but recent results have suggested it may help to abate the damage.\u003csup\u003e[3]\u003c\/sup\u003e The researchers outline that the peptide has a role \u003cem\u003e“in the modulation of immune and inflammatory pathways and their effects on autoimmune and inflammatory diseases.”\u003c\/em\u003e High levels of the peptide may thus help check further increased inflammation.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eLL-37 and Antimicrobial Characteristics\u003c\/strong\u003e\u003cbr\u003eLL-37 appears to be an important biomolecule of innate immunity and one of the initial proteins to activate during infection. Research findings in skin infection studies suggest that the peptide, though present in limited skin cells, appears to accumulate very fast when invading pathogens are present.\u003csup\u003e[4]\u003c\/sup\u003e It may work with other proteins, like beta-defensin 2, to fight infection. The peptide appears to bind to bacterial lipopolysaccharide (LPS) of the outer membrane of gram-negative bacteria. LPS is considered critical for the membrane integrity of these bacteria. The possible action of LL-37 to bind to and interfere with LPS may make it toxic for certain bacteria. LL-37 may act against gram-positive pathogens, as research on staph infections and other serious bacteria suggested. Research indicates that LL-37 \/ CAP-18 may improve lysozyme’s action, which destroys gram-positive bacteria like\u003cem\u003e Staph aureus.\u003c\/em\u003e\u003cbr\u003e\u003cbr\u003eLL-37 may also be heightened and exert antimicrobial actions against nearby potential threats in models of gastrointestinal ulcers, as they report increased peptide expression.\u003csup\u003e[5]\u003c\/sup\u003e This heightened production of LL-37 is likely influenced by the activation of Toll-like receptor 3 (TLR-3). TLR-3 is a type of receptor involved in the immune response, which may be activated by its specific ligand, polyinosinic-polycytidylic acid (poly(I)), a synthetic analog of double-stranded RNA. The interaction with poly(I) may trigger a series of intracellular signaling events that include the involvement of proteins such as Toll\/IL-1 receptor (TIR) domain-containing adaptor-inducing interferon (TRIF), tumor necrosis factor receptor-associated factor 6 (TRAF6), and transforming growth factor β-activated kinase 1 (TAK1). These proteins appear to play crucial roles in immune signaling pathways that might lead to the enhanced expression of LL-37. The peptide's role in the gastrointestinal tract extends to possibly mitigating microbial damage to the gastrointestinal (GI) mucosa via the interactions of the peptide with LPS. Furthermore, the presence of LL-37 may help reduce the secretion of pro-inflammatory cytokines such as interleukin-6 (IL-6) and IL-8, which are significant in the inflammatory response. This reduction is potentially observed in colonic subepithelial myofibroblasts (SEMFs), cells that are part of the connective tissue and may play a role in wound recovery and fibrosis. By moderating the inflammatory response through these interactions, LL-37 might contribute to safeguarding the integrity of the GI tract lining.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eLL-37 and Lung Disease Models\u003c\/strong\u003e\u003cbr\u003eLPS is found in several different organisms and, in some instances, may become airborne when an environment is contaminated by mold or other fungi. Normal lung tissue responds by producing mucus upon LPS inhalation. Unfortunately, the response is often insufficient to intercept toxic dust syndrome and respiratory diseases like asthma and COPD. LL-37 has been studied in research on toxic dust syndrome.\u003csup\u003e[6]\u003c\/sup\u003e LL-37 appears to promote the proliferation of epithelial cells and the closure of wounds in lung diseases. The peptide may attract airway epithelial cells to injury sites and help vascularization, wound recovery, and supply of nutrition to the newly formed tissue.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eLL-37 Peptide and Arthritis Models\u003c\/strong\u003e\u003cbr\u003eResearch in murine models observed high LL-37 levels in the joints of rat models of rheumatoid arthritis. Whether the peptide exerts positive or negative actions in such models is unknown. However, several findings indicate the potential of the peptide in inflammation. LL-37 deficiency does not appear to change the outcomes in animal models of arthritis or lupus.\u003csup\u003e[7]\u003c\/sup\u003e Animals expressing the peptide may show the same disease outcome as those lacking the peptide. These results indicate that the physiological reactions in enhanced levels of cathelicidins in arthritis are incidental.\u003cbr\u003e\u003cbr\u003ePeptides derived from LL-37 may reduce collagen damage, which occurs in inflammatory arthritis. Direct exposure of these peptides to arthritic joints in rats was observed to reduce both the severity of the disease and serum levels of antibodies against type II collagen. Direct interleukin-32 (IL-32) involvement in the severity of inflammatory arthritis has been reported. LL-37 and its derivatives may be able to regulate the level of IL-32 response. Researchers consider it reasonable to speculate that the peptide is protective in this disease scenario. Synovial fluid fibroblasts increase toll-like receptor 3 levels, which scientists consider worsens the arthritic condition by increasing inflammatory cytokine expression. LL-37 may interact with TLR4 and either promote pro-inflammatory or anti-inflammatory outcomes.\u003csup\u003e[8]\u003c\/sup\u003e It is yet to be confirmed if LL-37 \/ CAP-18 mediates the same actions against the backdrop of increased TLR3. The peptide has been examined in experimental studies to selectively decrease pro-inflammatory macrophage responses, and researchers suggest its regulation of inflammation to be selective.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eLL-37 and Intestinal Cancer\u003c\/strong\u003e\u003cbr\u003eCell culture-based research studies have suggested potential multifaceted functions of the peptide in the intestine. The peptide appears to improve the migration of cells necessary for epithelial barrier maintenance of the intestine. LL-37 may reduce apoptosis when there is intestinal inflammation, helping to reduce inflammation's causes and associated pathogenesis. Studies suggest LL-37 pairs with beta-defensin 2 to help in wound recovery. Research indicates that the peptides may work simultaneously to repair and maintain the intestinal epithelium while decreasing TNF-related cell death.\u003csup\u003e[9]\u003c\/sup\u003e Despite being the principal compounds researched in inflammatory bowel conditions, TNF-alpha inhibitors have been reported to exhibit adverse ancillary impacts. LL-37-exposure may potentially reduce the dependence on TNF-alpha inhibitors. Research in the peptide action on cancer cells has generated mixed reports.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eLL-37 and Blood Vessel Growth\u003c\/strong\u003e\u003cbr\u003eThe peptide appears to produce prostaglandin E2 (PGE2) in endothelial cells, which are cells that line the interior surface of blood vessels.\u003csup\u003e[10]\u003c\/sup\u003e In endothelial cells, PGE2 promotes the development of blood vessels via a process called angiogenesis. It is considered crucial to regulate angiogenesis as it impacts cancer development, stroke outcomes, heart disease, and wound recovery, among others. LL-37 helps to study angiogenesis in-depth to promote it in cardiac disease and discourage cancer milieu. Further research suggests that the peptide appears to support several critical functions of endothelial cells.\u003csup\u003e[11]\u003c\/sup\u003e These functions include cell proliferation, which is the process of cells multiplying; cell migration, which involves the movement of cells from one location to another; and the creation of tube-like structures that resemble small capillaries. Research conducted on mouse models with induced catabolism—where the mouse body breaks down molecules for energy—employed synthetic and natural recombinant versions of LL-37. This research tentatively indicates that exposure to LL-37 may promote the development of new blood vessels and the recovery of epithelial tissues, which include skin and organ linings. Such preliminary findings tentatively support the theory that LL-37 may play a vital role in enhancing wound recovery by possibly influencing the new blood vessel formation process, known as \u003cem\u003evascularization\u003c\/em\u003e.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eLL-37 and Immune Cells\u003c\/strong\u003e\u003cbr\u003eStudies suggest that LL-37 may potentially enhance the immune system's ability to respond to cellular damage.\u003csup\u003e[12]\u003c\/sup\u003e This enhancement might occur through the modulation of the immune system's recognition mechanisms for self-nucleic acids, which include DNA and RNA. It is speculated that this modulation occurs when LL-37 interacts with particular types of cellular receptors, notably scavenger receptors (SRs). These receptors are deemed key in a process known as \u003cem\u003eclathrin-dependent endocytosis\u003c\/em\u003e, which is believed to be crucial for activating inflammatory pathways in cells. In addition, the peptide LL-37 is thought to facilitate the association of double-stranded RNA (dsRNA) with scavenger receptors. This interaction might initiate a cascade of signaling events that ultimately lead to the expression of cytokines, important signaling molecules in the immune response. The study further suggests that the specific interaction between LL-37 and certain scavenger receptors, such as SR-A6 and SR-B1, may be vital. The research also explores the idea that LL-37 might influence the immune system by potentially altering the function of intracellular signaling pathways. These pathways include Toll-like receptors (TLRs) and interferon regulatory factors (IRFs), which are commonly activated in response to foreign nucleic acids. The study posits that through clathrin-mediated endocytosis, LL-37 may facilitate the entry of immune-modulating molecules into cells, an essential step for initiating an immune response. This suggests a sophisticated mechanism by which LL-37 might regulate immune reactions at a cellular level.\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"padding-bottom: 5px !important; margin-bottom: 25px !important;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eGordon YJ, Huang LC, Romanowski EG, Yates KA, Proske RJ, McDermott AM. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res. 2005 May;30(5):385-94. . PMID: 16020269; PMCID: PMC1497871.\u003c\/li\u003e\n\u003cli\u003eAlalwani SM, Sierigk J, Herr C, Pinkenburg O, Gallo R, Vogelmeier C, Bals R. The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils. Eur J Immunol. 2010 Apr;40(4):1118-26. . PMID: 20140902; PMCID: PMC2908514.\u003c\/li\u003e\n\u003cli\u003eKahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol. 2013 Nov 15;191(10):4895-901. . PMID: 24185823; PMCID: PMC3836506.\u003c\/li\u003e\n\u003cli\u003eReinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol. 2012 May;24(2):126-35. . Epub 2012 Apr 26. PMID: 22577261; PMCID: PMC3346901.\u003c\/li\u003e\n\u003cli\u003eKusaka; et al. Expression of human cathelicidin peptide LL-37 in inflammatory bowel disease. Clin Exp Immunol. 2018 Jan;19(11). Epub 2017 Sep 28.\u003c\/li\u003e\n\u003cli\u003eGolec M. Cathelicidin LL-37: LPS-neutralizing, pleiotropic peptide. Ann Agric Environ Med. 2007;14(1):1-4. PMID: 17655171.\u003c\/li\u003e\n\u003cli\u003eMoreno-Angarita A, Aragón CC, Tobón GJ. Cathelicidin LL-37: A new important molecule in the pathophysiology of systemic lupus erythematosus. J Transl Autoimmun. 2019 Dec 17;3:100029. . PMID: 32743514; PMCID: PMC7388365.\u003c\/li\u003e\n\u003cli\u003eSingh D, Vaughan R, Kao CC. LL-37 peptide enhancement of signal transduction by Toll-like receptor 3 is regulated by pH: identification of a peptide antagonist of LL-37. J Biol Chem. 2014 Oct 3;289(40):27614-24. . Epub 2014 Aug 4. PMID: 25092290; PMCID: PMC4183800.\u003c\/li\u003e\n\u003cli\u003ePiktel E, Niemirowicz K, Wnorowska U, Wątek M, Wollny T, Głuszek K, Góźdź S, Levental I, Bucki R. The Role of Cathelicidin LL-37 in Cancer Development. Arch Immunol Ther Exp (Warsz). 2016 Feb;64(1):33-46. . Epub 2015 Sep 22. PMID: 26395996; PMCID: PMC4713713.\u003c\/li\u003e\n\u003cli\u003eSalvado MD, Di Gennaro A, Lindbom L, Agerberth B, Haeggström JZ. Cathelicidin LL-37 induces angiogenesis via PGE2-EP3 signaling in endothelial cells, in vivo inhibition by aspirin. Arterioscler Thromb Vasc Biol. 2013 Aug;33(8):1965-72. doi: 10.1161\/ATVBAHA.113.301851. Epub 2013 Jun 13. PMID: 23766266.\u003c\/li\u003e\n\u003cli\u003eRamos R, Silva JP, Rodrigues AC, Costa R, Guardão L, Schmitt F, Soares R, Vilanova M, Domingues L, Gama M. Wound healing activity of the human antimicrobial peptide LL37. Peptides. 2011 Jul;32(7):1469-76. doi: 10.1016\/j.peptides.2011.06.005. Epub 2011 Jun 13.\u003c\/li\u003e\n\u003cli\u003eTakahashi, T., Kulkarni, N.N., Lee, E.Y. et al. Cathelicidin promotes inflammation by enabling binding of self-RNA to cell surface scavenger receptors. Sci Rep 8, 4032 (2018).\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786429071677,"sku":"sku2194756138911","price":300.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/LL_37-5MG-1.webp?v=1780466155"},{"product_id":"selank-10mg","title":"(🌴Anxiety relief) Selank Peptide (10mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003ch3\u003e\n\u003cbr\u003e😌 Anxiety relief\u003cbr\u003e🧠 Emotional stability\u003cbr\u003e🎯 Focus\/cognition\u003cbr\u003e😴 Stress management\u003cbr\u003e🧩 Nootropics\u003c\/h3\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eSelank Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eSelank is a small peptide studied for its potential nootropic and behavior-modifying functions in experimental models. It is a synthetic analog of naturally occurring Tuftsin. This immunomodulatory peptide is a short fragment from the immunoglobulin G (IgG), a natural tetrapeptide involved in certain functions that may regulate the immune system. Selank is also posited to possess additional potential for regulating immune cells, IL-6, a wide range of neurotransmitter systems, and brain-derived neurotrophic factor (BDNF).\u003cbr\u003e\u003cbr\u003eSelank differs in structure from the endogenous Tuftsin by an additional three amino acids in its chain, which have been supposed to enhance the metabolic stability and half-life of the synthetic peptide. Specifically, that is the Pro-Gly-Pro segment at the C-terminus of Selank, which might enhance its ability to move through various models, including the blood-brain barrier (BBB). The BBB is a highly selective and semi-permeable barrier that separates circulating blood from the tissues and extracellular fluid of the central nervous system, playing a vital role in regulating substance passage.\u003cbr\u003e\u003cbr\u003eThe inclusion of Pro-Gly-Pro may possibly increase BBB permeability by affecting the peptide's hydrophilicity or lipophilicity, which may enhance its affinity for the BBB's lipid-rich environment. Furthermore, the Pro-Gly-Pro sequence might interact with specific transport mechanisms or receptors at the BBB, possibly initiating facilitated transport or receptor-mediated endocytosis. These processes may enable Selank to circumvent the tight junctions that are said to typically restrict larger molecules.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e33\u003c\/sub\u003eH\u003csub\u003e57\u003c\/sub\u003eN\u003csub\u003e11\u003c\/sub\u003eO\u003csub\u003e9\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 751.88 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Thr-Lys-Pro-Arg-Pro-Gly-Pro\u003c\/p\u003e\n\u003ch3\u003eSelank Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eSelank and GABA Neurotransmission\u003c\/strong\u003e\u003cbr\u003eAs per Dr. Anastasiya Volkova of the Institute of Molecular Genetics in Russia, \u003cem\u003e“numerous clinical studies have [suggested] that Selank [may exhibit] strong antianxiety and neuroprotective effects in the [context] of anxiety. Selank and classical antianxiety [compounds] such as benzodiazepine have a similar mode of action. Selank allosterically modulates GABAA receptors and increases the inhibitory action of GABA.”\u003c\/em\u003e\u003cbr\u003e\u003cbr\u003eResearchers like Dr. Volkova have suggested that as a result of peptide activity, stress hormone levels may be reduced. Studies conducted by researchers focused on small concentrations of Selank exposure have observed a sedating action similar to benzodiazepines.\u003cbr\u003e\u003cbr\u003eIt has been suggested that the peptide may influence the expression of 7 genes and that it may moderately affect the expression of 45 other targets, all from a set of roughly 84 genes considered to be involved in GABA signaling.\u003csup\u003e[1]\u003c\/sup\u003e Researchers reported that their \u003cem\u003e“results [posited] that Selank caused a number of alterations in the expression of genes involved in neurotransmission.”\u003c\/em\u003e They suggested the peptide may stimulate gene expression in neurons and influence the affinity of GABA receptors for GABA. Synergism between Selank and benzodiazepines and other GABA receptor agonists appears to be mediated through alteration of the receptor affinity.\u003cbr\u003e\u003cbr\u003eResearch in rats observes that Selank and benzodiazepines, when alone, appear to have similar impacts on stress hormones, particularly in models of generalized anxiety. The synergistic potential of these compounds has not been fully explored.\u003csup\u003e[2]\u003c\/sup\u003e The impact of Selank on enkephalin degradation appears to modulate its influence on GABA receptors to a certain extent.\u003cbr\u003e\u003cbr\u003eStudies have suggested enkephalins with shorter blood stability may be present in models of anxiety and phobic disorders. This is apparently caused by increased enkephalinase activity in the blood, which may degrade the enkephalins. Studies in murine models of anxiety posit that the peptide appears to inhibit enkephalinase, stabilize enkephalins, reset the enzymatic pathway, and thus may preserve natural anxiolytic peptides.\u003csup\u003e[3]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eSelank Peptide and the Immune System\u003c\/strong\u003e\u003cbr\u003eSelank has been studied for its potential to inhibit the gene responsible for the production of the inflammatory cytokine IL-6 in research models of depression but not in control models.\u003csup\u003e[4]\u003c\/sup\u003e Researchers also note that \u003cem\u003e“the adaptogenic properties of selank may be beneficial [in the cases of exposure] to environmental stressors for the prevention of infectious diseases.”\u003c\/em\u003e Selank research suggests that compared to standard anxiolytic compounds, like benzodiazepines, it may improve asthenic symptoms such as fatigue and pain.\u003csup\u003e[5]\u003c\/sup\u003e This may be due to the peptide’s apparent stabilization of enkephalins and potential ability to modify the expression of IL-6. The peptide appears to affect the expression of nearly 34 genes in the inflammatory pathway, which may include those affecting chemokines, cytokines, and receptors. Specifically, it has been studied in relation to Bcl6 expression, which is considered to promote immune development.\u003cbr\u003e\u003cbr\u003eThis scientific study not only helps explore the complex potential impact of the peptide. It may also improve our understanding of immune systems in general. Selank and its truncated versions may mediate transient gene expression for C3, CAsp1, Il2rf, and Xcr1 in the mouse spleen. Selank may alter the immune system's balance and thereby modulate inflammation.\u003csup\u003e[6]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eSelank Peptide and Metabolic Actions on Lipid Metabolism\u003c\/strong\u003e\u003cbr\u003eSelank has been researched and compared to a placebo regarding its potential action on lipid metabolism in murine models of obesity.\u003csup\u003e[7]\u003c\/sup\u003e The analysis suggests that the group exposed to Selank appeared to exhibit reductions in cholesterol and fat levels, ranging approximately between 25% and 58%. This implies that Selank may potentially decrease specific forms of lipids, such as low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL) cholesterol, and triglycerides. This observation suggests that Selank might have a role, whether direct or indirect, in influencing lipid metabolism mechanisms and might exhibit hypocholesterolemic (cholesterol-lowering) and hypolipidemic (lipid-lowering) properties.\u003cbr\u003e\u003cbr\u003eFurther, the research indicated notable improvements in hemostasis-related parameters, including increased total fibrinolytic activity and reduced platelet aggregation. These changes might imply potential benefits in conditions that predispose to clot formation. Additionally, Selank's potential modulatory action on glucose homeostasis was suggested, indicating it might help maintain stable blood glucose levels. The study also reported an enhancement in the fat metabolism rate within the Selank group, which eventually aligned with the metabolism rate observed in control models. Weight measurements showed that the test group of research models had an average weight gain of 40g during the study period. In contrast, the Selank group maintained their weight throughout the study, with a gradual reduction observed upon peptide exposure.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eSelank Peptide and Nootropic Actions\u003c\/strong\u003e\u003cbr\u003eAnxiety and learning\/memory have shown a strong inverse association in studies conducted on test models by researchers. The peptide appears to potentially reduce the impact of anxiety on cognitive function. Selank research has suggested that the peptide may improve memory traceability and recall in rats.\u003csup\u003e[8]\u003c\/sup\u003e This improvement was independent of the anxiety levels of the rats. The peptide appears to trigger better memory recall through the hippocampal expression of 36 different genes.\u003cbr\u003e\u003cbr\u003eThe majority of the targets are membrane-associated proteins that regulate ion movement across cell membranes. Thus, the ion-dependent processes in learning and memory appear to be enhanced by the molecule. Selank researchers have posited its potential to help in formation and access of memories. It may also help to rescue memory and cognitive abilities after injury in rats exposed to neurotoxins. This inference is considered to be due to the apparent inhibition of catecholamines in the brain.\u003csup\u003e[9]\u003c\/sup\u003e Selank may thereby play a hand in the restoration of cognitive function after an injury.\u003cbr\u003e\u003cbr\u003eAnother study also investigated the potential nootropic actions of the synthetic peptide Selank in murine models with both normal and reduced learning abilities. Results in normal murine models suggested that Selank potentially enhanced the learning process, particularly notable by the third day of repeated exposure. The number of correct avoidance responses increased, and the number of errors decreased. This action was observed to persist, suggesting an improvement in memory retention.\u003cbr\u003e\u003cbr\u003eNotably, Selank's influence seemed to commence during the consolidation phase of learning. In models with initially reduced learning ability, Selank exhibited a rapid potential impact, with improvements observed from the first experimentation day. Researchers observed this group and indicated a progressive increase in correct responses and a decrease in errors across the training period. The data suggests that Selank might play a role in optimizing learning and memory processes by possibly enhancing the formation and consolidation of conditioned reflexes.[10]\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eSelank and Serotonin Neurotransmission\u003c\/strong\u003e\u003cbr\u003eResearch suggests that Selank might have the capability to interact with serotonin signaling pathways.\u003csup\u003e[12]\u003c\/sup\u003e Serotonin signaling is thought to play a role in regulating mood and anxiety in the brain. Studies using murine models with inhibited serotonin synthesis imply that Selank may contribute to the modulation of serotonin levels when serotonergic function is impaired.\u003cbr\u003e\u003cbr\u003eIt is hypothesized that Selank may enhance serotonin metabolism in the brainstem, inducing a potentially quick action on the serotonin system. The peptide is believed to potentially increase serotonin metabolic activity in brain regions involved in mood and anxiety regulation. Moreover, the study hypothesizes that Selank's ability to boost serotonin metabolism might provide a mechanism for addressing disturbances linked to reduced serotonin function.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eSelank and Neurotrophic Factors\u003c\/strong\u003e\u003cbr\u003eSelank might influence the expression of brain-derived neurotrophic factor (BDNF), a protein considered essential for the survival and growth of neurons in the brain.\u003csup\u003e[13]\u003c\/sup\u003e Some studies suggest that Selank may potentially elevate the levels of BDNF mRNA in the hippocampus, a brain region associated with memory formation and emotional regulation. This potential ability of Selank to enhance BDNF expression, especially in scenarios where stress and glucocorticoids may suppress BDNF levels, implies its potential importance in research exploring neuroplasticity.\u003c\/p\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSelank Peptide and Nociception\u003c\/strong\u003e\u003cbr\u003eEnkephalins are natural peptides that are considered to reduce the severity of nociception by interacting with opioid receptors. Research suggests that Selank might potentially inhibit enkephalin-degrading enzymes, which are deemed responsible for breaking down enkephalins.\u003csup\u003e[11]\u003c\/sup\u003e Enkephalins are naturally occurring ligands that bind to opioid receptors and are believed to be involved in regulating pain, mood, and stress responses. By possibly inhibiting these enzymes, Selank may slow the degradation of enkephalins, potentially increasing their availability and enhancing their actions.\u003cbr\u003e\u003cbr\u003eAdditionally, the research data indicated that Selank exposure might lead to an increase in the half-life (tau(1\/2)) of leu-enkephalin, a specific type of enkephalin, particularly in models of anxiety. This implies that Selank may prolong the presence of leu-enkephalin in the system, which might contribute to its anxiolytic actions. However, these findings still need to be investigated, and the precise mechanisms and extent of Selank's impact still needs to be fully understood.\u003csup\u003e[5] \u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eVolkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016 Feb 18;7:31. . PMID: 26924987; PMCID: PMC4757669.\u003c\/li\u003e\n\u003cli\u003eKasian A, Kolomin T, Andreeva L, Bondarenko E, Myasoedov N, Slominsky P, Shadrina M. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017;2017:5091027. . Epub 2017 Feb 9. PMID: 28280289; PMCID: PMC5322660.\u003c\/li\u003e\n\u003cli\u003eSokolov OY, Meshavkin VK, Kost NV, Zozulya AA. Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions. Bull Exp Biol Med. 2002 Feb;133(2):133-5. . PMID: 12432865.\u003c\/li\u003e\n\u003cli\u003eUchakina ON, Uchakin PN, Miasoedov NF, Andreeva LA, Shcherbenko VE, Mezentseva MV, Gabaeva MV, Sokolov OIu, Zozulia AA, Ershov FI. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-5. Russian. PMID: 18577961.\u003c\/li\u003e\n\u003cli\u003eZozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. Russian. PMID: 18454096.\u003c\/li\u003e\n\u003cli\u003eAgapova TIu, Agniullin IaV, Silachev DN, Shadrina MI, Slominskiĭ PA, Shram SI, Limborskaia SA, Miasoedov NF. [Effect of semax on the temporary dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus and frontal cortex]. Mol Gen Mikrobiol Virusol. 2008;(3):28-32. Russian. PMID: 18756821.\u003c\/li\u003e\n\u003cli\u003eN.F. Mjasoedov et al, The Influence of Selank on the Parameters of the Hemostasis System, Lipid Profile, and Blood Sugar Level in the Course of Experimental Metabolic Syndrome. April 14, 2014.\u003c\/li\u003e\n\u003cli\u003eSemenova TP, Kozlovskiĭ II, Zakharova NM, Kozlovskaia MM. [Experimental optimization of learning and memory processes by selank]. Eksp Klin Farmakol. 2010 Aug;73(8):2-5. Russian. PMID: 20919548.\u003c\/li\u003e\n\u003cli\u003eSemenova TP, Kozlovskaya MM, Zakharova NM, Kozlovskii II, Zuikov AV. Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny. Bull Exp Biol Med. 2007 Nov;144(5):689-91. . PMID: 18683497.\u003c\/li\u003e\n\u003cli\u003eKozlovskii II, Danchev ND. The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neurosci Behav Physiol. 2003 Sep;33(7):639-43.\u003c\/li\u003e\n\u003cli\u003eKost, N. V., Sokolov, O. I.u, Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. A., Miasoedov, N. F., \u0026amp; Zozulia, A. A. (2001). Ingibiruiushchee deĭstvie semaksa i selanka na énkefalindegradiruiushchie fermenty syvorotki krovi cheloveka [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]]. Bioorganicheskaia khimiia, 27(3), 180–183.\u003c\/li\u003e\n\u003cli\u003eSemenova TP, kozlovskiĭ II, Zakharova NM, Kozlovskaia MM. [Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA]. Eksp Klin Farmakol. 2009 Jul-Aug;72(4):6-8. Russian. PMID: 19803361.\u003c\/li\u003e\n\u003cli\u003eInozemtseva, L. S., Karpenko, E. A., Dolotov, O. V., Levitskaya, N. G., Kamensky, A. A., Andreeva, L. A., \u0026amp; Grivennikov, I. A. (2008). Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 421, 241–243.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786429104445,"sku":"sku2194756146315","price":120.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/Selank-10MG-2-1.webp?v=1780466157"},{"product_id":"hexarelin-5mg","title":"(💪Faster recovery) Hexarelin Peptide - (5mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is Hexarelin?\u003c\/p\u003e\n\u003cp\u003eHexarelin belongs to:\u003cbr\u003e👉 A “stronger version” of GHRP-6 \/ GHRP-2\u003c\/p\u003e\n\u003cp\u003eIt acts on:\u003c\/p\u003e\n\u003cp\u003eGhrelin receptors\u003cbr\u003eThe pituitary GH release pathway\u003cbr\u003e💪 Main Effects (Theory + User Feedback)\u003cbr\u003e🔥 1️⃣ Powerfully boosts GH secretion\u003c\/p\u003e\n\u003cp\u003eHexarelin is considered:\u003cbr\u003e👉 “One of the strongest” among early GHRP compounds\u003c\/p\u003e\n\u003cp\u003eMay result in:\u003c\/p\u003e\n\u003cp\u003eSignificantly increased GH pulses\u003cbr\u003eRise in IGF-1 (indirectly)\u003cbr\u003e💪 2️⃣ Muscle and Recovery\u003c\/p\u003e\n\u003cp\u003eCommon claims in the fitness community:\u003c\/p\u003e\n\u003cp\u003eFaster recovery\u003cbr\u003eImproved training tolerance\u003cbr\u003eAccelerated muscle repair\u003c\/p\u003e\n\u003cp\u003eHowever:\u003cbr\u003e⚠️ Human studies are limited; most evidence comes from anecdotal feedback.\u003c\/p\u003e\n\u003cp\u003e😴 3️⃣ Improved Sleep\u003c\/p\u003e\n\u003cp\u003eSome users report:\u003c\/p\u003e\n\u003cp\u003eIncreased deep sleep\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eHexarelin Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eHexarelin\u003c\/strong\u003e (also known as Examorelin) is a synthetic analog of ghrelin and shares a high degree of structural similarity to GHRP-6. Both are research peptides made of six amino acids that mimic the function of the endogenous hormone ghrelin and stimulate the release of growth hormone (hGH) from anterior pituitary gland cells. The only difference between Hexarelin and is the inclusion of a methyl group in the structure of Hexarelin. Like other ghrelin analogs, this peptide is reported by researchers to display a relative selectivity in its mode of action. However, researchers have commented that Hexarelin is also associated with an elevation in prolactin, adrenocorticotropic hormone (ACTH), and consequently cortisol.\u003csup\u003e[1][2]\u003c\/sup\u003e It has been extensively studied in relation to cardiac cell survival after ischemia and nutrient deprivation.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e47\u003c\/sub\u003eH\u003csub\u003e58\u003c\/sub\u003eN\u003csub\u003e12\u003c\/sub\u003eO\u003csub\u003e6\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 887.05 g\/mol\u003c\/p\u003e\n\u003cp class=\"grey-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e His-2-Me-D-Trp-Ala-Trp-D-Phe-Lys-NH2\u003c\/p\u003e\n\u003ch3\u003eHexarelin Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eHexarelin and Growth Hormone Secretagogue Receptors\u003c\/strong\u003e\u003cbr\u003eIt is theorized that Hexarelin functions by activating growth hormone secretagogue receptors (GHS-Rs), specifically targeting the GHSR-1a subtype.\u003csup\u003e[3]\u003c\/sup\u003e The activation of these receptors is thought to potentially trigger the release of growth hormone (GH), suggesting Hexarelin's role as a potential growth hormone secretagogue (GHS). GHS-Rs mediate the actions of ghrelin, an endogenous hormone that typically promotes GH release during fasting periods. It is conceivable that Hexarelin may mimic the role of ghrelin by engaging ghrelin receptors, particularly those located in key areas such as the pituitary gland and hypothalamus, to stimulate hGH secretion.\u003cbr\u003e\u003cbr\u003eGHSR-1a receptors are distributed throughout the hypothalamus and pituitary gland as well as across various regions of the nervous system and other bodily tissues. Therefore, it is suggested that Hexarelin's mechanisms might involve both direct and indirect stimulation of GH release. Direct actions might occur via actions on the GHS-Rs within the pituitary, while indirect actions could involve modulation of the hypothalamus. Upon binding to GHS-Rs, it is speculated that Hexarelin may induce a structural modification in the receptor, potentially initiating signaling cascades reliant on G-proteins. This might lead to the activation of pathways such as those involving protein kinase C (PKC), which might enhance the signaling required for GH secretion from pituitary cells. Nonetheless, it is also hypothesized that Hexarelin exposure could result in transient receptor desensitization, a state that could persist for several days or weeks.\u003csup\u003e[4]\u003c\/sup\u003e Overall, the activation of the GHSR-1a might represent an alternative route by which Hexarelin regulates hGH synthesis in the anterior pituitary cells, differing from the direct actions mediated by the native growth hormone-releasing hormone (GHRH) on the GHRH receptors in the pituitary gland cells.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eHexarelin and Muscle Cell Protection\u003c\/strong\u003e\u003cbr\u003eThe peptide has been suggested to protect cells inside and outside the heart muscle. Studies in Hexarelin and GHRP-6 observe how the peptides may control calcium flow and mitochondrial dysfunction in the muscles of rats suffering from cachexia (extreme weight loss due to illness or chemotherapy).\u003csup\u003e[5]\u003c\/sup\u003e The researchers report that the secretagogue may potentially \u003cem\u003e“protect skeletal muscle from mitochondrial damage and improve lean mass recovery.”\u003c\/em\u003e It also appears to keep muscle cells viable by maintaining mitochondrial integrity. Through its energy supply, Mitochondria help muscles carry out day-to-day functions. It has been suggested that calcium ion regulation is often disturbed due to chemotherapy and may be one of the principal causes of altered muscle and lean body mass. Researchers suggest the potential for Hexarelin and GHRP-6 to potentially support the reestablishment of proper calcium regulation. Additional studies have indicated that Hexarelin, a synthetic hexapeptide, might positively reduce muscle degradation in experimental settings that simulate catabolism and cachexia. Cachexia is a complex syndrome associated with severe muscle atrophy and weight loss. For instance, research involving experimental models exposed to catabolic agents showed a 12% decrease in muscle mass.\u003csup\u003e[6]\u003c\/sup\u003e However, introducing Hexarelin may have reduced this loss to approximately 7%. Another related study proposed that Hexarelin might have helped mitigate the decline in muscular strength typically observed when experimental models are subjected to catabolic agents.\u003csup\u003e[7]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eHexarelin and Cardiac Functions\u003c\/strong\u003e\u003cbr\u003eHexarelin appears to affect the heart through its association with the CD36 receptor and the GHSR. Research conducted on murine models suggests that the peptide appears to protect cardiac cells from injury in the backdrop of cardiac arrest.\u003csup\u003e[8]\u003c\/sup\u003e The scientists even note that Hexarelin \u003cem\u003e“may be a promising [research] agent for some cardiovascular conditions.”\u003c\/em\u003e Researchers suggest that the peptide may interact with the aforesaid receptors and potentially prevent apoptosis of the cardiac cells. The peptide may act to improve cardiac function, increasing the number of surviving cardiac cells and reducing the levels of malondialdehyde (cardiac cell death marker). Interestingly, the study also suggested GHRP-6 to be partially superior in function compared to ghrelin. Hexarelin has also been observed to ameliorate oxidative stress in cardiac cells during cardiac failure as well as to prevent myocardial remodeling in rats.\u003csup\u003e[9]\u003c\/sup\u003e Cardiac remodeling is characterized by a decrease in cardiac function and may be fatal. However, GHRP-6 or Hexarelin-exposed rats appeared to show significant improvement in their cardiac function compared to the controls. The molecular mechanisms underlying the function of the peptide have been suggested to involve an increase of phosphatase and tensin homolog (PTEN) activity and subsequent reduction in protein kinase B levels. While PTEN is considered to regulate cellular regeneration, protein kinase B appears to help modulate cell survival. GHRP-6 and Hexaralin may mediate cardiac remodeling by switching the nervous system response from sympathetic (includes increased blood pressure, heart rate, etc.) to parasympathetic. This regulation may help to improve short-term function. Moreover, when exposed to the peptide following cardiac arrest, studies with rat models observed a significant decrease in scar tissue arising from cardiac tissue healing. The peptide may have the potential for assisting in numerous cardiac damages as its mode of action is not hypothesized to be specific to protection against heart attack. Studies in rat models of diabetes have also observed Hexarelin to potentially improve cardiac function by altering the processing of calcium and potassium by cardiac muscle cells.\u003csup\u003e[10]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eHexarelin and Fat Cells\u003c\/strong\u003e\u003cbr\u003eDyslipidemia is the physiological condition of elevated fat levels in the blood. Interestingly, it also is considered to be an independent contributing factor for the onset of diabetes. GHRP-6 and Hexarelin studies have observed the peptides’ potential to correct dyslipidemia in the backdrop of insulin resistance (considered the first step in the pathway to diabetes).\u003csup\u003e[11]\u003c\/sup\u003e The peptide may also help to reduce blood sugar and insulin resistance as reported in rat models.\u003c\/p\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px !important;\"\u003e\u003cstrong\u003eHexarelin and Appetite\u003c\/strong\u003e\u003cbr\u003eIt has been suggested that Hexarelin might broadly stimulate ghrelin receptors beyond just targeting the pituitary gland, which might possibly impact appetite and hunger.\u003csup\u003e[12]\u003c\/sup\u003e When activated in certain areas of the nervous system, Ghrelin receptors may initiate cellular activities, leading to an increased release of hunger-promoting neuropeptides such as Neuropeptide Y (NPY) and Agouti-related peptide (AgRP). These neuropeptides play a pivotal role in the regulation of energy balance and the modulation of appetite. It is also hypothesized that Hexarelin could potentially decrease the production of melanocyte-stimulating hormone (α-MSH), an appetite-suppressing hormone, thereby possibly shifting the physiological balance toward enhanced hunger and promoting increased food consumption. Additionally, there is a possibility that Hexarelin may interact with the mesolimbic reward system, which is integral to the regulation of cravings for palatable food, through the potential activation of the GHSR-1a receptor. Such interaction might lead to the activation of cyclic adenosine monophosphate (cAMP) pathways, which may theoretically heighten the motivation to eat, thereby implying a potential influence of Hexarelin on altering feeding behaviors and reward-based eating patterns.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px !important;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eGhigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, Boghen MF, Deghenghi R, Camanni F. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. Eur J Endocrinol. 1996 Oct;135(4):407-12. . PMID: 8921821.\u003c\/li\u003e\n\u003cli\u003eMassoud, A. F., Hindmarsh, P. C., \u0026amp; Brook, C. G. (1996). Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. \u003cem\u003eThe Journal of clinical endocrinology and metabolism\u003c\/em\u003e, \u003cem\u003e81\u003c\/em\u003e(12), 4338–4341.\u003c\/li\u003e\n\u003cli\u003eTorsello A, Grilli R, Luoni M, Guidi M, Ghigo MC, Wehrenberg WB, Deghenghi R, Müller EE, Locatelli V. Mechanism of action of Hexarelin. I. Growth hormone-releasing activity in the rat. Eur J Endocrinol. 1996 Oct;135(4):481-8.\u003c\/li\u003e\n\u003cli\u003eRahim, A., O'Neill, P. A., \u0026amp; Shalet, S. M. (1998). Growth hormone status during long-term hexarelin therapy. \u003cem\u003eThe Journal of clinical endocrinology and metabolism\u003c\/em\u003e, \u003cem\u003e83\u003c\/em\u003e(5), 1644–1649.\u003c\/li\u003e\n\u003cli\u003eBresciani E, Rizzi L, Coco S, Molteni L, Meanti R, Locatelli V, Torsello A. Growth Hormone Secretagogues and the Regulation of Calcium Signaling in Muscle. Int J Mol Sci. 2019 Sep 5;20(18):4361. . PMID: 31491959; PMCID: PMC6769538.\u003c\/li\u003e\n\u003cli\u003eBresciani, E., Rizzi, L., Molteni, L., Ravelli, M., Liantonio, A., Ben Haj Salah, K., Fehrentz, J. A., Martinez, J., Omeljaniuk, R. J., Biagini, G., Locatelli, V., \u0026amp; Torsello, A. (2017). JMV2894, a novel growth hormone secretagogue, accelerates body mass recovery in an experimental model of cachexia. \u003cem\u003eEndocrine\u003c\/em\u003e, \u003cem\u003e58\u003c\/em\u003e(1), 106–114.\u003c\/li\u003e\n\u003cli\u003eConte, E., Camerino, G. M., Mele, A., De Bellis, M., Pierno, S., Rana, F., Fonzino, A., Caloiero, R., Rizzi, L., Bresciani, E., Ben Haj Salah, K., Fehrentz, J. A., Martinez, J., Giustino, A., Mariggiò, M. A., Coluccia, M., Tricarico, D., Lograno, M. D., De Luca, A., Torsello, A., … Liantonio, A. (2017). Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia. \u003cem\u003eJournal of cachexia, sarcopenia and muscle\u003c\/em\u003e, \u003cem\u003e8\u003c\/em\u003e(3), 386–404.\u003c\/li\u003e\n\u003cli\u003eMao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. J Geriatr Cardiol. 2014 Sep;11(3):253-8. . PMID: 25278975; PMCID: PMC4178518.\u003c\/li\u003e\n\u003cli\u003eMcDonald H, Peart J, Kurniawan N, Galloway G, Royce S, Samuel CS, Chen C. Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction. Physiol Rep. 2018 May;6(9):e13699. . PMID: 29756411; PMCID: PMC5949285.\u003c\/li\u003e\n\u003cli\u003eMosa RM, Zhang Z, Shao R, Deng C, Chen J, Chen C. Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases. Endocrine. 2015 Jun;49(2):307-23. \u003ca href=\"https:\/\/doi.org\/10.1007\/s12020-015-0531-z\" rel=\"noopener\" target=\"_blank\"\u003edoi: 10.1007\/s12020-015-0531-z\u003c\/a\u003e. Epub 2015 Feb 4. PMID: 25645463.\u003c\/li\u003e\n\u003cli\u003eMosa R, Huang L, Wu Y, Fung C, Mallawakankanamalage O, LeRoith D, Chen C. Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice. Endocrinology. 2017 Oct 1;158(10):3174-3187. \u003ca href=\"https:\/\/doi.org\/10.1210\/en.2017-00168\" rel=\"noopener\" target=\"_blank\"\u003edoi: 10.1210\/en.2017-00168\u003c\/a\u003e. PMID: 28977588; PMCID: PMC5659698.\u003c\/li\u003e\n\u003cli\u003eBresciani, E., Pitsikas, N., Tamiazzo, L., Luoni, M., Bulgarelli, I., Cocchi, D., Locatelli, V., \u0026amp; Torsello, A. (2008). Feeding behavior during long-term hexarelin administration in young and old rats. \u003cem\u003eJournal of endocrinological investigation\u003c\/em\u003e, \u003cem\u003e31\u003c\/em\u003e(7), 647–652. \u003ca href=\"https:\/\/doi.org\/10.1007\/BF03345618\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1007\/BF03345618\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786429137213,"sku":"sku2194756135209","price":180.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/Hexarelin-5MG-2-1.webp?v=1780466158"},{"product_id":"adipotide-ftpp-10mg","title":"(🔥Fat loss) Adipotide FTPP 10mg-10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is Adipotide \/ FTPP?\u003c\/p\u003e\n\u003cp\u003eAdipotide (also known as FTPP) is designed to:\u003c\/p\u003e\n\u003cp\u003eTarget blood vessels in adipose tissue\u003cbr\u003eDisrupt the environment necessary for fat cells to survive\u003cbr\u003eInduce apoptosis (cell death) in fat cells\u003c\/p\u003e\n\u003cp\u003eIts mechanism of action is unique; it does not rely on traditional “fat burning,” but rather:\u003c\/p\u003e\n\u003cp\u003e👉 “Fat loss by cutting off blood supply”\u003c\/p\u003e\n\u003cp\u003e🔥 Mechanism of Action (Key Points)\u003cbr\u003e🧪 1️⃣ Targets Fat Vessels\u003c\/p\u003e\n\u003cp\u003eAdipotide binds to specific receptors on the surface of adipose tissue:\u003c\/p\u003e\n\u003cp\u003e➡️ It targets only the vascular system of adipose tissue\u003cbr\u003e➡️ It does not directly “burn fat,” but rather causes fat cells to become oxygen-deprived\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eAdipotide FTPP Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eAdipotide FTPP is a category of proapoptotic peptides intended to eliminate fat cells.\u003csup\u003e[1]\u003c\/sup\u003e They appear to cut off the blood supply specifically to the adipose tissues and not the vessels supplying blood to the rest of the organism. Reports of studies performed in monkeys have suggested their potential to induce weight loss, which may improve symptoms of insulin resistance and reduces the symptoms of type 2 diabetes.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e Adipotide\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e152\u003c\/sub\u003eH\u003csub\u003e252\u003c\/sub\u003eN\u003csub\u003e44\u003c\/sub\u003eO\u003csub\u003e42\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 2611.41 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys—Gly-Gly--(Lys-Leu-Ala-Lys-Leu-Ala-Lys)2\u003c\/p\u003e\n\u003ch3\u003eAdipotide FTPP Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eAdipotide FTPP Mechanism of Action\u003c\/strong\u003e\u003cbr\u003eAdipotide has been suggested to exert action by binding to the receptors for two specific proteins, ANXA2 (Annexin A2) and prohibitin (PHB). It appears that these receptors may be expressed in a wide range of cells, but immunohistochemical analysis hypothesizes that they potentially form a unique ANXA2-prohibitin receptor system that are apparently found in white fat tissue.\u003csup\u003e[2] \u003c\/sup\u003eIt appears that these receptors were found on the endothelial cells of blood vessels that support white fat cells. Furthermore, research suggests that these receptors may play a role in regulating fatty acid transport in white adipose tissues (WAT).\u003csup\u003e[3]\u003c\/sup\u003e To potentially explore this notion, the researchers disrupted the binding between ANXA2 and prohibitin genetically or by utilizing a blocking peptide. Their findings seem to indicate that the efficiency of fatty acid transport might depend on the interaction between ANXA2 and prohibitin. Moreover, the study suggests that the interaction between ANXA2 and prohibitin may facilitate the transport of fatty acids from the endothelium into adipocytes. The researchers also stumbled upon the revelation that ANXA2 and prohibitin form a complex alongside the fatty acid transporter CD36.\u003cbr\u003e\u003cbr\u003eThis intricate connection involving ANXA2, prohibitin, and CD36 potentially plays a role in mediating fatty acid transport in white adipose tissues. Furthermore, the researchers noticed that the coexistence of prohibitin and CD36 on the surface of adipocytes appears to be induced by extracellular fatty acids. This lead them to the hypothesis that the presence of fatty acids in the external environment may trigger the interaction between prohibitin and CD36 on the adipocyte surface. Hypothetically, inhibiting the ANXA2 protein may lead to hypertrophy of white adipose cells due to reduced uptake of fatty acids. On the other hand, prohibitin is a multifunctional membrane-associated protein that may be thought to regulate cell survival and growth. By shuttling from the cell's membrane to its nucleus, it may hypothetically trigger apoptosis. Thus, the scientists commented that \u003cem\u003e“suggest that an unrecognized biochemical interaction between ANX2 and PHB regulates CD36-mediated fatty acid transport in WAT, thus revealing a new potential pathway for intervention in metabolic diseases.”\u003c\/em\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eAdipotide FTPP Structure\u003c\/strong\u003e\u003cbr\u003eAdipotide appears to have a unique structure consisting of the amino acid sequence GKGGRAKDC-GG-D(KLAKLAK)2. The nine amino acid sequence CKGGRAKDC may exhibit a specific affinity to the ANXA2-prohibitin receptor system found in the blood vessels supporting white adipose cells.\u003csup\u003e[4]\u003c\/sup\u003e The researchers utilized phage display, a technique that is considered to enable the identification of specific peptide motifs, to isolate a peptide sequence CKGGRAKDC. Moreover, the CKGGRAKDC peptide appears to associate with a membrane protein called prohibitin, which has been identified as a potential vascular marker of adipose tissue. By directing a proapoptotic peptide towards prohibitin in the adipose vasculature, the researchers induced the ablation (removal) of white fat. This resulted in the possible resorption of established white adipose tissue and the potential normalization of metabolism. As a consequence, rapid obesity reversal was reported to be achieved. It is suggested that prohibitin is expressed in the blood vessels of white fat. However, it is crucial to note that the study solely focuses on elucidating the mechanisms involved and did not provide any definitive suggestions or implications regarding its potential.\u003cbr\u003e\u003cbr\u003eAt the same time, (KLAKLAK)2 may disrupt mitochondrial membranes upon receptor-mediated cell internalization and possibly cause programmed cell death. As Adipotide may bind to prohibitin in white adipose vasculature, it potentially triggers apoptosis and hypothetically results in the ablation of white fat cells. According to research, Adipotide and other similar peptidomimetics may hold potential for reducing both subcutaneous and visceral fat and may even target intra-organ fat, such as in fatty liver.\u003csup\u003e[5]\u003c\/sup\u003e In fact, the researchers posit that \u003cem\u003e“vascular-targeted nanotherapy has the potential to contribute to the control of adipose function and ectopic fat deposition associated with obesity and the metabolic syndrome.”\u003c\/em\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eAdipotide FTPP and Cancer Cells\u003c\/strong\u003e\u003cbr\u003eCancerous tissues can grow rapidly and become metastatic due to the large network of blood vessels. Suppose prohibitin, found in several cancer types, is targeted. In that case, it may be possible to mitigate cancer in a more focused manner and avoid the associated negative impacts brought about due to damage to surrounding tissues in certain chemotherapy scenarios. Some researchers posit that there may be a potential association between excess fat tissue cells and the occurrence of cancer cells. One study discussed several potential mechanisms that may help explain the potential association between obesity and the occurrence of aggressive prostate cancer cells (PCa), aka tumorigenesis.\u003csup\u003e[6]\u003c\/sup\u003e Three main mechanisms are highlighted: the insulin\/insulin-like growth factor (IGF)-1 axis, sex hormones, and adipokine signaling. The insulin\/IGF-1 axis appears implicated in the potential tumorigenesis associated with obesity, including PCa. It is suggested that high insulin levels resulting from a hyperinsulinemic state induced by diet may potentially accelerate tumor cell growth in PCa models.\u003cbr\u003e\u003cbr\u003eThe presence of the insulin receptor in PCa indicates a potential for insulin to stimulate its growth. Studies have associated higher serum C-peptide concentrations, serving as a surrogate for insulin levels, with an increase in PCa-specific mortality. Thus, it is hypothesized that insulin likely plays a key role in potentially explaining the connection between obesity and aggressive PCa. Obesity and hyperinsulinemia also potentially result in increased levels of bioactive IGF-1, a growth factor implicated in various cancers. Elevated circulating IGF-1 has been associated with an increased incidence of PCa, particularly in detectable cases. The upregulation of the IGF-1 receptor accompanies the transition of androgen-dependent PCa cell lines to androgen independence, and studies have suggested that IGF-1 potentially promotes PCa progression. Therefore, it is posited that IGF-1 may be associated with aggressive PCa, although its association with less aggressive, PSA-detected tumors remains uncertain. Testosterone (T) is potentially aromatized to estradiol (E) within adipocytes and prostate cells.\u003cbr\u003e\u003cbr\u003eObesity, characterized by increased adipose tissue mass and upregulation of the aromatization pathway, leads to potentially elevated serum and intracellular E levels. Although epidemiologic data does not consistently support a clear association between serum E and PCa risk, preclinical studies suggest that E may potentially promote PCa development and progression. Obesity is considered a state of chronic subclinical inflammation influenced by altered levels of adipokines. Leptin, potentially elevated in obesity, appears to exert pro-tumor impacts in PCa cell lines, inducing proliferation, inhibiting apoptosis, and increasing migration. However, epidemiologic studies do not consistently report a clear positive association between leptin and PCa risk or fatal PCa. On the other hand, adiponectin, which is considered to be reduced in obesity, predominantly exhibits anti-tumor effects. Reduced levels of adiponectin have potentially been associated with metastatic and fatal PCa. While the role of leptin in the link between obesity and aggressive PCa remains unclear, adiponectin appears to be associated with advanced aggressive PCa, reflecting the overall connection between obesity and PCa.\u003cbr\u003e\u003cbr\u003eObesity is also potentially associated with elevated serum interleukin (IL)-6 levels, primarily originating from adipose tissue. PCa cells and primary PCas potentially produce IL-6 and express IL-6 receptors, enabling them to respond to this proinflammatory adipokine.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eAdipotide and Glucose Tolerance\u003c\/strong\u003e\u003cbr\u003eGlucose tolerance, a common parameter in characterizing diabetes, is studied by performing a blood test and confirmed by testing fasting glucose levels. In another method, a specific amount of glucose is consumed, and then blood sugar levels are estimated. Metabolic syndromes such as diabetes have traditionally been controlled by nutritional intake and physical activity. Both require immense patience and dedication as the outcomes can take months, if not years, to exhibit significant improvement. Research with Adipotides has noted rapid weight-independent improvement in glucose tolerance in animal research models.\u003csup\u003e[7]\u003c\/sup\u003e This highlights the observation that reducing white fat by adipotide FTPP may simultaneously reduce glucose tolerance irrespective of the model’s weight. Although it is unclear whether Adipotide FTPP peptide may directly induce fat loss or whether it may decrease the appetite (an indirect factor), the former is more likely as changes in fat cell density and improved glucose tolerance have been observed even without associated weight loss.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eAdipotide And Fat Loss\u003c\/strong\u003e\u003cbr\u003eResearch on rhesus monkeys suggested the potential of this novel peptide to induce apoptosis, specifically in the vessels supplying blood to the white adipose tissues.\u003csup\u003e[8]\u003c\/sup\u003e The result being no blood cells and hence, the ensuing death of these fat cells. The eventual outcomes reported were rapid weight loss, decreased body mass index, and improved insulin sensitivity. Such changes were attributed in part to the potential of Adipotide FTPP to change the eating pattern of the monkeys, as the monkeys who exhibit a positive weight loss also exhibited a reduced appetite. Research has suggested that Adipotide is associated with prohibitin, a membrane protein receptor present in blood vessels of white fat tissues and some cancer cells.\u003c\/p\u003e\n\u003ch3\u003eFuture Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eAnti-angiogenic molecules like Adipotites target the blood vessels and are considered a potential agent in cancer studies.\u003csup\u003e[9]\u003c\/sup\u003e Most of the research with Adipotides have been focused on their potential in fat loss and diabetes. They have been suggested to target the blood vessels of adipose tissues in which they supposedly induce apoptosis.\u003c\/p\u003e\n\u003ch3 style=\"color: #555; margin-top: 25px;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"padding-bottom: 5px !important; margin-bottom: 25px !important;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eKolonin, M. G., Saha, P. K., Chan, L., Pasqualini, R., \u0026amp; Arap, W. (2004). Reversal of obesity by targeted ablation of adipose tissue. Nature medicine, 10(6), 625–632.\u003c\/li\u003e\n\u003cli\u003eStaquicini, F. I., Cardó-Vila, M., Kolonin, M. G., Trepel, M., Edwards, J. K., Nunes, D. N., Sergeeva, A., Efstathiou, E., Sun, J., Almeida, N. F., Tu, S. M., Botz, G. H., Wallace, M. J., O'Connell, D. J., Krajewski, S., Gershenwald, J. E., Molldrem, J. J., Flamm, A. L., Koivunen, E., Pentz, R. D., … Arap, W. (2011). Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. \u003ci\u003eProceedings of the National Academy of Sciences of the United States of America\u003c\/i\u003e, \u003ci\u003e108\u003c\/i\u003e(46), 18637–18642.\u003c\/li\u003e\n\u003cli\u003eSalameh, A., Daquinag, A. C., Staquicini, D. I., An, Z., Hajjar, K. A., Pasqualini, R., Arap, W., \u0026amp; Kolonin, M. G. (2016). Prohibitin\/annexin 2 interaction regulates fatty acid transport in adipose tissue. \u003ci\u003eJCI insight\u003c\/i\u003e, \u003ci\u003e1\u003c\/i\u003e(10), e86351.\u003c\/li\u003e\n\u003cli\u003eKolonin, M. G., Saha, P. K., Chan, L., Pasqualini, R., \u0026amp; Arap, W. (2004). Reversal of obesity by targeted ablation of adipose tissue. \u003ci\u003eNature medicine\u003c\/i\u003e, \u003ci\u003e10\u003c\/i\u003e(6), 625–632.\u003c\/li\u003e\n\u003cli\u003eHossen, N., Kajimoto, K., Akita, H., Hyodo, M., \u0026amp; Harashima, H. (2013). A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. \u003ci\u003eJournal of controlled release : official journal of the Controlled Release Society\u003c\/i\u003e, \u003ci\u003e171\u003c\/i\u003e(2), 104–112.\u003c\/li\u003e\n\u003cli\u003eAllott, E. H., Masko, E. M., \u0026amp; Freedland, S. J. (2013). Obesity and prostate cancer: weighing the evidence. \u003ci\u003eEuropean urology\u003c\/i\u003e, \u003ci\u003e63\u003c\/i\u003e(5), 800–809.\u003c\/li\u003e\n\u003cli\u003eHossen, N., Kajimoto, K., Akita, H., Hyodo, M., \u0026amp; Harashima, H. (2013). A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. Journal of controlled release : official journal of the Controlled Release Society, 171(2), 104–112.\u003c\/li\u003e\n\u003cli\u003eBarnhart, K. F., Christianson, D. R., Hanley, P. W., Driessen, W. H., Bernacky, B. J., Baze, W. B., Wen, S., Tian, M., Ma, J., Kolonin, M. G., Saha, P. K., Do, K. A., Hulvat, J. F., Gelovani, J. G., Chan, L., Arap, W., \u0026amp; Pasqualini, R. (2011). A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science translational medicine, 3(108), 108ra112.\u003c\/li\u003e\n\u003cli\u003eThuaud, F., Ribeiro, N., Nebigil, C. G., \u0026amp; Désaubry, L. (2013). Prohibitin ligands in cell death and survival: mode of action and therapeutic potential. Chemistry \u0026amp; biology, 20(3), 316–331.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786429202749,"sku":"sku2194756126571","price":200.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/Adipotide-FTPP-10mg-2-1.webp?v=1780466160"},{"product_id":"aod-9604-5mg","title":"(🔥Fat loss) AOD 9604 (5mg) -10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is AOD-9604?\u003c\/p\u003e\n\u003cp\u003eFull name of AOD-9604:\u003cbr\u003e👉 Anti-Obesity Drug 9604\u003c\/p\u003e\n\u003cp\u003eEssentially:\u003c\/p\u003e\n\u003cp\u003eThe C-terminal fragment (177–191) of HGH\u003cbr\u003emodified for stability (more resistant to degradation)\u003cbr\u003e🔥 Primary functions (research focus)\u003cbr\u003e🧪 1️⃣ Promotes fat breakdown\u003c\/p\u003e\n\u003cp\u003eResearch suggests it may:\u003c\/p\u003e\n\u003cp\u003eEnhance fat oxidation\u003cbr\u003eInhibit lipogenesis\u003cbr\u003ePromote fatty acid release\u003c\/p\u003e\n\u003cp\u003e👉 Core positioning: “Fat-burning peptide”\u003c\/p\u003e\n\u003ch3\u003eAOD 9604 Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eAOD 9604 is a modified peptide initially developed as an offshoot in obesity research. It modifies the peptide of the growth hormone hGH by adding a tyrosine residue to the N-terminus. The proposed mode of action of AOD 9604 has been suggested by researchers to be restricted to promoting lipolysis, thus linking the synthetic compound to obesity research.\u003csup\u003e[1]\u003c\/sup\u003e The peptide does not appear to affect levels of insulin or IGF1 in studies thus far; therefore, it does not appear to trigger diabetes development or induce glucose intolerance in test models, though further studies are necessary to explore this aspect.\u003csup\u003e[2]\u003c\/sup\u003e\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e AOD-9604\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e78\u003c\/sub\u003eH\u003csub\u003e123\u003c\/sub\u003eN\u003csub\u003e23\u003c\/sub\u003eO\u003csub\u003e23\u003c\/sub\u003eS\u003csub\u003e2\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 1815.1 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe\u003c\/p\u003e\n\u003ch3\u003eAOD 9604 Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eAOD 9604 Structure\u003c\/strong\u003e\u003cbr\u003eScientists hypothesize that different parts of the hGH molecule may possess different properties and induce different effects in test models.\u003csup\u003e[3]\u003c\/sup\u003e It has been suggested that only the last 15 amino acids may mediate any fat-burning potential of the hormone. The fragment was initially named hGH 177-191 and was subsequently modified by adding tyrosine to create AOD 9401, potentially to help stabilize the molecule. This modification led to the production of a 16-amino acid fragment called AOD 9604.\u003csup\u003e[4]\u003c\/sup\u003e Interestingly, the researchers comment, \u003cem\u003e\"AOD 9604 does not interact with the hGH receptor.”\u003c\/em\u003e This modification may have made the hGH Fragment 176-191 relatively more stable than other peptides.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eAOD 9604 Mechanism of Action\u003c\/strong\u003e\u003cbr\u003eAOD 9604 has mainly been studied in murine models, and significant experiments have involved relatively large amounts of AOD 9604.\u003csup\u003e[5]\u003c\/sup\u003e These experiments reportedly resulted in a 50% reduction in weight following exposure to the research models. However, it is important to note that the fragment appears to lack any other associated action of hGH, such as a potential increase of IGF-1 (insulin-like growth factor-1), insulin resistance, or cell proliferation. Therefore, the compound may not possess the potential muscle-preserving and anabolic action typically associated with growth hormones. Nevertheless, it appears that AOD 9604 may stimulate weight loss through mechanisms similar to hGH, as it may trigger various cellular pathways that might lead to the release of fatty acids from adipose cells.\u003cbr\u003e\u003cbr\u003eAdditionally, researchers have posited that the peptide may affect the activity of lipases, a group of enzymes that prevent the return of fat to adipose tissues.\u003csup\u003e[6]\u003c\/sup\u003e It is worth noting that AOD 9604 does not appear to affect natural hGH production and does not appear to act as a growth hormone secretagogue. Moreover, it does not appear to impact hunger hormone signaling to either increase or decrease appetite. Murine models comparing AOD 9604 and hGH have reported different outcomes in lean and obese cases.\u003csup\u003e[4]\u003c\/sup\u003e In lean murine models, hGH appears to increase lean body mass, whereas AOD 9604 or a placebo did not appear to produce the same action. Hence, researchers have speculated that AOD 9604 may not be effective in increasing the size of muscle cells and contributing to muscle hypertrophy. However, in obese murine models, both hGH and AOD 9604 appear to exert a weight loss potential. The scientists also commented that there was an apparent 40% reduction in adipose tissue in the hGH group compared to 28% with AOD 9604.\u003cbr\u003e\u003cbr\u003eTherefore, experiments suggest that AOD 9604 may hold reduced potential compared to hGH in stimulating the release of fats from adipose cells.\u003csup\u003e[7]\u003c\/sup\u003e The researchers also posit that \u003cem\u003e“the lipolytic actions of both hGH and AOD 9604 are not mediated directly through the β3-AR although both compounds increase β3-AR expression, which may subsequently contribute to enhanced lipolytic sensitivity.”\u003c\/em\u003e Growth hormone likely promotes a greater release of fats from adipose cells due to its proposed impact on insulin resistance. By reducing glucose uptake, it may force cells to potentially utilize more fat instead. In contrast, the fragment AOD 9604 does not appear to increase insulin resistance. Additionally, anecdotal data suggests that AOD 9604 may potentially offer some impact, including modest improvements in cholesterol levels and insulin sensitivity, but it is yet to be confirmed by murine models.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eAOD 9604 and Obesity\u003c\/strong\u003e\u003cbr\u003eAOD 9604 has been brought into clinical trials with the objective of targeting obesity using a peptide similar to hGH. Phase 2b clinical trials conducted on 300 obese test subjects in Australia observed that the peptide appeared to result in consistent weight loss over 12 weeks when introduced once daily.\u003csup\u003e[8]\u003c\/sup\u003e The rate of weight reduction in test subjects was consistently compared to the placebo cohort, and weight loss appeared to hold steady over the entire study period. This observation indicated that the peptide is unlikely to generate resistance, and thus continued influence of the peptide might result in a pronounced effect. Study in this area is ongoing. Researchers have also utilized mice models to explore the underlying mechanism of AOD 9604.\u003cbr\u003e\u003cbr\u003eAn initial hypothesis proposed that AOD 9604 may bind and activate β-3-adrenergic receptors, which are present on the surface of white adipose tissues. Upon binding to the cognate receptors, the peptide may trigger downstream signaling, which may mobilize the fat cells from storage mode to a usable state by enhancing the rate of metabolism. Interestingly, mice genetically mutated in β-3-adrenergic receptors underwent fat loss, possibly through apoptosis of the white adipose tissues.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eAOD 9604 and Cardiac Disease\u003c\/strong\u003e\u003cbr\u003eAOD 9604 may host the potential to improve cardiac function indirectly by mobilizing fat and reducing obesity. The peptide may reduce the chances of cardiac disease induced by obesity. Apart from its proposed principal function of decreasing fat burden, research teams have suggested other mechanisms by which the peptide might improve cardiac conditions. These pathways are independent of β-3-adrenergic receptors and appear to improve general metabolism, improving cardiac function.\u003csup\u003e[9]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eAOD 9604 and Joints\u003c\/strong\u003e\u003cbr\u003eResearch suggests that AOD 9604 may influence arthritic joints in rabbits, and may have contributed to an improvement in pain perception and decreased movement disability.\u003csup\u003e[10]\u003c\/sup\u003e Researchers have speculated that AOD 9604 may promote the growth of cartilage tissue in the arthritic joints but have yet to fully investigate this hypothesis. Experimental examination and microscopic cartilage structure analysis in affected joints have indicated positive results upon AOD 9604 influence in osteoarthritis test subjects.\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"padding-bottom: 5px !important; margin-bottom: 25px !important;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eNg, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., \u0026amp; Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD 9604) of human growth hormone. Hormone research, 53(6), 274–278.\u003c\/li\u003e\n\u003cli\u003eCox, H. D., Smeal, S. J., Hughes, C. M., Cox, J. E., \u0026amp; Eichner, D. (2015). Detection and in vitro metabolism of AOD 9604. Drug testing and analysis, 7(1), 31–38.\u003c\/li\u003e\n\u003cli\u003eNg, F. M., Jiang, W. J., Gianello, R., Pitt, S., \u0026amp; Roupas, P. (2000). Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. \u003ci\u003eJournal of molecular endocrinology\u003c\/i\u003e, \u003ci\u003e25\u003c\/i\u003e(3), 287-298.\u003c\/li\u003e\n\u003cli\u003eHeffernan, M. A., Thorburn, A. W., Fam, B., Summers, R., Conway-Campbell, B., Waters, M. J., \u0026amp; Ng, F. M. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. \u003ci\u003eInternational journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity\u003c\/i\u003e, \u003ci\u003e25\u003c\/i\u003e(10), 1442–1449.\u003c\/li\u003e\n\u003cli\u003eNg, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., \u0026amp; Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. \u003ci\u003eHormone research\u003c\/i\u003e, \u003ci\u003e53\u003c\/i\u003e(6), 274–278.\u003c\/li\u003e\n\u003cli\u003eKopchick, J. J., Berryman, D. E., Puri, V., Lee, K. Y., \u0026amp; Jorgensen, J. O. (2020). The effects of growth hormone on adipose tissue: old observations, new mechanisms. \u003ci\u003eNature Reviews Endocrinology\u003c\/i\u003e, \u003ci\u003e16\u003c\/i\u003e(3), 135-146.\u003c\/li\u003e\n\u003cli\u003eHeffernan, M., Summers, R. J., Thorburn, A., Ogru, E., Gianello, R., Jiang, W. J., \u0026amp; Ng, F. M. (2001). The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice. \u003ci\u003eEndocrinology\u003c\/i\u003e, \u003ci\u003e142\u003c\/i\u003e(12), 5182-5189.\u003c\/li\u003e\n\u003cli\u003eBray, G. A., \u0026amp; Greenway, F. L. (2007). Pharmacological treatment of the overweight patient. Pharmacological reviews, 59(2), 151–184.\u003c\/li\u003e\n\u003cli\u003eHeffernan, M., Summers, R. J., Thorburn, A., Ogru, E., Gianello, R., Jiang, W. J., \u0026amp; Ng, F. M. (2001). The effects of human GH and its lipolytic fragment (AOD 9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182–5189.\u003c\/li\u003e\n\u003cli\u003eKwon, D. R., \u0026amp; Park, G. Y. (2015). Effect of Intra-articular Injection of AOD 9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Annals of clinical and laboratory science, 45(4), 426–432.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786429268285,"sku":"sku2194756125337","price":120.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/AOD-9604-5mg-2-1.webp?v=1780466162"},{"product_id":"melanotan-1-10mg","title":"(🌴melanin production) Melanotan 1 (10mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003eIts core functions are:\u003cbr\u003e➡️ Activates the MC1R receptor\u003cbr\u003e➡️ Increases melanin production\u003cbr\u003e➡️ Enhances skin pigmentation\u003c\/p\u003e\n\u003cp\u003e☀️ Main Effects (Theoretical + Medical Applications)\u003cbr\u003e🧴 1️⃣ Increases skin pigmentation\u003cbr\u003eSkin tans more easily\u003cbr\u003eReduces the risk of sunburn (to some extent)\u003cbr\u003ePromotes an “even tan”\u003cbr\u003e🛡️ 2️⃣ Photoprotective Effects (Medical Applications)\u003c\/p\u003e\n\u003cp\u003eAfamelanotide is medically used for:\u003c\/p\u003e\n\u003cp\u003eRare photosensitivity disorders (such as erythropoietic protoporphyria, EPP)\u003c\/p\u003e\n\u003cp\u003ePatients cannot be exposed to sunlight normally; it can:\u003c\/p\u003e\n\u003cp\u003eImprove light tolerance\u003cbr\u003eReduce pain and light-induced damage\u003c\/p\u003e\n\u003ch3\u003eMelanotan 1 Peptide\u003c\/h3\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back-d\"\u003eMelanotan 1 () is a synthetic equivalent of alpha-melanocyte-stimulating hormone (alpha-MSH). The peptide has been exhaustively researched through observation of research models displaying signs of erythropoietic protoporphyria to reduce potential phototoxicity or UV-related damage.\u003csup\u003e[1]\u003c\/sup\u003e It has been suggested that the peptide may have the potential to influence diverse physiological processes like feeding patterns, central nervous system operations, blood pressure, and more.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 1646.8 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e78\u003c\/sub\u003eH\u003csub\u003e111\u003c\/sub\u003eN\u003csub\u003e21\u003c\/sub\u003eO\u003csub\u003e19\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back\"\u003e\u003cstrong\u003eSynonym(s):\u003c\/strong\u003e MT-1\u003c\/p\u003e\n\u003ch3\u003eMelanotan 1 Research\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\"\u003eMelanotan 1 is structurally and functionally similar to the physiological alpha-melanocyte-stimulating hormone (alpha-MSH), with the exception of a few choice amino acid substitutions. This includes substitutions such as the substitution of methionine and L-phenylalanine at the fourth and seventh positions, with norleucine and D-phenylalanine. Alpha-MSH is primarily thought to impact melanocytes, dermal cells, and hair follicle cells, which are considered to be responsible for pigmentation. In scientific studies, this hormone appears to interact with melanocortin receptor 1, potentially thus mediating its role. Alpha-MSH is considered to be a non-selective agonist of melanocortin receptors 1, 3, 4, and 5.\u003csup\u003e[2]\u003c\/sup\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eHere is a basic overview of what researchers have to say about each of these and other related receptors:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe melanocortin 1 receptor (MC1R) is speculated to be present in melanocytes in cells from skin structure, hair, and eye tissues, and it's the main target of MT-1.\u003c\/li\u003e\n\u003cli\u003eThe melanocortin 2 receptor (MC2R) is believed to be located in the adrenal cortex, the outer layer of the adrenal glands. It is proposed that this receptor might participate in the production of cortisol, and neither MT-1 nor Alpha-MSH interacts with it.\u003c\/li\u003e\n\u003cli\u003eThe melanocortin 3 receptor (MC3R) is believed to be expressed in several tissues, including the brain and placenta. MC3R may contribute to the regulation of appetite in experimental models.\u003c\/li\u003e\n\u003cli\u003eThe melanocortin 4 receptor (MC4R) is thought to be situated within the central nervous system, particularly in the hypothalamus. It is speculated that this receptor might influence nerve cells associated with regulating copulatory behavior and arousal.\u003c\/li\u003e\n\u003cli\u003eThe melanocortin 5 receptor (MC5R) is expressed across multiple tissues, but its role still needs to be established.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eMT-1 was initially developed to induce melanin production and pigmentation by interacting with the same receptors. These two amino acid modifications may help by increasing receptor target affinity and supporting molecular stability for a longer half-life. Subsequent research on the peptide and other melanocortin-binding proteins helped scientists better explore the melanocortin signaling system.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eMelanotan 1 and Melanin\u003c\/strong\u003e\u003cbr\u003eMT-1 may influence the synthesis of melanin by interacting with melanocortin 1 receptors found on melanocytes—the cells believed to produce melanin pigment in the dermal tissues. Some studies suggest that MT-1 may have a higher affinity for MC1Rs compared to α-MSH, potentially enhancing melanin production and possibly leading to increased dermal layer pigmentation even without exposure to UV light. It is thought that melanin contributes to the coloration of various tissues and may serve protective functions, such as absorbing UV radiation. There are indications that melanin exists primarily in two forms: eumelanin, which is associated with brown or black hues, and pheomelanin, which is linked to red or yellow colors.\u003cbr\u003e\u003cbr\u003eResearchers posit that “\u003cem\u003ewhen Melanotan I activates MC1R, cAMP is produced, and it activates microphthalmia transcription factor (MITF) expression, which induces the expression of enzymes for eumelanin production.\u003c\/em\u003e”\u003csup\u003e[3]\u003c\/sup\u003e Consequently, MT-1 has been studied for its melanin-inducing potential in laboratory models exposed to ultraviolet radiation.\u003csup\u003e[4]\u003c\/sup\u003e The work observed that models exposed to MT-1 exhibited a reported 75% increase in pigmentation and roughly 47% less burn. Melanotan 1 appeared to induce similar pigmentation in models compared to controls, even with 50% less ultraviolet light exposure. The pigmentation persisted on these subjects for three weeks longer than those exposed only to UV light. Variant MC1 receptors may induce less epidermal layer pigmentation than wild-type MC1 receptors.\u003cbr\u003e\u003cbr\u003eIn this genetic backdrop, exposure to MT-1 may increase melanin density, induce substantial pigmentation, and potentially mediate photoprotection. MT-1 is also studied in the context of Vitiligo. Studies noted that combinatorial exposure of the peptide with UVB light appeared to promote both the synthesis of melanin and the proliferation of melanocytes. About 50 % of the MT-1 exposed vitiligo models exhibited apparent rapid re-pigmentation and a decrease in vitiligo patching. MT-1 may impact hypopigmented scars based on the outcome of the vitiligo research study. Overexposure to UV light may lead to scaly growth, also referred to as actinic or solar keratosis. This precancerous lesion has been associated with the development of squamous cell carcinoma.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eMelanotan 1 and Cognitive Decline, Alzheimer’s Disease\u003c\/strong\u003e\u003cbr\u003eMT-1 exposure appeared to protect the nerve tissue of transgenic murine models from cognitive decline and the onset of Alzheimer’s disease.\u003csup\u003e[5]\u003c\/sup\u003e The researchers suggested that the melanocortin receptor activation by MT-1 \u003cem\u003e“restores the impaired homeostatic processes and microglial reactivity in the hippocampus in APP\/PS1 mice.”\u003c\/em\u003e Even short-term exposure to the peptide was observed in an experimental study to decrease amyloid-beta plaques and neuronal apoptosis in murine models of moderate AD. This may support cognitive function and synaptic transmission in the MT-1 exposed animals. In the same study, inhibiting the action of MT-1 at the MC4 receptor appeared to mitigate all of the positive potential actions of the peptide.\u003cbr\u003e\u003cbr\u003eResearchers have posited that MC4 receptor stimulation may have stimulatory potential for neurogenesis and cognitive function recovery in murine AD models. All AD-linked biomarkers appeared to decrease significantly even with limited exposure to the peptide. The MC4 receptor is the sole melanocortin receptor to be expressed on astrocytes, the feeder cells that help to protect and provide nutrition to neurons. MT-1 is under study for its potential to support the production of brain-derived neurotrophic factor (BDNF) and may stimulate astrocyte functioning. BDNF is an endogenously occurring molecule in nerve tissue that is considered crucial to maintaining the stability of synapses and general neurogenesis.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eMelanotan 1 and Blood Pressure, Stroke\u003c\/strong\u003e\u003cbr\u003eMT-1 appears to selectively help control hypertension in murine models without impacting control models with normal blood pressure.\u003csup\u003e[6]\u003c\/sup\u003e This action suggests that MT-1 may have the potential to modulate blood pressure without hypotension. Additionally, MT-1 may have favorable potential in models of ischemia that is often the consequence of high blood pressure and turbulent blood flow, such as stroke. Studies have suggested that exposure to the peptide even nine hours after the induction of a stroke model may help mitigate brain cell damage and cell death, as well as support parameters of learning and memory in research models.\u003csup\u003e[7]\u003c\/sup\u003e\u003cbr\u003e\u003cbr\u003eThese researchers have posited that the underlying mechanism may be MT-1, which may assist in rerouting learning and memory circuits in the brain. Researchers propose that the peptide may support synaptic plasticity and promote long-term functional recovery of the brain. The most important mediator in this process is posited to be the expression of the Zif268 gene, which is suggested to be overexpressed in animals exposed to Melanotan 1.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eMelanotan 1 and Neuroinflammation Models\u003c\/strong\u003e\u003cbr\u003eThe activation of melatonin receptors was recently observed to potentially suppress inflammation in the central nervous system in murine models. T helper cells attack the myelin sheath in neurons, leading to neuronal dysfunction and even death due to multiple sclerosis. The damage was apparently reversed in research studies through the introduction of melatonin. Thus, we may hypothesize that by upregulating melatonin expression with the help of peptides like MT-1, there may be a notable reduction in neuroinflammation levels.\u003csup\u003e[8]\u003c\/sup\u003e Uveitis is another inflammatory disorder of the eye tissues which is considered to lead to vision loss. Upregulated melatonin synthesis may suppress T-cell function and may have positive potential.\u003csup\u003e[9]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"grey-back-d\"\u003e\u003cstrong\u003eMelanotan 1 and Tissue Fibrosis\u003c\/strong\u003e\u003cbr\u003ePreliminary studies using rodent models hint that enhancing MC1 receptor activity—akin to the stimulation by MT-1—may potentially offer anti-fibrotic actions in tissues experiencing acute or chronic inflammation.\u003csup\u003e[10]\u003c\/sup\u003e Researchers have employed gene modification techniques to increase MC1R expression, which may alleviate experimentally induced liver cell fibrosis and possibly reduce the elevated expression of genes associated with fibrogenesis and inflammation. These findings suggest that upregulated MC1R activity might influence the fibrotic process by modulating gene expressions involved in fibrogenesis and inflammatory responses.\u003cbr\u003e\u003cbr\u003eOne hypothesized mechanism for these potential protective actions against liver cell fibrosis might involve the modulation of matrix metalloproteinase (MMP) activity and the suppression of tissue inhibitors of MMPs (TIMPs). MMPs are believed to play a crucial role in degrading the extracellular matrix, with their activity thought to be finely balanced by TIMPs. Collected data indicates that activating MC1R may significantly support MMP activity while decreasing the activation of α-smooth muscle actin (α-SMA) and cyclooxygenase-2 (COX-2), markers commonly associated with inflammation and fibrogenesis.\u003cbr\u003e\u003cbr\u003eFurthermore, MC1R activation is thought to downregulate the mRNA expressions of liver cell transforming growth factor β1 (TGF-β1), collagen α1, and various cell adhesion molecules, which are considered key contributors to fibrosis progression. It is also noteworthy that MC1R activation might suppress the expression of COX-2 and cell adhesion molecules, suggesting a potential anti-inflammatory pathway through which MT-1 and similar compounds may exert further anti-fibrogenic action.\u003csup\u003e[10]\u003c\/sup\u003e\u003cb\u003e\u003cem\u003e\u003c\/em\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv style=\"margin-bottom: 30px;\" class=\"white-back-d\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eWensink D, Wagenmakers MAEM, Langendonk JG. Afamelanotide is used to prevent phototoxicity in erythropoietic protoporphyria. Expert Rev Clin Pharmacol. 2021 Feb;14(2):151-160. . PMID: 33507118.\u003c\/li\u003e\n\u003cli\u003eCai, M., \u0026amp; Hruby, V. J. (2016). The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases. Current protein \u0026amp; peptide science, 17(5), 488–496.\u003c\/li\u003e\n\u003cli\u003eMun, Y., Kim, W., \u0026amp; Shin, D. (2023). Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects. \u003cem\u003eInternational journal of molecular sciences\u003c\/em\u003e, \u003cem\u003e24\u003c\/em\u003e(15), 12152.\u003c\/li\u003e\n\u003cli\u003eKoikov L, Starner RJ, Swope VB, Upadhyay P, Hashimoto Y, Freeman KT, Knittel JJ, Haskell-Luevano C, Abdel-Malek ZA. Development of hMC1R Selective Small Agonists for Sunless Tanning and Prevention of Genotoxicity of UV in Melanocytes. J Invest Dermatol. 2021 Jul;141(7):1819-1829. . Epub 2021 Feb 18. PMID: 33609553; PMCID: PMC9009400.\u003c\/li\u003e\n\u003cli\u003eLau JKY, Tian M, Shen Y, Lau SF, Fu WY, Fu AKY, Ip NY. Melanocortin receptor activation alleviates amyloid pathology and glial reactivity in an Alzheimer’s disease transgenic mouse model. Sci Rep. 2021 Feb 23;11(1):4359. . PMID: 33623128; PMCID: PMC7902646.\u003c\/li\u003e\n\u003cli\u003edo Carmo JM, da Silva AA, Wang Z, Fang T, Aberdein N, Perez de Lara CE, Hall JE. Role of the brain melanocortins in blood pressure regulation. Biochim Biophys Acta Mol Basis Dis. 2017 Oct;1863(10 Pt A):2508-2514. . Epub 2017 Mar 6. PMID: 28274841; PMCID: PMC5587353.\u003c\/li\u003e\n\u003cli\u003eAhmed TJ, Montero-Melendez T, Perretti M, Pitzalis C. Curbing Inflammation through Endogenous Pathways: Focus on Melanocortin Peptides. Int J Inflam. 2013;2013:985815. . Epub 2013 May 7. PMID: 23738228; PMCID: PMC3664505.\u003c\/li\u003e\n\u003cli\u003eWurtman R. Multiple Sclerosis, Melatonin, and Neurobehavioral Diseases. Front Endocrinol (Lausanne). 2017 Oct 23;8:280. . PMID: 29109699; PMCID: PMC5660121\u003c\/li\u003e\n\u003cli\u003eSande PH, Dorfman D, Fernandez DC, Chianelli M, Domínguez Rubio AP, Franchi AM, Silberman DM, Rosenstein RE, Sáenz DA. Treatment with melatonin after the onset of experimental uveitis attenuates ocular inflammation. Br J Pharmacol. 2014 Dec;171(24):5696-707. . PMID: 25131343; PMCID: PMC4290711.\u003c\/li\u003e\n\u003cli\u003eLee TH, Jawan B, Chou WY, Lu CN, Wu CL, Kuo HM, Concejero AM, Wang CH. Alpha-melanocyte-stimulating hormone gene therapy reverses carbon tetrachloride-induced liver fibrosis in mice. J Gene Med. 2006 Jun;8(6):764-72. \u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.1002\/jgm.899\" target=\"_blank\"\u003edoi: 10.1002\/jgm.899\u003c\/a\u003e. PMID: 16508911.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786429333821,"sku":"sku2194756140145","price":120.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/Melanotan-1-10MG-2-1.webp?v=1780466163"},{"product_id":"mgf-5mg","title":"(💪Muscle Recovery) MGF (Mechano-Growth Factor) (5mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cul\u003e\n\u003cli data-section-id=\"ej48m2\" data-start=\"249\" data-end=\"258\"\u003e💥 Muscle Recovery\u003cbr\u003e🔥 Muscle Growth\u003cbr\u003e🩹 Post-Workout Repair\u003cbr\u003e⚡ Reduced Recovery Time\u003cbr\u003e📈 Enhanced Muscle Adaptation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eMGF Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eMechano-Growth Factor (MGF) is an alternative name for the Insulin-like Growth Factor-1Eb (IGF-1Eb), an isoform of IGF-1. It has been studied for its potential in remodeling muscles, cellular survival, and cellular proliferation.\u003csup\u003e[1]\u003c\/sup\u003e New studies on this specific isoform highlight its potential for activating satellite cells in skeletal muscle, suggesting that this particular isoform may also activate satellite cells in skeletal muscle, protect neurons, and help overcome muscle mass loss.\u003csup\u003e[2]\u003c\/sup\u003e The principal function of MGF is its possible efficacy in reparating severe muscle wear and tear. Further, its concentration appears to correspond with skeletal muscle growth and differentiation found in rodent models.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e Mechano-Growth Factor\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e124\u003c\/sub\u003eH\u003csub\u003e204\u003c\/sub\u003eN\u003csub\u003e42\u003c\/sub\u003eO\u003csub\u003e41\u003c\/sub\u003eS\u003csub\u003e1\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 2971.99 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e yr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys-Cys\u003c\/p\u003e\n\u003ch3\u003eMechano-Growth Factor (MGF) Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eMechano-Growth Factor (MGF) and Inflammation\u003c\/strong\u003e\u003cbr\u003eInflammatory cells, such as macrophages and specific signaling molecules, are considered to bring about muscle cell regeneration when released. Macrophages have been considered to produce MGF in the context of muscle inflammation. IGF-1Ea (MGF) not only appears to exhibit anti-inflammatory characteristics but may also potentially extend the life of macrophages. The specific relevance of this activity is hitherto known, but it is speculated that the influence of MGF may improve the rate of muscle cell recovery through macrophage modulation.\u003csup\u003e[3]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eMechano-Growth Factor (MGF) and Cell Aging\u003c\/strong\u003e\u003cbr\u003eIGF-1 has multiple variants, and the synthesis of these isoforms is considered to be influenced by a variety of factors. The splicing and formation of different splice variants of IGF-1 appear to be affected by developmental factors, hormones like growth and steroid hormones, cellular death and regeneration, or cell aging. Cell age is considered to be a strong factor in the regulation of IGF-1 splicing. The predominant variants in control models appear to be class 1 and class 2, whereas older models with less effective cell cycle regulation appear to show prevalence of class 1Ea. The switch in the predominant splice variant acts as a relevant starting point and helps to understand the biology of cell aging better. It has been suggested that MGF may reduce the loss of function and proliferation of muscle cells over time, though an in-depth study is essential.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eMechano-Growth Factor (MGF) and Cardiac Cells\u003c\/strong\u003e\u003cbr\u003eThe peptide was reported by researchers to potentially protect cardiac muscles from ischemia in sheep models of myocardial infarction (heart attack). The work found a 35% decrease in cardiomyocyte compromise after introducing MGF following cardiac arrest.\u003csup\u003e[4]\u003c\/sup\u003e The researchers also concluded that \u003cem\u003e“the E domain of MGF protects the myocardium against ischemia, thus improving cardiac function post-MI.” \u003c\/em\u003eAnother study\u003csup\u003e[5]\u003c\/sup\u003e was conducted to evaluate if MGF might influence cardiac muscle cells under hypoxic conditions, a similar scenario to ischemia, marked by a deficient oxygen supply. In this study, mouse models were subjected to hypoxia, maintaining a low oxygen environment of just 1%, precipitating cellular apoptosis, also known as programmed cell death. Following exposure to MGF in these models, there was an observation suggesting that the peptide may facilitate the migration of stem cells toward the cardiac tissue, which might conceivably impede the apoptosis process. Specifically, it appears that MGF may encourage the movement of mesenchymal stem cells, which may differentiate into various cell types, including cardiac cells. This migratory action seems to exhibit a chemotactic action, potentially useful for directing stem cells to regions compromised by injury or disease. This hypothesis is supported by preliminary data indicating elevated levels of the Bcl-2 gene, which is implicated in promoting cell survival.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eMechano-Growth Factor (MGF) and Muscle Cell Growth\u003c\/strong\u003e\u003cbr\u003eMGF appears to promote hypertrophy and repair of muscle by stimulating muscle stem cells (called satellite cells). Research in murine models observed a 25% increase in the size of mean muscle fiber following MGF exposure for three weeks.\u003csup\u003e[6]\u003c\/sup\u003e The researchers outline that \u003cem\u003e“The discovery of MGF and muscle IGF-1 provides a link between physical activity and gene expression. This underlines the need for [aged models to maintain activity] as the locally produced growth factors supplement the circulating IGF-1 levels.”\u003c\/em\u003e The peptide is speculated to improve muscle conditions in degenerative diseases and stimulate the positive action of exertion on muscles. The latter speculation stems from the underlying significance of muscle mass in supporting baseline metabolism. Duchenne Muscular Dystrophy (DMD), a severe degenerative muscular disease, is often combated by transplanting precursors of muscle cells (called myogenic precursor cells). Transplantation is considered to help improve dystrophin production and ameliorate disease conditions; however, low survival rates persist in transplantation studies. Mouse studies have suggested that MGF may help survive the precursor cells, thus making the transplantation successful.\u003csup\u003e[7]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eMechano-Growth Factor (MGF) and Brain Development\u003c\/strong\u003e\u003cbr\u003eStudies on the brains of developing mice have indicated the presence of MGF as early as 2010. The study sheds light on the potential neuroprotective characteristics of the peptide.\u003csup\u003e[8]\u003c\/sup\u003e Researchers suggest that MGF appears to be over-expressed in the hypoxic brains of rats in the regions of the brain that undergo neuron regeneration. The influence of the peptide on neuron function was suggested in the murine model of ALS (Lou Gehrig’s Disease). ALS is characterized by loss of motor neurons and overall progressive weakness. Exposure to MGF appeared to improve both actions. Research is ongoing.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eMechano-Growth Factor (MGF) and Cartilage\u003c\/strong\u003e\u003cbr\u003eCartilage, a crucial connective tissue, is not often cited for rapid recovery due to considerations including inadequate blood supply and a lack of stem cells necessary for significant tissue regeneration. Studies have suggested that MGF may be capable of supporting cartilage regeneration. Through its alleged impact on ensuring the survival of chondrocytes following mechanical stimuli, in the backdrop of physical stress and damage to the cartilage tissue, MGF may increase survival and migration rates of chondrocytes (via YAP signaling and other pathways) to injury sites.\u003csup\u003e[9]\u003c\/sup\u003e Overloading chondrocytes may induce apoptosis, leading to disc degeneration in the spine under continued mechanical stress. MGF may help to inhibit the apoptosis of these cells, inhibiting disc degeneration of the spine.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eMechano-Growth Factor (MGF) and Muscle Fibrosis\u003c\/strong\u003e\u003cbr\u003eResearchers have explored the role of MGF in muscle fibrosis, a recovery process impairing muscle function.\u003csup\u003e[10]\u003c\/sup\u003e A study utilized murine models with induced muscle contusions and macrophage depletion. Preliminary findings suggest MGF might promote functional and structural recovery in damaged tissues by reducing fibrosis rates and lowering inflammatory cytokines, chemokines, and stress-related factors. It is speculated that MGF may inhibit fibrosis by suppressing type I and III collagen expression, key components of the fibrotic extracellular matrix. Observations also indicated a potential decrease in oxidative stress markers and matrix metalloproteinases (MMPs), suggesting MGF's role in attenuating inflammatory responses to muscle injury. Moreover, the study noted a possible decrease in contused muscle prevalence, which might have facilitated tissue repair. The action of MGF on satellite cells and immune cell dynamics post-injury, vital for muscle regeneration, appeared minimal, supported by observations of stable MyoD and myogenin levels—markers of satellite cell activity. Additionally, MGF might modulate the inflammatory environment in injured muscles, detailed by reduced expression of significant pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin-1 beta (IL-1β), and transforming growth factor-beta (TGF-β), and chemokines like CCL2, CCL5, and CXCR4, and a possible reduction in gp91phox expression, a key player in oxidative stress.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eMechano-Growth Factor (MGF) and Muscle Cell Aging\u003c\/strong\u003e\u003cbr\u003eOne study aimed to evaluate MGF's potential impact on muscle cells across varying cell populations.\u003csup\u003e[11]\u003c\/sup\u003e Cultures of muscle cells ranging from the neonatal phase to the aged phase were exposed to MGF. MGF appeared to postpone cellular senescence, particularly in younger cells. This finding implies that MGF may have the potential to sustain muscle functionality and its ability to regenerate with age. In younger muscle cells specifically, an apparent elevation in the rate of cell proliferation was detected following MGF exposure, an action not mirrored in older cells. Instead, in the older cohorts, there was a notable enhancement in muscle hypertrophy, which refers to the enlargement of muscle cells typically seen as an adaptive response to various stresses and stimuli. Concurrently, the study noted a diminishment in the population of reserve cells. Generally inactive and undifferentiated, these cells are considered crucial as a potential source for future cell differentiation. Furthermore, the formation of myotubes, believed to be a critical step in muscle development involving the fusion of muscle precursor cells, was potentially stimulated by MGF across all age groups. This stimulation may lead to improved muscle function, facilitated by an increased presence of contractile proteins. These proteins are considered vital components that may enable muscle contraction and potentially affect overall muscle performance.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\" style=\"margin-bottom: 30px !important;\"\u003e\u003cstrong\u003eMechano-Growth Factor (MGF) and Bone Cells\u003c\/strong\u003e\u003cbr\u003eOne experiment\u003csup\u003e[12]\u003c\/sup\u003e investigated the potential of MGF in the context of bone cell regeneration. The experiment involved 27 experimental models, each with a surgically created 5-millimeter defect in their bone structure. These models were exposed to either MGF or a control compound over five days. Subsequent histological analysis tentatively indicated that the bone tissues exposed to MGF exhibited apparent improved recovery processes when compared to those receiving the control and those exposed to IGF-1, suggesting possible unique cellular interactions. Preliminary data hinted that MGF might potentially influence the cell division process and might activate the Mitogen-Activated Protein Kinase-Extracellular Signal-Regulated Kinase 1\/2 (MAPK-Erk1\/2) signaling pathway. These observations propose that MGF's mechanism might involve intricate strategies to foster cellular growth and tissue repair. This supports the hypothesis that MGF may be crucial in enhancing bone repair, although further studies are needed to confirm these actions.\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px !important;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eYang SY \u0026amp; Goldspink G (2002). Different roles of the IGF-IEc peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett 522, 156-160.\u003c\/li\u003e\n\u003cli\u003eHill M \u0026amp; Goldspink G (2003). Expression and splicing of the insulin­like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. J Physiol 549, 409-418.\u003c\/li\u003e\n\u003cli\u003eSun KT, Cheung KK, Au SWN, Yeung SS, Yeung EW. Overexpression of Mechano-Growth Factor Modulates Inflammatory Cytokine Expression and Macrophage Resolution in Skeletal Muscle Injury. Front Physiol. 2018 Jul 26;9:999. . PMID: 30140235; PMCID: PMC6094977.\u003c\/li\u003e\n\u003cli\u003eCarpenter V, Matthews K, Devlin G, Stuart S, Jensen J, Conaglen J, Jeanplong F, Goldspink P, Yang SY, Goldspink G, Bass J, McMahon C. Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart Lung Circ. 2008 Feb;17(1):33-9. . Epub 2007 Jun 19. PMID: 17581790.\u003c\/li\u003e\n\u003cli\u003eDoroudian G, Pinney J, Ayala P, Los T, Desai TA, Russell B. Sustained delivery of MGF peptide from microrods attracts stem cells and reduces apoptosis of myocytes. Biomed Microdevices. 2014 Oct;16(5):705-15.\u003c\/li\u003e\n\u003cli\u003eGoldspink G, Yang SY. Effects of activity on growth factor expression. Int J Sport Nutr Exerc Metab. 2001 Dec;11 Suppl:S21-7. . PMID: 11915923.\u003c\/li\u003e\n\u003cli\u003eGoldspink G, Yang SY, Skarli M \u0026amp; Vrbova G (1996). Local growth regulation is associated with an isoform of IGF-I that is expressed in normal muscles but not in dystrophic muscles. J Physiol 495, 162.\u003c\/li\u003e\n\u003cli\u003eZabłocka B, Goldspink PH, Goldspink G, Górecki DC. Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? Front Endocrinol (Lausanne). 2012 Nov 1;3:131. . PMID: 23125840; PMCID: PMC3485521.\u003c\/li\u003e\n\u003cli\u003eSong Y, Xu K, Yu C, Dong L, Chen P, Lv Y, Chiang MYM, Li L, Liu W, Yang L. The use of mechano growth factor to prevent cartilage degeneration in knee osteoarthritis. J Tissue Eng Regen Med. 2018 Mar;12(3):738-749. . Epub 2017 Oct 6. PMID: 28599103.\u003c\/li\u003e\n\u003cli\u003eLiu X, Zeng Z, Zhao L, Chen P, Xiao W. Impaired Skeletal Muscle Regeneration Induced by Macrophage Depletion Could Be Partly Ameliorated by MGF Injection. Front Physiol. 2019 May 17;10:601.\u003c\/li\u003e\n\u003cli\u003eKandalla PK, Goldspink G, Butler-Browne G, Mouly V. Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev. 2011 Apr.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786429595965,"sku":"sku2194756140145","price":180.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/MGF-5MG-1.webp?v=1780466165"},{"product_id":"tesamorelin","title":"(🔥Reduce visceral fat) Tesamorelin Peptide (5MG \u0026 10MG) -10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003ch3\u003eReduce deep abdominal fat\u003cbr\u003eGet rid of a “beer belly”\u003cbr\u003eReduce the accumulation of visceral fat\u003cbr\u003e\u003cbr\u003eTesamorelin Peptide\u003c\/h3\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back-d\"\u003eTesamorelin is a chemically altered growth hormone-releasing hormone (GHRH) analog, that similar to the original is made of 44 amino acids. This peptide is a trans-3-hexanoic acid version of natural GHRH. The trans-3-hexanoic acid group is added to the N-terminus, while the C-terminus is amidated and acetylated. Tesamorelin appears to mediate the positive influence of GHRH and other GHRH analogs such as GRF (1-29), CJC-1295, and . The trans-3-hexanoic acid modification may increase its stability and half-life. Both Tesamorelin and CJC-1295 appear to maintain the physiological activity of GHRH, without disrupting the physiological rhythm of GH release.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e221\u003c\/sub\u003eH\u003csub\u003e366\u003c\/sub\u003eN\u003csub\u003e72\u003c\/sub\u003eO\u003csub\u003e67\u003c\/sub\u003eS\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 5136 g\/mol\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e trans-hexenoyl-acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-AsnSer-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-LeuGln-Asp-Ile-Met-Ser-Arg-GlnGln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu\u003c\/p\u003e\n\u003ch3\u003eTesamorelin Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eTesamorelin and the Pituitary Gland\u003c\/strong\u003e\u003cbr\u003eTesamorelin might potentially interact with the pituitary gland by possibly binding to GHRH receptors, which might initiate a sequence of molecular events. Researchers propose that it may cause structural alterations in the receptor, thereby activating intracellular signaling pathways.\u003csup\u003e[1, 2]\u003c\/sup\u003e They have noted that this binding process is likely followed by a significant conformational change, involving the transmembrane helix 6 (TM6), which may open the intracellular face for G protein coupling. One potential pathway might involve the stimulation of cyclic adenosine monophosphate (cAMP) production within pituitary cells. This might be achieved through the activation of the enzyme adenylate cyclase, which may convert ATP (adenosine triphosphate) to cAMP. It is suggested that increased cAMP levels might activate protein kinase A (PKA), leading to protein phosphorylation and GHRH receptor activation by Tesamorelin. This cascade might stimulate the synthesis and secretion of growth hormone (hGH) from somatotrophs in the pituitary gland. Research indicates that Tesamorelin may induce up to a 69% rise in overall growth hormone levels, as measured by the 12-hour area under the curve (AUC), which quantifies the total hormone concentration over 12 hours. Additionally, there may be approximately a 55% increase in the average pulse area of growth hormone, which reflects the amount of hormone released during each pulse. Furthermore, levels of insulin-like growth factor 1 (IGF-1) apparently surged by 122%.\u003csup\u003e[3]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eTesamorelin and Growth Hormone Deficiency, HIV\u003c\/strong\u003e\u003cbr\u003eHighly active antiretroviral therapy (HAART) may trigger endocrine and metabolic disorders, including growth hormone (GH) deficiency. In cases of HIV infection, the pituitary gland function may be altered, inducing a general growth hormone deficiency in one-third of research models used to study the impacts of HAART.\u003csup\u003e[4]\u003c\/sup\u003e Tesamorelin has been employed in research to measure its potential impact in supplementing growth hormone deficiency by inducing natural hormone production.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eTesamorelin and Lipodystrophy\u003c\/strong\u003e\u003cbr\u003eTesamorelin is principally researched within the context of HIV-associated lipodystrophy, which is considered to be caused by viral infection and possible adverse consequences of certain antiretroviral procedures. Lipodystrophy is characterized by an irregular distribution and storage of fat cells, which can often result in visceral obesity. Visceral obesity refers to the abnormal accumulation of fat around and within internal organs, and it has been tentatively linked to a range of metabolic disturbances. These disturbances may include insulin resistance, which impairs the organism’s ability to regulate blood sugar levels; elevated levels of low-density lipoprotein (LDL) cholesterol, often referred to as \"bad\" cholesterol due to its association with increased risk of cardiovascular disease; and hyperuricemia, which is an excessive concentration of uric acid in the blood. Tesamorelin has been hypothesized to potentially mitigate these metabolic disturbances due to its speculated action on adiposity. The peptide appeared to reduce adiposity by up to 20% of the models examined in one study.\u003csup\u003e[5]\u003c\/sup\u003e The researchers noted that \u003cem\u003e“The odds of response of VAT ‹140 cm2 was 3.9 times greater for Tesamorelin-... [cases] than … the control.” \u003c\/em\u003eAnother experiment that lasted for over 52 weeks and involved over 800 research models suggested that the peptide may lead to a mean of -17.5% reduction in visceral adiposity. In addition there were apparent reductions in triglycerides by a mean of -48 mg\/dl, cholesterol by a mean of -8 mg\/dl, and non-high-density lipoprotein by a mean of -7 mg\/dl.\u003csup\u003e[6]\u003c\/sup\u003e Further research into Tesamorelin that has involved reviews of multiple experiments has suggested it may lead to an apparent reduction of up to -25% reduction in visceral fat among lipodystrophy models.\u003csup\u003e[7]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eTesamorelin and Cholesterol Metabolism\u003c\/strong\u003e\u003cbr\u003eEctopic fat deposition, such as in visceral organs, epicardium, and liver, has been linkedto elevated inflammation, which may increase the risk of lipids and cholesterol imbalance. Tesamorelin studies posit that the peptide may reduce triglyceride, total cholesterol, and non-HDL-C.\u003csup\u003e[8]\u003c\/sup\u003e The peptide may potentially decrease inflammatory response through the control of excess adiposity.\u003csup\u003e[9]\u003c\/sup\u003e The researchers note that \u003cem\u003e“[models exposed to] Tesamorelin with ≥8% reduction in VAT have significantly improved triglyceride levels, adiponectin levels, and preservation of glucose homeostasis over 52 weeks.”\u003c\/em\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eTesamorelin and Peripheral Nerve Damage\u003c\/strong\u003e\u003cbr\u003ePeripheral nerve damage may potentially trigger debilitating motor and sensory challenges. Research in intervention of such damage is limited, as nerve cells present a challenge to regenerate. Studies suggest that growth hormone manipulation might improve peripheral nerve injury and increase both rate and extent of repair.\u003csup\u003e[10]\u003c\/sup\u003e Tesamorelin is being actively researched in this area for its potential for inducing growth hormone release.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eTesamorelin and Neurodegenerative Issues\u003c\/strong\u003e\u003cbr\u003eGHRH analogs, including Tesamorelin, have been researched for their potential to improve cognitive ability in dementia models. A randomized, double-blind, placebo-controlled study was conducted with a large cohort over a period of 20 weeks at The University of Washington School of Medicine. The study observed that Tesamorelin and other GHRH analogs may influence dementia by increasing gamma-aminobutyric acid (GABA) in the brain and decreasing myo-insoitol (MI).\u003csup\u003e[11]\u003c\/sup\u003e These findings suggest greater avenues of potential for Tesamorelin research.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eTesamorelin and Muscle Anabolism\u003c\/strong\u003e\u003cbr\u003eA research study was conducted to explore the potential of Tesamorelin on the structural quality of muscle tissues, using computed tomography (CT) scans.\u003csup\u003e[12]\u003c\/sup\u003e The findings from this study indicated a possible association between Tesamorelin and improvements in muscle tissue density and volume. Specifically, the study observed that certain muscle groups, namely the rectus abdominis, psoas major, and paraspinal muscles, exhibited more pronounced changes which included either an increase in muscle density and volume or a reduction in intramuscular fat content. From a statistical standpoint, the differences in muscle density and size, as well as the decrease in fat content within these muscles, were significantly greater than those observed in a control group.\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"grey-back-d\"\u003e\u003cstrong\u003eTesamorelin and Liver Adiposity\u003c\/strong\u003e\u003cbr\u003eResearch has indicated that Tesamorelin might lower hepatic fat fraction (HFF). \u003csup\u003e[13]\u003c\/sup\u003e The study observed a reduction in absolute hepatic fat by 4.7% among Tesamorelin-exposed models, while the control group exhibited no change. This represents a relative decrease in liver fat by 37%, which might suggest a potential benefit in reducing liver fat accumulation. Furthermore, 35% of the Tesamorelin group achieved a hepatic fat fraction below 5%, in contrast to just 4% in the control. In terms of liver tissue fibrosis, Tesamorelin appeared to slow its progression, with only 10.5% of the Tesamorelin group showing fibrosis progression, compared to 37.5% in the placebo. Nevertheless, Tesamorelin did not seem to significantly improve pre-existing fibrosis. The observed reduction in liver fat was correlated with improvements in fibrosis, hinting at a possible mechanistic connection between reduced liver fat and decreased fibrosis progression. Additionally, Tesamorelin appeared to exhibit anti-inflammatory properties, as indicated by reductions in c-reactive protein (CRP) levels. Despite these promising findings, Tesamorelin did not significantly impact liver enzymes, such as alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT), overall. However, it did reduce ALT levels in models of elevated baseline levels. Metabolic parameters, including fasting glucose and hemoglobin A1c, were not significantly altered, suggesting that Tesamorelin might have a neutral action on glucose regulation during the study period.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e\u003cem\u003eDisclaimer:  Research chemicals are intended solely for laboratory experimentation and\/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and\/or qualified professionals. All information shared in this article is for educational purposes only.\u003c\/em\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv style=\"padding-bottom: 5px !important; margin-bottom: 25px !important;\" class=\"white-back-d\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eSpooner, L. M., \u0026amp; Olin, J. L. (2012). Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. The Annals of pharmacotherapy, 46(2), 240–247.\u003c\/li\u003e\n\u003cli\u003eZhou, F., Zhang, H., Cong, Z., Zhao, L. H., Zhou, Q., Mao, C., Cheng, X., Shen, D. D., Cai, X., Ma, C., Wang, Y., Dai, A., Zhou, Y., Sun, W., Zhao, F., Zhao, S., Jiang, H., Jiang, Y., Yang, D., Eric Xu, H., … Wang, M. W. (2020). Structural basis for activation of the growth hormone-releasing hormone receptor. Nature communications, 11(1),\u003c\/li\u003e\n\u003cli\u003eStanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011 Jan;96(1):150-8. . Epub 2010 Oct 13. PMID: 20943777; PMCID: PMC3038486.\u003c\/li\u003e\n\u003cli\u003eRochira, V., \u0026amp; Guaraldi, G. (2017). Growth hormone deficiency and immunodeficiency virus. Best practice \u0026amp; research. Clinical endocrinology \u0026amp; metabolism, 31(1), 91–111. .\u003c\/li\u003e\n\u003cli\u003eMangili, A., Falutz, J., Mamputu, J. C., Stepanians, M., \u0026amp; Hayward, B. (2015). Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PloS one, 10(10), e0140358. .\u003c\/li\u003e\n\u003cli\u003eFalutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of Tesamorelin (TH9507), a growth hormone-releasing factor analog, in immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. . Epub 2010 Jun 16. PMID: 20554713.\u003c\/li\u003e\n\u003cli\u003eSivakumar T, Mechanic O, Fehmie DA, Paul B. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials. HIV Med. 2011 Sep;12(8):453-62. doi: 10.1111\/j.1468-1293.2010.00906.x. Epub 2011 Jan 25. PMID: 21265979.\u003c\/li\u003e\n\u003cli\u003eFalutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., \u0026amp; Grinspoon, S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England journal of medicine, 357(23), 2359–2370. .\u003c\/li\u003e\n\u003cli\u003eStanley, T. L., Falutz, J., Marsolais, C., Morin, J., Soulban, G., Mamputu, J. C., Assaad, H., Turner, R., \u0026amp; Grinspoon, S. K. (2012). Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving Tesamorelin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 54(11), 1642–1651. .\u003c\/li\u003e\n\u003cli\u003eTuffaha, S. H., Singh, P., Budihardjo, J. D., Means, K. R., Higgins, J. P., Shores, J. T., Salvatori, R., Höke, A., Lee, W. P., \u0026amp; Brandacher, G. (2016). Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury. Expert opinion on therapeutic targets, 20(10), 1259–1265. .\u003c\/li\u003e\n\u003cli\u003eFriedman, S. D., Baker, L. D., Borson, S., Jensen, J. E., Barsness, S. M., Craft, S., Merriam, G. R., Otto, R. K., Novotny, E. J., \u0026amp; Vitiello, M. V. (2013). Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA neurology, 70(7), 883–890. .\u003c\/li\u003e\n\u003cli\u003eAdrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. \u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.14283\/jfa.2018.45\" target=\"_blank\"\u003edoi: 10.14283\/jfa.2018.45\u003c\/a\u003e. PMID: 31237318; PMCID: PMC6766405.\u003c\/li\u003e\n\u003cli\u003eStanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Aepfelbacher, J., Buckless, C., Tsao, A., Kellogg, A., Branch, K., Lee, H., Liu, C. Y., Corey, K. E., Chung, R. T., Torriani, M., Kleiner, D. E., Hadigan, C. M., \u0026amp; Grinspoon, S. K. (2019). Effects of Tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The lancet. HIV, 6(12), e821–e830.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003cdiv\u003eAll orders ship same day if placed by 12 PST.\u003c\/div\u003e\n\u003cdiv class=\"vbni\"\u003e\u003cem\u003e Only qualified and licensed professionals should handle these products. Any information found on Biotech Peptides is strictly for educational purposes only. Refer to our \u003ca href=\"https:\/\/biotechpeptides.com\/terms-and-conditions\/\"\u003eterms and conditions\u003c\/a\u003e for more details.\u003c\/em\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"10mg","offer_id":51786429661501,"sku":"sku2194756148783","price":160.0,"currency_code":"USD","in_stock":true},{"title":"5mg","offer_id":51786429694269,"sku":"sku2194756148784","price":120.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/TESAMORELIN-1-1.webp?v=1780466166"},{"product_id":"ghk-cu-50mg-copper","title":"(🌴Skin Repair and Anti-Aging) GHK-CU (Copper) (50mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is GHK-Cu?\u003c\/p\u003e\n\u003cp\u003eGHK-Cu = Gly-His-Lys + Copper (copper ions)\u003c\/p\u003e\n\u003cp\u003eIt is a tripeptide that occurs naturally in the human body; it is present in plasma and tissues but decreases with age.\u003c\/p\u003e\n\u003cp\u003e✨ Key Functions (Supported by Research)\u003cbr\u003e🧴 1️⃣ Skin Repair and Anti-Aging (Most Well-Established)\u003c\/p\u003e\n\u003cp\u003eGHK-Cu has been the most extensively studied in the skincare field:\u003c\/p\u003e\n\u003cp\u003eStimulates collagen production\u003cbr\u003eImproves skin elasticity\u003cbr\u003eReduces fine lines and wrinkles\u003cbr\u003eAccelerates wound healing\u003c\/p\u003e\n\u003cp\u003e👉 Commonly used as an “anti-aging skincare ingredient”\u003c\/p\u003e\n\u003cp\u003e🧠 2️⃣ Anti-inflammatory and Tissue Repair\u003c\/p\u003e\n\u003cp\u003eResearch suggests it may:\u003c\/p\u003e\n\u003cp\u003eReduce inflammatory factors\u003cbr\u003ePromote wound healing\u003cbr\u003eAccelerate soft tissue repair\u003cbr\u003eImprove the skin barrier\u003cbr\u003e💇 3️⃣ Scalp and Hair Health\u003c\/p\u003e\n\u003cp\u003eCommon uses:\u003c\/p\u003e\n\u003cp\u003ePromote hair follicle activity\u003cbr\u003eImprove hair loss (as an adjunct)\u003cbr\u003eEnhance scalp microcirculation\u003cbr\u003e🧬 4️⃣ Gene Expression Regulation (Research Focus)\u003c\/p\u003e\n\u003cp\u003eA unique feature of GHK-Cu:\u003c\/p\u003e\n\u003cp\u003e👉 It may influence the expression of hundreds of genes related to repair and inflammation\u003c\/p\u003e\n\u003cp\u003eTherefore, it is referred to as:\u003cbr\u003e“Signal-regulating peptide”\u003c\/p\u003e\n\u003cp\u003e💉 Common Formulations\u003cbr\u003eSkincare serums (most common)\u003cbr\u003eScalp care products\u003cbr\u003eInjections\/solutions for research\u003c\/p\u003e\n\u003ch3\u003eGHK-Cu Peptide\u003c\/h3\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back-d\"\u003eGHK-Cu is a naturally occurring peptide that was first purified from blood plasma, though its traces have also been identified in both saliva and urine. Experimental research in GHK-Cu indicates the peptide may host the potential to impact tissue repair and affect certain immunological functions.\u003csup\u003e[1]\u003c\/sup\u003e The peptide has been studied for its potential in mitigating cell aging, inducing protein synthesis, minimizing free-radical damage, preventing bacterial infection, and improving the function of skin fibroblasts. Research in this multifaceted peptide is still ongoing.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e14\u003c\/sub\u003eH\u003csub\u003e23\u003c\/sub\u003eCuN\u003csub\u003e6\u003c\/sub\u003eO\u003csub\u003e4\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 340.38 g\/mol\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"grey-back\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Gly-His-LysCu.xHAc\u003c\/p\u003e\n\u003ch3\u003eGHK-Cu Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHK-Cu and Skin Cells\u003c\/strong\u003e\u003cbr\u003eGHK-Cu is a natural component of blood and has been studied for its potential impact on dermal regeneration pathways. Research in skin cultures has suggested that GHK may stimulate the synthesis as well as the breaking down of collagen, glycosaminoglycans, and other components of the skin’s extracellular matrix like proteoglycans and chondroitin sulfate. This potential appears to be partially mediated through the positive action of GHK-Cu recruitment on fibroblasts, endothelial cells, and immune cells. The peptide appears to attract these cells to the wound site and coordinates their activity in repairing the damage. The peptide has also been researched for its potential modulation of collagen synthesis. Research in the roles of GHK-Cu suggests its actions may be mediated partially via an expression of transforming growth factor Beta. It is likely that the peptide works through various biochemical pathways and may modify gene expression. Studies in mice suggest that GHK-Cu may increase the rate of wound healing in burns by as much as 33%.\u003csup\u003e[1]\u003c\/sup\u003e The peptide appears to recruit immune cells and fibroblasts to sites of injury and may promote the development of new blood vessels at these sites.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHK-Cu and Cognitive, Nervous System Functions\u003c\/strong\u003e\u003cbr\u003eThe mechanism behind neuronal death, which occurs in degenerative diseases such as Alzheimer’s, is poorly understood. Studies have suggested GHK-Cu’s potential to inhibit loss in neuronal function, which has been associated with such diseases.\u003csup\u003e[2]\u003c\/sup\u003e In these studies, the molecule has been observed to enhance angiogenesis in the nervous system, to potentially stimulate nerve outgrowth, and decrease inflammation in the central nervous system. Further scientific studies support the theory that it may alter the expression profiles of pathological genes and help reset a state of controlled function in dysfunctional systems. Natural GHK-Cu expression is considered to naturally decrease. Some scientists believe that GHK-Cu may possibly exert neuroprotective action against natural insults like gene dysregulation. The peptide has been suggested to protect neurons in rat brains from apoptosis through the well-known miR-339-59\/VEGFA pathway, which is considered to become active after brain bleeds and stroke. In the rat models, GHK-Cu was reported to improve the neurological deficits in the brain, reducing swelling and preventing neuronal death associated with over-expression of miR-339-5p.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHK-Cu and Bacteria\u003c\/strong\u003e\u003cbr\u003eGHK-Cu, in combination with certain fatty acids, may create a potentially antimicrobial compound acting against bacteria and fungi that is considered to interfere with tissue repair processes. Diabetes research has suggested that GHK-Cu may exert such action, with findings reporting a combination of standard procedure and GHK-Cu to induce a 40% increase in wound closure and a 27% reduction in infection rates as opposed to control groups.\u003csup\u003e[3]\u003c\/sup\u003e Similar results have also been noted from studies in ischemic wounds. Researchers report that \u003cem\u003e“GHK-Cu improved healing of ischemic wounds and suppresses inflammation by lowering the level of acute-phase inflammatory cytokines such as TGF-beta and TNF-alpha.”\u003c\/em\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eGHK-Cu and Lungs\u003c\/strong\u003e\u003cbr\u003eStudies in murine models have suggested that GHK-Cu may protect the lungs against fibrosis.\u003csup\u003e[4]\u003c\/sup\u003e The study has also explored the mechanistic action of the peptide. It was observed to modulate TNF-alpha and IL-6 levels, both of which are considered to function as inflammatory molecules and may affect the extracellular matrix and smooth muscles of the lungs. The peptide may reduce lung inflammation, thereby enhancing collagen production and preventing fibrotic remodeling. GHK-Cu was also suggested to be effective in murine research models of acute respiratory distress syndrome (ARDS). This inflammatory lung condition may become aggravated very fast and may be fatal. ARDS is linked with injury and infection. Once again, the suggested underlying mechanism of the peptide action is decreasing the expression of TNF-alpha and IL-6.\u003csup\u003e[5]\u003c\/sup\u003e\u003cbr\u003e\u003cbr\u003eIn another study, GHK-Cu was investigated for its potential actions on inflammation within a murine model of emphysema induced by cigarette smoke (CS). The experimentation with GHK-Cu appeared to reduce inflammation in the lung tissues of these models. This action was indicated by a decrease in inflammatory cytokines such as IL-1β and TNF-α in the bronchoalveolar lavage fluid, suggesting that GHK-Cu may have an inhibitory action on these proinflammatory markers. Furthermore, the study noted an apparent reduction in myeloperoxidase (MPO) activity, which is primarily found in neutrophils and is an enzyme involved in the model's response to inflammation. These findings suggest that GHK-Cu might potentially attenuate the inflammatory response triggered by CS exposure. The mechanism behind the potential anti-inflammatory action of GHK-Cu may be associated with its influence on the NF-κB pathway, a key regulator of inflammation. The study observed that GHK-Cu exposure possibly suppresses the activation of NF-κB by modifying the phosphorylation of its inhibitor IκBα, thereby reducing the expression of inflammatory mediators. Additionally, the pre-exposure with GHK-Cu was posited to decrease i-NOS levels through the NF-κB pathway, linking it further to anti-inflammatory processes.\u003csup\u003e[6]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eGHK-Cu and Pain Perception\u003c\/strong\u003e\u003cbr\u003eIn rat models, the exposure of GHK-Cu was reported to exhibit a concentration-dependent impact on pain-induced behavior. The peptide appeared to deliver analgesic effects mediated through increased levels of the natural painkiller L-lysine.\u003csup\u003e[7]\u003c\/sup\u003e The researchers reported that \u003cem\u003e“It was found the L-lysine residue plays the key role in these effects, because they were observed under the influence of L-lysine [introduction] in [concentrations] close to its equimolar content in the studied tripeptide.”\u003c\/em\u003e Similar studies have suggested the potential of the peptide to enhance levels of L-arginine, another analgesic amino acid.\u003csup\u003e[8]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"grey-back-d\"\u003e\u003cstrong\u003eGHK-Cu and Oxidative Stress\u003c\/strong\u003e\u003cbr\u003eOne research hypothesis suggests that GHK may contribute to reducing the release of iron from ferritin, which catalyzes lipid peroxidation. Specifically, data indicates that GHK may restrict the formation of iron complexes in damaged tissues, potentially reducing inflammation.\u003csup\u003e[9]\u003c\/sup\u003e The proposed mechanism of GHK involves its interaction with the pathways controlling iron release from ferritin, potentially reducing iron release by approximately 87%. This reduction may theoretically lessen inflammation and oxidative stress in impacted tissues. Furthermore, a palmitoylated form of the compound, Pal-GHK, may also decrease the generation of reactive oxygen species and inflammatory cytokines, while potentially enhancing the activity of antioxidant enzymes. In a study conducted using a mouse model, Pal-GHK appeared to inhibit the activation of the Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) and p38 mitogen-activated protein kinase (MAPK) signaling pathways. Both pathways play significant roles in the inflammatory process.\u003csup\u003e[10]\u003c\/sup\u003e NF-κB is a protein complex that functions as a transcription factor, regulating the expression of genes involved in immune and inflammatory responses. The p38 MAPK pathway is considered to be heavily involved in cellular responses to stress and inflammation. Pal-GHK might inhibit p38 MAPK activation by obstructing the upstream kinases that activate this pathway or interfering with the signaling molecules responsible for its phosphorylation. Such inhibition might diminish the inflammatory response, reducing cellular stress. This, in turn, may result in decreased infiltration of inflammatory cells into lung tissues in murine models, alongside lower levels of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) production, further mitigating tissue damage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv style=\"margin-bottom: 30px;\" class=\"white-back-d\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003ePickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018 Jul 7;19(7):1987. . PMID: 29986520; PMCID: PMC6073405.\u003c\/li\u003e\n\u003cli\u003ePickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sci. 2017 Feb 15;7(2):20. . PMID: 28212278; PMCID: PMC5332963.\u003c\/li\u003e\n\u003cli\u003ePickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. 2012;2012:324832. . Epub 2012 May 10. PMID: 22666519; PMCID: PMC3359723.\u003c\/li\u003e\n\u003cli\u003eZhou XM, Wang GL, Wang XB, Liu L, Zhang Q, Yin Y, Wang QY, Kang J, Hou G. GHK Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice by Suppressing TGFβ1\/Smad-Mediated Epithelial-to-Mesenchymal Transition. Front Pharmacol. 2017 Dec 12;8:904. . PMID: 29311918; PMCID: PMC5733019.\u003c\/li\u003e\n\u003cli\u003ePark JR, Lee H, Kim SI, Yang SR. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016 Sep 6;7(36):58405-58417. . PMID: 27517151; PMCID: PMC5295439.\u003c\/li\u003e\n\u003cli\u003eZhang, Q., Yan, L., Lu, J., \u0026amp; Zhou, X. (2022). Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Frontiers in molecular biosciences, 9, 925700.\u003c\/li\u003e\n\u003cli\u003eSever’yanova LА, Dolgintsev ME. Effects of Tripeptide Gly-His-Lys in Pain-Induced Aggressive-Defensive Behavior in Rats. Bull Exp Biol Med. 2017 Dec;164(2):140-143. . Epub 2017 Nov 27. PMID: 29181666\u003c\/li\u003e\n\u003cli\u003eSever’yanova LА, Plotnikov DV. Binding of Glyprolines to L-Arginine Inverts Its Analgesic and Antiagressogenic Effects. Bull Exp Biol Med. 2018 Sep;165(5):621-624. . Epub 2018 Sep 17. PMID: 30225713\u003c\/li\u003e\n\u003cli\u003eMiller, D. M., DeSilva, D., Pickart, L., \u0026amp; Aust, S. D. (1990). Effects of glycyl-histidyl-lysyl chelated Cu(II) on ferritin dependent lipid peroxidation. Advances in experimental medicine and biology, 264, 79–84.\u003c\/li\u003e\n\u003cli\u003eSakuma, S., Ishimura, M., Yuba, Y., Itoh, Y., \u0026amp; Fujimoto, Y. (2018). The peptide glycyl-ʟ-histidyl-ʟ-lysine is an endogenous antioxidant in living organisms, possibly by diminishing hydroxyl and peroxyl radicals. International journal of physiology, pathophysiology and pharmacology, 10(3), 132–138.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786429727037,"sku":"sku2194756126571","price":200.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/GHK-Cu-1-1.webp?v=1780466168"},{"product_id":"pt-141-10mg-bremelanotide","title":"（❤️Sexual desire） PT-141 (Bremelanotide) Peptide (10mg) -10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003ch4\u003ePT-141 (Bremelanotide) is a peptide primarily associated with libido and sexual arousal.\u003cbr\u003eUnlike many fitness peptides, it acts on:\u003cbr\u003e🧠 the central nervous system (specifically melanocortin receptors),\u003cbr\u003erather than directly affecting blood vessels or hormones.\u003c\/h4\u003e\n\u003ch4\u003eIts most well-known approved pharmaceutical version is:\u003cbr\u003eVyleesi\u003c\/h4\u003e\n\u003ch4\u003eThis is an FDA-approved prescription medication for:\u003c\/h4\u003e\n\u003ch4\u003etreating Hypoactive Sexual Desire Disorder (HSDD) in certain women.\u003c\/h4\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003ePT-141 (Bremelanotide) Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003ePT-141, also known as Bremelanotide, was derived from a synthetic melanocortin analog known as Melanotan 2 (MT-2). A melanocortin analog, such as PT-141 and MT-2, is considered to be any synthetic compound designed to mimic or influence the functions of natural melanocortin peptides. These peptides, such as the alpha-melanocyte stimulating hormone (α-MSH), may be involved in a range of physiological processes including appetite regulation, energy homeostasis, immune responses, and skin cell pigmentation. PT-141 is a melanocortin analog that was developed to interact with Melanocortin-4 Receptor (MC-4R). It has been studied for a variety of potential characteristics and bioactivities through its interaction with this receptor. Apart from MC-4R, there are other melanocortin receptors like MC-1R, MC-2R, MC-3R, and MC-5R, each associated with different potential functions. For instance, MC-1R may be primarily involved in skin cell and hair follicle pigmentation, MC-2R appears to play a crucial role in the adrenal axis and stress response, MC-3R is implicated in the regulation of energy homeostasis, and MC-5R has been linked to exocrine function and thus impacts processes such as sweating and sebum production.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e Bremelanotide\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e50\u003c\/sub\u003eH\u003csub\u003e68\u003c\/sub\u003eN\u003csub\u003e14\u003c\/sub\u003eO\u003csub\u003e10\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 1025.18 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)-OH\u003c\/p\u003e\n\u003ch3\u003ePT-141 Peptide Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003ePT-141 Peptide (Bremelanotide) and the Melanocortin-4 Receptors\u003c\/strong\u003e\u003cbr\u003ePT-141 appears to uniquely stimulate the MC-4R, which may trigger cascades in the central nervous system which impact the brain region that controls reproductive and copulatory behavior.\u003csup\u003e[1]\u003c\/sup\u003e The researchers suggest that \u003cem\u003e“The erectogenic potential of PT-141, its tolerability profile and its [potential] to cause significant erections in [cases that otherwise] do not have an adequate response to a PDE5 inhibitor suggest that PT-141 may provide an alternative [avenue for ED research].”\u003c\/em\u003e Studies in mice agonist binding to MC-4R reported sexual arousal and increased copulation activity in both males and females.\u003csup\u003e[2]\u003c\/sup\u003e The mechanism of PT-141 appears to be different from compounds that manage blood flow to the genitals.\u003csup\u003e[3][4]\u003c\/sup\u003e Researchers suggest that MC-4R agonism, potentially combined with existing modalities, may encourage both physiological and psychological alterations. In a meticulously designed study, researchers conducted a randomized, double-blinded, placebo-controlled, crossover clinical trial to explore the potential stimulation of the Melanocortin-4 receptor on neural pathways involved in sexual processing. Initial findings suggest that PT-141 as an agonist may potentially enhance sexual desire for a duration up to 24 hours, in comparison to a placebo. During the functional neuroimaging segment of the study, there was an apparent increase in activity observed in the cerebellar and supplementary motor areas. These regions are deemed crucial for motor control and planning. Conversely, there was a possible reduction in activation within the secondary somatosensory cortex, an area involved in processing sensory information, specifically when under the influence of visual stimuli, differing from responses observed with the placebo. Additionally, it was theorized that MC-4R agonists like PT-141 might enhance the functional connectivity between the amygdala, a key region in emotion regulation, and the insula, which is involved in perception and emotional responses, during exposure to the stimuli. This was in contrast to the actions noted with the placebo. These preliminary observations led researchers to suggest that MC-4R agonists could potentially enhance the neural processing associated with sexual arousal and behavior.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003ePT-141 Peptide (Bremelanotide) and Cavernous Tissues\u003c\/strong\u003e\u003cbr\u003eDespite suggestions that the mechanism of PT-141 appears to be different from compounds that manage blood flow to the genitals, some scholars propose that compounds classified as melanocortin agonists, such as PT-141, might exhibit properties conducive to inducing erections by influencing the concentrations of vasodilators within specific tissues.\u003csup\u003e[5]\u003c\/sup\u003e Research has explored the possible involvement of the nitric oxide (NO)-cyclic guanosine monophosphate (cyclic GMP) pathway in the action of melanocortin agonists on erectile function. This pathway is posited as pivotal in many processes, including the regulation of vascular tone and blood flow within cavernosal tissues. One particular study investigated this by conducting experiments where the pudendal nerves, which are considered vital for erectile function, were bilaterally transected, and nitric oxide synthase (the enzyme responsible for producing NO) was blocked using a specific inhibitor known as L-NAME.\u003csup\u003e[5]\u003c\/sup\u003e The findings from these experiments suggested that disrupting the pudendal nerves or inhibiting nitric oxide synthesis might potentially diminish the Melanocortin-agonist-induced increases in pressure within cavernosal tissues, observed in anesthetized mouse models. These tissues are deemed key structures involved in achieving an erection due to their role in trapping blood within the cavernosal tissues. Consequently, the data cautiously suggest that activating central melanocortin receptors with melanocortin agonists like PT-141 may lead to enhanced cavernosal pressure, presumably through the enhanced release of NO by neurons, although this mechanism remains speculative and requires further confirmation.\u003c\/p\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003ePT-141 Peptide (Bremelanotide) and Cell Survival\u003c\/strong\u003e\u003cbr\u003eThe MC-1R receptor may be an important stimulus of DNA repair pathways, and is of relevance in cell survival.\u003csup\u003e[6]\u003c\/sup\u003e The scientists reported that \u003cem\u003e“MC1R signalling activates antioxidant, DNA repair and survival pathways.”\u003c\/em\u003e PT-141 retains some MC-1R activity, despite being biased towards MC-3Rs and MC-4Rs.\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eRosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004 Apr;16(2):135-42.\u003c\/li\u003e\n\u003cli\u003eRössler AS, Pfaus JG, Kia HK, Bernabé J, Alexandre L, Giuliano F. The melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat. Pharmacol Biochem Behav. 2006 Nov;85(3):514-21. . Epub 2006 Nov 20. PMID: 17113634.\u003c\/li\u003e\n\u003cli\u003eClayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016 Jun;12(3):325-37. . Epub 2016 May 16. PMID: 27181790; PMCID: PMC5384512.\u003c\/li\u003e\n\u003cli\u003eMiller MK, Smith JR, Norman JJ, Clayton AH. Expert opinion on existing and developing drugs to treat female sexual dysfunction. Expert Opin Emerg Drugs. 2018 Sep;23(3):223-230. . Epub 2018 Oct 11. PMID: 30251897.\u003c\/li\u003e\n\u003cli\u003ePfaus, J. G., Shadiack, A., Van Soest, T., Tse, M., \u0026amp; Molinoff, P. (2004). Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences of the United States of America, 101(27), 10201–10204.\u003c\/li\u003e\n\u003cli\u003eMaresca V, Flori E, Picardo M. Skin phototype: a new perspective. Pigment Cell Melanoma Res. 2015 Jul;28(4):378-89. . Epub 2015 Apr 11. PMID: 25786343.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786429890877,"sku":"sku2194756145081","price":140.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/PT-141-10MG-1.webp?v=1780466170"},{"product_id":"fragment-176-191-5mg","title":"（🔥Fat Loss） Fragment 176-191 (5mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cp\u003e🧬 What is Fragment 176–191?\u003c\/p\u003e\n\u003cp\u003eIt is the segment of the HGH (human growth hormone) molecule comprising:\u003c\/p\u003e\n\u003cp\u003e👉 Amino acids 176 through 191\u003c\/p\u003e\n\u003cp\u003eScientists have discovered that:\u003c\/p\u003e\n\u003cp\u003eThis region is primarily associated with “lipolysis”\u003cbr\u003eIt does not contribute to IGF-1 growth or bone growth\u003c\/p\u003e\n\u003cp\u003eTherefore, it has been isolated for separate study.\u003c\/p\u003e\n\u003cp\u003e🔥 Main Effects (Theory + Animal Studies)\u003cbr\u003e🧪 1️⃣ Promotes lipolysis\u003c\/p\u003e\n\u003cp\u003eStudies suggest it may:\u003c\/p\u003e\n\u003cp\u003eIncrease fat oxidation\u003cbr\u003eInhibit lipogenesis\u003cbr\u003ePromote the release of fatty acids from fat cells\u003c\/p\u003e\n\u003cp\u003e👉 Core Goal: Fat Loss\u003c\/p\u003e\n\u003ch2\u003eFragment 176-191 Peptide\u003c\/h2\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eFragment 176-191 peptide (Frag 176-191) is a short segment of growth hormone (hGH) and is sometimes referred to as the “\u003cem\u003elipolytic fragment\u003c\/em\u003e.” The name was coined from initial research on animal systems, which suggested that Fragment 176-191 may potentially increase fat cell metabolism in genetically engineered obese mice. Growth hormone (hGH) supplementation is considered by scientists to generally suppress carbohydrate metabolism, alter sensitivity towards insulin, promote long bone growth, and heighten insulin-like growth factor-1 (IGF-1) levels. Extensive animal studies have suggested that this synthetic fragment may mimic the lipolytic action of hGH without other actions.\u003csup\u003e[1]\u003c\/sup\u003e\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e78\u003c\/sub\u003eH\u003csub\u003e125\u003c\/sub\u003eN\u003csub\u003e23\u003c\/sub\u003eO\u003csub\u003e23\u003c\/sub\u003eS\u003csub\u003e2\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 1817.1 g\/mol\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Tyr-Leu-Arg-Ile-Val-Gin-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e Frag 176-191\u003c\/p\u003e\n\u003ch3\u003eFragment 176-191 Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eFragment 176-191 Structure\u003c\/strong\u003e\u003cbr\u003eFragment 176-191 is the shortened C-terminal fragment of hGH, encompassing a sequence of 16 amino acids. Researchers who synthesized the peptide assert that the structure corresponds to the final 16 amino acids of the hGH molecule and the peptide, therefore, is speculated to act as the \"\u003cem\u003elipolytic fragment\u003c\/em\u003e\" of hGH. The designation \"\u003cem\u003elipolytic\u003c\/em\u003e\" indicates that this fragment may have characteristics that facilitate the degradation of lipids or fats. In an aim to improve the stability of this peptide, the first amino acid in the sequence of hGH Fragment 176-191 has been replaced with tyrosine. As a result, this altered peptide is sometimes also known as Fragment tyr-hGH 177-191 or . Incorporating tyrosine at the N-terminus is thought to bolster the peptide's stability. Additionally, preliminary data suggests a naturally occurring disulfide bond between two cysteine amino acids in the original hGH and in Frag 176-191. This disulfide bond is presumed to play a role in maintaining the structural integrity of the molecule, thereby possibly enhancing its resilience and capacity to resist degradation under various environmental conditions, such as exposure to gastric acids and digestive enzymes.\u003csup\u003e[2]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eFragment 176-191 and Cartilage\u003c\/strong\u003e\u003cbr\u003eExperimental research in Fragment 176-191 suggests its potential in cartilage regeneration.\u003csup\u003e[3]\u003c\/sup\u003e To investigate the potential action of this peptide on knee osteoarthritis, scientists employed a model to mimic the condition by damaging knee cartilage by introducing type II collagenase. This particular enzyme is speculated to act in degrading the cartilage cellular matrix, mimicking the pathological changes seen in osteoarthritis. After inducing cartilage damage, the damaged knee models were organized into four distinct groups for 4-7 weeks: the researchers exposed the first group to a control compound saline (Group 1), the second was exposed to hyaluronic acid (Group 2), the third experimental group was exposed to Fragment 176-191 peptide (Group 3), and the fourth group was exposed to a combination of Fragment 176-191 peptide and hyaluronic acid (Group 4). To assess the potential actions of these experimental interventions, the severity of cartilage damage was systematically evaluated using both morphological and histopathological methods. Additionally, the extent of lameness was measured eight weeks post-initiation of the experimental protocols, providing insights into the functional outcomes of the interventions. The researchers commented, \"\u003cem\u003eMean gross morphological and histopathological scores were significantly higher in Group 1 than in Groups 2, 3, and 4, and the scores were significantly lower in Group 4 than in Groups 2 and 3. The lameness period in Group 4 was significantly shorter than those in Groups 1, 2, and 3.\u003c\/em\u003e” The findings indicate that both the hyaluronic acid and the Fragment 176-191 peptide may exhibit superior potential compared to saline in promoting cartilage regeneration. This hypothesis stems from the posited interactions between these two compounds, where hyaluronic acid may support moisture retention and lubrication, while Fragment 176-191 may play a role in the regeneration and repair of the model tissues.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eFragment 176-191 and Hypoglycemia\u003c\/strong\u003e\u003cbr\u003eThe C terminal end of hGH principally has been considered to bring about hypoglycemic (low blood sugar) levels in murine models.\u003csup\u003e[4]\u003c\/sup\u003e Screening of at least six different fragments obtained from the C terminal section of hGH has suggested that Fragment 176-191 may be a potentially effective synthetic derivative of hGH in research on blood sugar control. The hypoglycemic potential is considered secondary to maintaining an increased expression of insulin in blood plasma.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eFragment 176-191 and Fat Cells\u003c\/strong\u003e\u003cbr\u003eThe fat cell dissolution potential of Fragment 176-191 stems from research hypothesizing the peptide’s capacity to increase the production of beta-3 adrenergic receptors (3-AR or ADRB3).\u003csup\u003e[5]\u003c\/sup\u003e More specifically, the researchers posted that Fragment 176-191 may be “\u003cem\u003ecapable of increasing the repressed levels of beta(3)-AR RNA in obese mice to levels comparable with those in lean mice.\u003c\/em\u003e” An elevated density of beta-3 adrenergic receptors on adipocyte membranes potentially heightens these cells' sensitivity to lipolytic cues. This implies that although Fragment 176-191 might not interact directly with ADRB3, the increased number of these receptors might amplify the lipolytic activity prompted by endogenous catecholamines, notably adrenaline, which is posited to activate these receptors directly. Thus, agonist activity of the Fragment 176-191 peptide upon interaction with ADRB3 appeared to directly enhance fat burning in adipose tissue. Fragment 176-191 might initiate additional cellular signaling pathways that may indirectly enhance fat metabolism. For example, it might influence processes that either elevate the production of key enzymes involved in lipolysis or potentially enhance the cell's responsiveness to lipolytic signals through the regulation of secondary messengers within the cell. Here, lipolysis is the process of fat breakdown occurring in adipocytes, primarily driven by lipolytic enzymes. Secondary messengers are intracellular molecules believed to intensify signals from cell surface receptors to the internal biochemical systems. This amplification is crucial for orchestrating intricate cellular reactions to external signals. Research indicates that genetically modified mice that lack ADRB3 may be resistant to the action of hGH \/ Fragment 176-191. One experimental study observed that Fragment 176-191 exposure appeared to induce up to 50% weight reduction in obese mice over three weeks. Interestingly, the peptide appeared to mediate weight reduction only in obese mice but not in lean mice during the same span of exposure. The results suggest that secondary pathways may be involved in energy homeostasis, which may be capable of maintaining fat reserve in lean mice by overriding the ADRB3 pathway.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eFragment 176-191 and Fat Tissue Mass\u003c\/strong\u003e\u003cbr\u003eIn the realm of scientific inquiry, the potential of Fragment 176-191 in reducing total levels of fat mass has been probed using rigorously structured clinical trials, such as the METAOD005 study. This specific trial aimed to assess the efficacy of the peptide in reducing adipose tissue over a period of 12 weeks. Preliminary findings suggest that test subjects in one of the Fragment 176-191 groups may have experienced a notable reduction in fat tissue mass, with an average weight loss of approximately 5.7 pounds. Furthermore, there is a tentative suggestion that this peptide might positively influence lipid and glucose metabolism. However, additional studies are necessary to thoroughly explore these possibilities.\u003csup\u003e[6]\u003c\/sup\u003e\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eHabibullah MM, Mohan S, Syed NK, Makeen HA, Jamal QMS, Alothaid H, Bantun F, Alhazmi A, Hakamy A, Kaabi YA, Samlan G, Lohani M, Thangavel N, Al-Kasim MA. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Des Devel Ther. 2022 Jun 27;16:1963-1974. . PMID: 35783198; PMCID: PMC9249349.\u003c\/li\u003e\n\u003cli\u003eMoré, M. I., \u0026amp; Kenley, D. (2014). Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. \u003cem\u003eJournal of Endocrinology and Metabolism\u003c\/em\u003e, \u003cem\u003e4\u003c\/em\u003e(3), 64-77.\u003c\/li\u003e\n\u003cli\u003eKwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015 Summer;45(4):426-32. PMID: 26275694.\u003c\/li\u003e\n\u003cli\u003eNg FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978 May;234(5):E521-6. . PMID: 645904.\u003c\/li\u003e\n\u003cli\u003eHeffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. . PMID: 11713213.\u003c\/li\u003e\n\u003cli\u003eStier, H., Vos, E., \u0026amp; Kenley, D. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. \u003cem\u003eJournal of Endocrinology and Metabolism\u003c\/em\u003e, \u003cem\u003e3\u003c\/em\u003e(1-2), 7-15.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786430054717,"sku":"sku2194756127805","price":120.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/Frag-176-191-5mg-1.webp?v=1780466171"},{"product_id":"peg-mgf-5mg","title":"（💪Muscle recovery） PEG-MGF (Pegylated MGF) Peptide - 5mg - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e💪 Muscle recovery\u003cbr\u003e🔥 Muscle growth\u003cbr\u003e🩹 Tissue repair\u003cbr\u003e⚡ Improved post-workout recovery\u003c\/p\u003e\n\u003cp\u003eAfter PEGylation:\u003cbr\u003e➡️ Longer half-life\u003cbr\u003e➡️ Theoretically longer duration of action.\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003ePEG-MGF Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003ePegylated Mechano-growth factor (PEG-MGF) is a peptide that originates from the IGF-I (main anabolic mediator of growth hormone) gene sequence, which undergoes a process called alternative splicing.\u003csup\u003e[1]\u003c\/sup\u003e This process allows for the synthesis of additional segments, which form new functional molecules. During stress or injury, it has been suggested that muscles produce an alternative peptide called IGF-IEc, which contains extra \"exons\" or domains. This is thought to result in an additional segment at the C-terminus of IGF-I, known as the Ec-peptide, which comprises 40 amino acids.\u003csup\u003e[2]\u003c\/sup\u003e\u003cbr\u003e\u003cbr\u003eMGF, or mechano-growth factor, is a synthetic peptide that represents the last 24 amino acids from the naturally occurring IGF-IEc molecule (the Ec-peptide). This 24 amino acid fragment is also called the E-domain or MGF-E and is thought to mediate the beneficial actions of IGF-IEc on muscle recovery and cell proliferation.\u003csup\u003e[5]\u003c\/sup\u003e. It appears to stimulate myoblast (muscle cell) proliferation and differentiation. It has further been researched for its potential to increase endurance, stimulate the function of the immune system, and possible applications that may decrease cholesterol. PEG-MGF may also hasten wound healing via immune function regulation. The up-regulation of IGF-IEc, sometimes referred to as full-length MGF, during periods of stress or injury has been correlated by researchers with the proliferation of satellite cells and muscle cells. This suggests a potential role in muscle tissue repair and regeneration.\u003csup\u003e[3][4]\u003c\/sup\u003e\u003cbr\u003e\u003cbr\u003eThe attachment of a polyethylene glycol moiety to another chemical compound is termed \u003cem\u003e“Pegylation.”\u003c\/em\u003e Pegylation appears to increase the plasma stability of a compound like by decreasing its clearance and potentially masking its immunogenicity. Pegylation may be considered a common and typically advantageous modification. MGF appears to have a shorter half-life than other peptides. With this in mind, the pegylation of the peptide may overcome any rapid clearance.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e Pegylated MGF, Pegylated Mechano Growth Factor\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e121\u003c\/sub\u003eH\u003csub\u003e200\u003c\/sub\u003eN\u003csub\u003e42\u003c\/sub\u003eO\u003csub\u003e39\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys\u003c\/p\u003e\n\u003ch3\u003ePEG-MGF Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003eCurrently, research on PEG-MGF is limited. Therefore, the experimentation explained below has been conducted with MGF-E and full-length MGF instead. PEG-MGF is thought to have similar properties combined with improved stability.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003ePEG-MGF and Skeletal Muscle Cell Injury\u003c\/strong\u003e\u003cbr\u003eInjury, which normally occurs during muscle resistance activity, may activate mechano-growth factor (MGF) mRNA in muscle tissues. Researchers observed a substantial 163% rise from baseline levels in closed trials.\u003csup\u003e[6]\u003c\/sup\u003e This increase suggests a direct response of MGF to mechanical stimuli and muscle injury.\u003cbr\u003e\u003cbr\u003eAdditionally, a surge in growth hormone levels, typically accompanying muscle resistance, may further complicate this molecular interaction. Data indicates a 456% rise in MGF mRNA during resistance activities, while an increase in growth hormone alone may influence MGF mRNA expression by about 80% from baseline. It is hypothesized that MGF plays a critical role in mitigating muscle damage and promoting tissue repair in response to mechanical stress.\u003cbr\u003e\u003cbr\u003eMurine studies suggest that exposure to MGF in the muscles may decrease proinflammatory hormone production, reduce oxidative stress, and protect muscle cells.\u003csup\u003e[7]\u003c\/sup\u003e Scientists observe that \u003cem\u003e“Although MGF overexpression did not obviously affect muscle regeneration outcomes, the findings are novel and provide insights on the physiological roles of MGF in muscle regeneration.”\u003c\/em\u003e Researchers Sun et al. also suggested that MGF may regulate muscle inflammation and are also helped by the recruitment of neutrophils and macrophages to injury sites.\u003csup\u003e[7]\u003c\/sup\u003e The research mentioned above is based on prior reports of induction of IGF-1Ea and IGF-1Eb (both closely related to MGF) by muscle injury. This function suggests that PEG-MGF may produce impacts similar to IGF-1. This may lead to improved muscle repair, enhanced fat metabolism, and overall increases in lean body mass.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003ePEG-MGF and Skeletal Muscle Cell Growth\u003c\/strong\u003e\u003cbr\u003eA research experiment examining the correlative effects of MGF reported a 25% increase in mean muscle fiber size in exercising mice. Researchers Goldspink and Jakeman considered it a concerning limitation, as the peptide might require direct exposure to every muscle to mediate hypertrophy possibly.\u003csup\u003e[8]\u003c\/sup\u003e Further research implies that the potential of MGF on muscle cell growth may depend on the age of the cellular lineage.\u003csup\u003e[8]\u003c\/sup\u003e In this research, muscle cell cultures from multiple stages of test subject cell maturity were assessed after being exposed to MGF. Findings indicated that in younger cells, MGF appeared to promote increased cell proliferation. This may suggest the potential for enhanced muscle growth and regenerative capabilities.\u003cbr\u003e\u003cbr\u003eHowever, this proliferation was not observed in older cells. In these older cells, there was a noticeable increase in muscle hypertrophy, reflected by an enlarged muscle cell size. Interestingly, the study noted a significant decrease in the number of reserve cells, which typically remain undifferentiated and do not immediately merge into myotubes. This reduced proportion of reserve cells in the culture was evident.\u003cbr\u003e\u003cbr\u003eMyotubes, essential structures in muscle development formed by the fusion of muscle cells, were apparently enhanced in size across all age groups by MGF. This enhancement likely improved the muscle’s functional abilities through the elevated expression of muscle-specific contractile proteins. This observation is crucial as it implies that MGF may promote these reserve cells to become more actively involved in muscle formation.\u003csup\u003e[9]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003ePEG-MGF and Heart Muscle\u003c\/strong\u003e\u003cbr\u003eResearch carried out by researchers at the University of Illinois by Doroudian et al. observed that MGF may inhibit hypoxia-induced programmed cell death (apoptosis) of cardiac muscle cells.\u003csup\u003e[10]\u003c\/sup\u003e The peptide appears to promote regeneration and healing after a cardiac event by recruiting cardiac stem cells to the site of tissue injury. Researchers report that rats given MGF within eight hours of hypoxia appeared to exhibit less cell death and greater stem cell recruitment compared to placebo controls. Dr. Doroudian, the lead author of the research, suggests that the MGF exposure to damaged cardiac tissues may have provided a localized impact to control pathologic hypertrophy and lessen cardiac remodeling. The researchers' observations propose that the peptide might support the proliferation and enlargement (hypertrophy) of stem cells within cardiac tissue, potentially aiding in cell survival.\u003cbr\u003e\u003cbr\u003eIn particular, MGF seems to enhance the movement of mesenchymal stem cells (MSCs). MSCs are a type of multipotent stromal cell that may differentiate into a variety of cell types, including those found in the heart. This migratory response may exhibit a chemotactic action, meaning it may attract stem cells to regions impacted by damage or disease. Early data suggests an increase in the expression levels of the Bcl-2 gene. Bcl-2 is a gene that is commonly linked to cell growth and survival, which seems to support this hypothesis, although further validation is necessary.\u003cbr\u003e\u003cbr\u003eA group of other researchers, namely Carpenter et al., have reported similar observations with a 35% approximate reduction of heart muscle cell apoptosis upon peptide exposure in cardiomyocyte injury models.\u003csup\u003e[11]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003ePEG-MGF and Bone Repair, Growth\u003c\/strong\u003e\u003cbr\u003ePEG-MGF has been observed to promote osteoblast proliferation and hasten bone repair in bone defect models.\u003csup\u003e[12] \u003c\/sup\u003eThe models exposed to high concentrations of MGF appeared to exhibit equivalent bone recovery in just four weeks compared to controls in six weeks duration. Findings from the study indicate that MGF could potentially impact the cell cycle by possibly arresting it at certain phases. Furthermore, MGF might activate the Mitogen-Activated Protein Kinase (MAPK) and Extracellular Signal-Regulated Kinase 1\/2 (Erk1\/2) signaling pathway. This pathway is significant in transmitting signals from the cell surface to DNA in the cell’s nucleus, which may impact various cellular activities, including growth and division. The data suggests that MGF might employ a complex approach to promote cell proliferation, which appears to involve modifications to cell cycle dynamics and the activation of specific molecular pathways.\u003cbr\u003e\u003cbr\u003eThese pathways are believed to play essential roles in cellular repair and regeneration, indicating that MGF could possibly influence cellular functions on multiple levels. The exact mechanisms remain uncertain, and further investigation is required to understand how MGF interacts with these cellular processes fully. These findings highlight the peptide's promising potential from the perspective of researchers studying bone tissues and repair.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003ePEG-MGF and Cartilage\u003c\/strong\u003e\u003cbr\u003eMGF may also improve the function of chondrocytes, the cells essential for cartilage function and deposition. Studies in mice suggest that MGF may promote the migration of chondrocytes from bone – their site of origin – into cartilage, where they appear to function.\u003csup\u003e[13]\u003c\/sup\u003e The researchers also noted that \u003cem\u003e“The results also demonstrate that the degeneration of OA cartilage may be delayed by MGF [exposure]\u003c\/em\u003e\u003cem\u003e partially via unfolded protein response regulated by protein kinase RNA-like endoplasmic reticulum kinase.”\u003c\/em\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003ePEG-MGF and Dental Activity\u003c\/strong\u003e\u003cbr\u003ePeriodontal ligament cell culture studies indicate that the pegylated peptide may improve osteogenic differentiation and potentially enhance MMP-1 and MMP-2 expression.\u003csup\u003e[14]\u003c\/sup\u003e These factors may improve the repair of ligaments, such as those that attach teeth to bone. The peptide may even have the potential to salvage damaged or avulsed dental material.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003ePEG-MGF and Neuroprotection\u003c\/strong\u003e\u003cbr\u003eResearcher Alexander Walker reviewed a study based on the long-term consequences of elevated levels of MGF in the brain and central nervous system.\u003csup\u003e[15]\u003c\/sup\u003e The work observes how increased MGF may potentially influence neuron degeneration. Mice exposed to the peptide appeared to maintain their cognitive ability and function optimally for long into old age. As per Walker, “\u003cem\u003ethe efficacy of MGF in the brain is age-dependent\u003c\/em\u003e,” as the mice in the study had shown better outcomes initially and over the long term if the peptide over-expression occurred earlier in life.\u003cbr\u003e\u003cbr\u003eMGF exposure may improve muscle weakness and decrease the loss of motor neurons in murine models of ALS. According to Dluzniewska et al., MGF is naturally produced in the brain after hypoxic injury and is over-expressed in the segments with the greatest neuronal damage.\u003csup\u003e[16]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003ePEG-MGF and Muscle Cell Scarring\u003c\/strong\u003e\u003cbr\u003eResearchers have explored the potential role of MGF in muscle scarring, a condition that may impair muscle function.\u003csup\u003e[17]\u003c\/sup\u003e Muscle scarring involves the excessive development of connective tissue in response to injury, which hinders muscle movement and function. One study used murine models, inducing muscle contusions and depleting macrophages to observe the actions. Initial findings suggest that MGF might aid in the functional and structural recovery of damaged muscle tissues by potentially reducing fibrosis and lowering levels of inflammatory cytokines, chemokines, and stress-related factors.\u003cbr\u003e\u003cbr\u003eThere is speculation that MGF may inhibit fibrosis by suppressing the expression of type I and III collagen, which are said to be key components of the extracellular matrix involved in fibrotic tissue development. Observations also indicated a potential decrease in markers of oxidative stress and matrix metalloproteinases (MMPs), which degrade extracellular matrix proteins. This suggests a potential role for MGF in mitigating the inflammatory response following muscle injury. The study also noted a possible reduction in muscle contusions, which might facilitate tissue repair processes.\u003cbr\u003e\u003cbr\u003eMGF's impact on satellite cells and immune cell dynamics post-injury appeared minimal, which researchers inferred from stable levels of MyoD and myogenin, markers indicating satellite cell activity. Additionally, MGF might influence the inflammatory environment in injured muscles. This was suggested by reduced expression of significant pro-inflammatory cytokines observed by researchers, such as tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin-1 beta (IL-1β), and transforming growth factor-beta (TGF-β). Chemokines like CCL2, CCL5, and CXCR4 also appeared to be less expressed, along with a possible reduction in gp91phox, a component involved in oxidative stress. These findings hint at MGF's potential role in modulating inflammation and remodeling within skeletal muscle tissues.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eMatheny, R. W., Jr, Nindl, B. C., \u0026amp; Adamo, M. L. (2010). Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology, 151(3), 865–875.\u003c\/li\u003e\n\u003cli\u003eLi, C., Vu, K., Hazelgrove, K., \u0026amp; Kuemmerle, J. F. (2015). Increased IGF-IEc expression and mechano-growth factor production in intestinal muscle of fibrostenotic Crohn's disease and smooth muscle hypertrophy. American journal of physiology. Gastrointestinal and liver physiology, 309(11), G888–G899.\u003c\/li\u003e\n\u003cli\u003eJanssen, J. A., Hofland, L. J., Strasburger, C. J., van den Dungen, E. S., \u0026amp; Thevis, M. (2016). Potency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations. PloS one, 11(3), e0150453.\u003c\/li\u003e\n\u003cli\u003eEsposito, S., Deventer, K., \u0026amp; Van Eenoo, P. (2012). Characterization and identification of a C-terminal amidated mechano growth factor (MGF) analogue in black market products. Rapid communications in mass spectrometry : RCM, 26(6), 686–692.\u003c\/li\u003e\n\u003cli\u003eDai, Z., Wu, F., Yeung, E. W., \u0026amp; Li, Y. (2010). IGF-IEc expression, regulation and biological function in different tissues. Growth hormone \u0026amp; IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 20(4), 275–281.\u003c\/li\u003e\n\u003cli\u003eHameed M, Lange KH, Andersen JL, Schjerling P, Kjaer M, Harridge SD, Goldspink G. The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men. J Physiol. 2004 Feb 15;555(Pt 1):231-40. . Epub 2003 Oct 17. PMID: 14565994; PMCID: PMC1664832.\u003c\/li\u003e\n\u003cli\u003eSun KT, Cheung KK, Au SWN, Yeung SS, Yeung EW. Overexpression of Mechano-Growth Factor Modulates Inflammatory Cytokine Expression and Macrophage Resolution in Skeletal Muscle Injury. Front Physiol. 2018 Jul 26;9:999. . PMID: 30140235; PMCID: PMC6094977.\u003c\/li\u003e\n\u003cli\u003eGoldspink G. Research on mechano growth factor: its potential for optimising physical training as well as misuse in doping. Br J Sports Med. 2005 Nov;39(11):787-8; discussion 787-8. . PMID: 16244184; PMCID: PMC1725070.\u003c\/li\u003e\n\u003cli\u003eKandalla PK, Goldspink G, Butler-Browne G, Mouly V. Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev. 2011 Apr.\u003c\/li\u003e\n\u003cli\u003eDoroudian G, Pinney J, Ayala P, Los T, Desai TA, Russell B. Sustained delivery of MGF peptide from microrods attracts stem cells and reduces apoptosis of myocytes. Biomed Microdevices. 2014 Oct;16(5):705-15.\u003c\/li\u003e\n\u003cli\u003eCarpenter V, Matthews K, Devlin G, Stuart S, Jensen J, Conaglen J, Jeanplong F, Goldspink P, Yang SY, Goldspink G, Bass J, McMahon C. Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart Lung Circ. 2008 Feb;17(1):33-9. \u003ca href=\"https:\/\/doi.org\/10.1016\/j.hlc.2007.04.013\" rel=\"noopener\" target=\"_blank\"\u003edoi: 10.1016\/j.hlc.2007.04.013\u003c\/a\u003e. Epub 2007 Jun 19. PMID: 17581790.\u003c\/li\u003e\n\u003cli\u003eDeng M, Zhang B, Wang K, Liu F, Xiao H, Zhao J, Liu P, Li Y, Lin F, Wang Y. Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits. Int Orthop. 2011 Jul;35(7):1099-106. \u003ca href=\"https:\/\/doi.org\/10.1007\/s00264-010-1141-2\" rel=\"noopener\" target=\"_blank\"\u003edoi: 10.1007\/s00264-010-1141-2\u003c\/a\u003e. Epub 2010 Nov 6. PMID: 21057789; PMCID: PMC3167400.\u003c\/li\u003e\n\u003cli\u003eSong Y, Xu K, Yu C, Dong L, Chen P, Lv Y, Chiang MYM, Li L, Liu W, Yang L. The use of mechano growth factor to prevent cartilage degeneration in knee osteoarthritis. J Tissue Eng Regen Med. 2018 Mar;12(3):738-749. \u003ca href=\"https:\/\/doi.org\/10.1002\/term.2493\" rel=\"noopener\" target=\"_blank\"\u003edoi: 10.1002\/term.2493\u003c\/a\u003e. Epub 2017 Oct 6. PMID: 28599103.\u003c\/li\u003e\n\u003cli\u003eChen JT, Wang Y, Zhou ZF, Wei KW. [Mechano-growth factor regulated cyclic stretch-induced osteogenic differentiation and MMP-1, MMP-2 expression in human periodontal ligament cells by activating the MEK\/ERK1\/2 pathway]. Shanghai Kou Qiang Yi Xue. 2019 Feb;28(1):6-12. Chinese. PMID: 31080992.\u003c\/li\u003e\n\u003cli\u003eTang JJ, Podratz JL, Lange M, Scrable HJ, Jang MH, Windebank AJ. Mechano growth factor, a splice variant of IGF-1, promotes neurogenesis in the aging mouse brain. Mol Brain. 2017 Jul 7;10(1):23. \u003ca href=\"https:\/\/doi.org\/10.1186\/s13041-017-0304-0\" rel=\"noopener\" target=\"_blank\"\u003edoi: 10.1186\/s13041-017-0304-0\u003c\/a\u003e. PMID: 28683812; PMCID: PMC5501366.\u003c\/li\u003e\n\u003cli\u003eDluzniewska J, Sarnowska A, Beresewicz M, Johnson I, Srai SK, Ramesh B, Goldspink G, Górecki DC, Zabłocka B. A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia. FASEB J. 2005 Nov;19(13):1896-8. \u003ca href=\"https:\/\/doi.org\/10.1096\/fj.05-3786fje\" rel=\"noopener\" target=\"_blank\"\u003edoi: 10.1096\/fj.05-3786fje\u003c\/a\u003e. Epub 2005 Sep 6. PMID: 16144956.\u003c\/li\u003e\n\u003cli\u003eLiu X, Zeng Z, Zhao L, Chen P, Xiao W. Impaired Skeletal Muscle Regeneration Induced by Macrophage Depletion Could Be Partly Ameliorated by MGF Injection. Front Physiol. 2019 May 17;10:601. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31164836\/\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/31164836\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786430185789,"sku":"sku2194756143847","price":150.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/PEG_MGF-5MG-1.webp?v=1780466173"},{"product_id":"bpc-157","title":"（💪Repair + Anti-inflammatory + Tissue Regeneration） BPC-157 (5mg) - Biotech Peptides","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is BPC-157?\u003c\/p\u003e\n\u003cp\u003eBPC-157 is a synthetic peptide derived from a fragment of gastric mucin and is classified as a “protective\/repair peptide.”\u003c\/p\u003e\n\u003cp\u003eIt is not:\u003c\/p\u003e\n\u003cp\u003e❌ A muscle-building agent (like IGF-1)\u003cbr\u003e❌ A GH stimulator (like CJC \/ Ipamorelin)\u003c\/p\u003e\n\u003cp\u003eInstead, it falls under:\u003cbr\u003e👉 Repair + Anti-inflammatory + Tissue Regeneration\u003c\/p\u003e\n\u003cp\u003e🩹 Core Effects (Research + Experience)\u003cbr\u003e🔥 1️⃣ Tissue Repair (Core Effect)\u003c\/p\u003e\n\u003cp\u003eBPC-157 has been studied for:\u003c\/p\u003e\n\u003cp\u003eMuscle strains\u003cbr\u003eLigament injuries\u003cbr\u003eTendinitis\u003cbr\u003eJoint soft tissue injuries\u003c\/p\u003e\n\u003cp\u003e👉 In the fitness community, it’s often called:\u003cbr\u003e“injury recovery peptide”\u003c\/p\u003e\n\u003cp\u003e🧠 2️⃣ Nerve and Vascular Repair (Research Focus)\u003c\/p\u003e\n\u003cp\u003eSome animal studies suggest it may:\u003c\/p\u003e\n\u003cp\u003ePromote angiogenesis\u003cbr\u003ePromote nerve repair\u003cbr\u003eAccelerate soft tissue healing\u003cbr\u003e🧴 3️⃣ Gastrointestinal Protection (Original Source)\u003c\/p\u003e\n\u003cp\u003eOne of BPC’s sources and functions is:\u003c\/p\u003e\n\u003cp\u003eGastric mucosal protection\u003cbr\u003eGastric ulcer repair\u003cbr\u003eRegulation of intestinal inflammation\u003c\/p\u003e\n\u003cp\u003eSo some people also use it for:\u003c\/p\u003e\n\u003cp\u003eIBS (Irritable Bowel Syndrome)\u003cbr\u003eGastritis-related issues (research\/anecdotal)\u003cbr\u003e💪 Why the fitness community loves it so much\u003c\/p\u003e\n\u003cp\u003eBecause it addresses a core issue:\u003c\/p\u003e\n\u003cp\u003e👉 “Slow recovery from training injuries”\u003c\/p\u003e\n\u003cp\u003eCommon uses discussed:\u003c\/p\u003e\n\u003cp\u003eRotator cuff injuries\u003cbr\u003eElbow inflammation (tennis elbow)\u003cbr\u003eKnee soft tissue issues\u003cbr\u003eRecovery from strains\u003c\/p\u003e\n\u003cp\u003eMany people say:\u003cbr\u003e➡️ Recovery speed is “noticeably faster”\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eBPC-157 Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eBPC-157, Body Protection Compound-157, is obtained from the parent protein Body Protection Compound (BPC). BPC is a naturally occurring protein in the digestive tract.\u003csup\u003e[1]\u003c\/sup\u003e BPC -57 is a penta-decapeptide made up of 15 amino acids, and is derived from a stretch of endogenous BPC identified and isolated from gastric juice. Animal studies have suggested its potential in supporting tissue repair processes in muscle, tendon, and torn ligaments. It may further protect organs and potentially prevent gastric ulcer development.\u003csup\u003e[2] \u003c\/sup\u003eSikiric et al. noted that there was \"\u003cem\u003ea strong protection, noted following [exposure to] BPC 157.\" \u003c\/em\u003e BPC-157 also has the potential to enhance the function of the digestive tract and prevent against irritable bowel syndrome (IBS), gastrointestinal cramps, and Crohn’s disease. The peptide also has possible analgesic characteristics.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e62\u003c\/sub\u003eH\u003csub\u003e98\u003c\/sub\u003eN\u003csub\u003e16\u003c\/sub\u003eO\u003csub\u003e22\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 1419.556 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e L-Valine,glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-Lprolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-;glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyllysyl-L-prolyl-L-alanyl-L- alpha-aspartylL-alpha-aspartyl-L-alanylglycyl-L-leucyl-L-valine\u003c\/p\u003e\n\u003ch3\u003eBPC-157 Peptide Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eBPC-157 and Wound Healing\u003c\/strong\u003e\u003cbr\u003eThe GI tract's mucosal barrier is considered to protect the underlying tissues from the harmful actions of bile, gastric acid, and other compounds necessary for the digestion and absorption of nutrients from food. BPC-157 is believed to help preserve the structural integrity of the mucosal layer. The role appears to be partially mediated through the recruitment of fibroblasts. Fibroblasts are considered to produce extracellular matrix proteins such as fibrin, collagen, elastin, and others. BPC-157 has been suggested to promote the proliferation and faster migration of fibroblasts in a concentration-dependent manner.\u003csup\u003e[3]\u003c\/sup\u003e In another research study it was hypothesized that BPC-157 may have led to an acceleration in wound closure compared to the control group via an improvement in the formation of granulation tissue, reepithelialization, dermal remodeling, and collagen deposition. There is a possibility that BPC-157 may have promoted the expression of vascular endothelial growth factor (VEGF) in the injured skin tissues.\u003csup\u003e[4]\u003c\/sup\u003e Moreover, the researchers commented that BPC-157 may have shown a potential to enhance umbilical vein endothelial cell proliferation (HUVECs). Furthermore, there may have been a significant increase in the migration of HUVECs, as indicated by the comments from wound healing assays. BPC-157 possibly resulted in an upregulation of VEGF-a expression and acceleration of vascular tube formation. It also appeared that BPC-157 may have regulated the phosphorylation level of extracellular signal-regulated kinases 1 and 2 (ERK1\/2) and their downstream targets, including c-Fos, c-Jun, and Egr-1. These molecules are hypothesized to potentially play significant roles in cell growth, migration, and angiogenesis.\u003csup\u003e[4]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eBPC-157 and Vascular Growth and Collateralization\u003c\/strong\u003e\u003cbr\u003eThe peptide has the potential as an angiogenic, and studies suggest it may enhance endothelial cells’ growth and proliferation, which line the walls of blood vessels. Research in rats has observed that the peptide may substantially increase the collateral blood vessel growth rate in the setting of ischemia.\u003csup\u003e[5]\u003c\/sup\u003e That action has been primarily observed in the GI tract, but research has noted similar observations in muscle, neurological, and cardiovascular tissues. Research using chicken embryos has posited that BPC-157 may also have the potential to promote vascular growth through activation of VEGFR2 pathway. VEGFR2 is a cell surface receptor active in nitric oxide signaling and is considered to support cell activity and proliferation. BPC-157 may promote vascular “running” in cultured cells. This is the growth and development of new blood vessels towards a site of injury or around the area of blood clot to reach out to distal tissues and thus protect cellular function.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eBPC-157 and Tendon Healing\u003c\/strong\u003e\u003cbr\u003eBPC-157 studies have observed potential in connective tissue healing such as ligament, bone, and tendon. Ligament and tendon injuries take a long time to heal due to the poor blood supply to these tissues. There is slower migration of fibroblasts and wound-healing cells to these sites of injury owing to the poor blood supply, and therefore the repair process is obstructed. The peptide has the potential to improve the collateralization and density of fibroblasts in the sites of injury in research involving rat tendons.\u003csup\u003e[6]\u003c\/sup\u003e More specifically, the study also hypothesized that BPC-157 might accelerate the outgrowth of tendon fibroblasts from tendon explants. This suggests that BPC-157 may potentially promote the growth of new cells in the injured tendon. Further, the survival of the cells to which BPC-157 was applied may be significantly increased when exposed to H(2)O(2) stress, indicating a potential protective action against oxidative stress. BPC-157 may also enhance the migration of tendon fibroblasts, as indicated by the transwell filter migration assay used in the study. This may imply that BPC-157 potentially promotes the movement of tendon fibroblasts. Moreover, BPC-157 may accelerate the spreading of tendon fibroblasts on culture dishes, suggesting potentially increased cell adhesion and attachment.\u003csup\u003e[6] \u003c\/sup\u003eThis experimental research has suggested BPC-157 to be a positive impactor in comparison to EFG, bFGF, and VGF hormones. Immunostaining assays involving FITC conjugated phalloidin have suggested BPC-157 to enhance F-actin formation in fibroblasts. F-actin is considered to be crucial for cell structure and function and promotes cell migration. Immunoblotting experiments have noted that BPC-157 appears to increase the phosphorylation of paxillin and FAK proteins, which are considered crucial for cellular migration. More specifically, BPC-157 may induce F-actin formation in tendon fibroblasts, potentially indicating enhanced cytoskeletal organization and cell motility. Further analysis using Western blotting indicates that BPC-157 may activate the FAK (focal adhesion kinase) and paxillin proteins. The phosphorylation levels of FAK and paxillin may increase with BPC-157, while the total amounts of these proteins may remain unchanged. This potentially suggests that BPC-157 may activate the FAK-paxillin pathway, which may be involved in the promotion of tendon fibroblast migration and cell adhesion.\u003csup\u003e[6]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eBPC-157 and Antioxidant Characteristics\u003c\/strong\u003e\u003cbr\u003eStudies in rat models have proposed that BPC-157 may exhibit antioxidant characteristics, and may help to neutralize oxidative stress molecules like nitric oxide and malondialdehyde (MDA) and reactive oxygen species in the GI tract.\u003csup\u003e[7]\u003c\/sup\u003e Research further hypothesized that modified Lactococcus lactis bacteria may increase the amount of the peptide in cell culture and can possibly deliver it to the GI tract.\u003cbr\u003eAnother study aimed to evaluate early functional recovery and inflammation in tendon cells after the application of BPC-157.\u003csup\u003e[8]\u003c\/sup\u003e. The researchers utilized the Achilles functional index (AFI), myeloperoxidase activity, histological inflammatory cell influx, and vascular index as potential markers. The results suggest that BPC-157 may have improved functional recovery, as indicated by a potential increase in AFI values at all time points. This improvement was hypothesized to be attributed to its purported anti-inflammatory action, including a potential decrease in myeloperoxidase (MPO) activity and histological inflammatory cell influx. Furthermore, BPC-157 potentially increased the formation of new blood vessels, as inferred by a possible increase in the vascular index. On the other hand, methylprednisolone also possibly decreased MPO activity and histological inflammatory cell influx, suggesting its potential anti-inflammatory action. However, methylprednisolone hypothetically decreased the formation of new blood vessels and may not have significantly affected early functional recovery.\u003csup\u003e[8] \u003c\/sup\u003eAnother study examined the proposed action of a pentadecapeptide BPC-157 on inflammation and bone resorption in experimental periodontitis. Inflammation was assessed using the Evans blue plasma extravasation technique and histology. Evans blue extravasation refers to the potential leakage of Evans blue dye from blood vessels into the surrounding tissues, which potentially indicates increased vascular permeability, possibly associated with inflammation. The histological analysis appeared to provide visual evidence of inflammation. The results indicated that the induction of periodontitis potentially induced an increase in Evans blue extravasation, histological signs of inflammation, and alveolar bone destruction. However, the exposure to BPC-157 appeared to significantly reduce plasma extravasation, histological alterations potentially associated with inflammation, and alveolar bone resorption.\u003csup\u003e[9]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eBPC-157 and and the Central Nervous System\u003c\/strong\u003e\u003cbr\u003eThe potential of BPC-157 has been investigated in a murine model of traumatic brain injury (TBI), suggesting positive outcomes. The peptide appeared to lead to a significant attenuation of TBI-induced damage and improved early outcomes based on the observed experiments. During the 24-hour post-injury period, there seemed to be minimal mortality. The severity of traumatic lesions, such as subarachnoid and intraventricular hemorrhage, brain laceration, and hemorrhagic laceration, appeared to be less pronounced in the BPC-157 group. Furthermore, there seemed to be a considerable improvement in brain edema. Hypothetically, if introduced prior to TBI, BPC-157 may have exhibited an improved conscious\/unconscious\/death ratio. Moreover, the immediate presentation of BPC-157 before injury may have also reduced the damage in murine models subjected to a force impulse.\u003csup\u003e[10]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px !important;\"\u003e\u003cstrong\u003eBPC-157 and Bees\u003c\/strong\u003e\u003cbr\u003eColony collapse disorder (CCD) is a syndrome that causes entire colonies of bees to decline rapidly and die entirely, possibly due to \u003cem\u003eNosema ceranae\u003c\/em\u003e fungal infection in the GI tract of bees. The addition of BPC-157 in bee food noted significant improvement of the bee GI tract and hive survival. In this experimental research, the peptide appeared successful in natural field settings to reduce the impact of CCD on bees, important natural pollinators of many crop plants.\u003cb\u003e\u003cem\u003e\u003c\/em\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"padding-bottom: 5px !important; margin-bottom: 25px !important;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eJelovac, N., Sikirić, P., Rucman, R., Petek, M., Perović, D., Konjevoda, P., Marović, A., Seiwerth, S., Grabarević, Z., Sumajstorcić, J., Dodig, G., \u0026amp; Perić, J. (1998). A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine. Biological psychiatry, 43(7), 511–519.\u003c\/li\u003e\n\u003cli\u003eSikirić, P., Mazul, B., Seiwerth, S., Grabarević, Z., Rucman, R., Petek, M., Jagić, V., Turković, B., Rotkvić, I., Mise, S., Zoricić, I., Jurina, L., Konjevoda, P., Hanzevacki, M., Gjurasin, M., Separović, J., Ljubanović, D., Artuković, B., Bratulić, M., Tisljar, M., … Sumajstorcić, J. (1997). Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress. Digestive diseases and sciences, 42(3), 661–671.\u003c\/li\u003e\n\u003cli\u003eTkalcević, V. I., Cuzić, S., Brajsa, K., Mildner, B., Bokulić, A., Situm, K., Perović, D., Glojnarić, I., \u0026amp; Parnham, M. J. (2007). Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. European journal of pharmacology, 570(1-3), 212–221.\u003c\/li\u003e\n\u003cli\u003eHuang, T., Zhang, K., Sun, L., Xue, X., Zhang, C., Shu, Z., Mu, N., Gu, J., Zhang, W., Wang, Y., Zhang, Y., \u0026amp; Zhang, W. (2015). Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. \u003ci\u003eDrug design, development and therapy\u003c\/i\u003e, \u003ci\u003e9\u003c\/i\u003e, 2485–2499.\u003c\/li\u003e\n\u003cli\u003eHsieh, M. J., Liu, H. T., Wang, C. N., Huang, H. Y., Lin, Y., Ko, Y. S., Wang, J. S., Chang, V. H., \u0026amp; Pang, J. S. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of molecular medicine (Berlin, Germany), 95(3), 323–333.\u003c\/li\u003e\n\u003cli\u003eChang, C. H., Tsai, W. C., Lin, M. S., Hsu, Y. H., \u0026amp; Pang, J. H. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of applied physiology (Bethesda, Md. : 1985), 110(3), 774–780.\u003c\/li\u003e\n\u003cli\u003eŠkrlec, K., Ručman, R., Jarc, E., Sikirić, P., Švajger, U., Petan, T., Perišić Nanut, M., Štrukelj, B., \u0026amp; Berlec, A. (2018). Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities. Applied microbiology and biotechnology, 102(23), 10103–10117.\u003c\/li\u003e\n\u003cli\u003eKrivic, A., Majerovic, M., Jelic, I., Seiwerth, S., \u0026amp; Sikiric, P. (2008). Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. \u003ci\u003eInflammation research : official journal of the European Histamine Research Society ... [et al.]\u003c\/i\u003e, \u003ci\u003e57\u003c\/i\u003e(5), 205–210.\u003c\/li\u003e\n\u003cli\u003eKeremi, B., Lohinai, Z., Komora, P., Duhaj, S., Borsi, K., Jobbagy-Ovari, G., Kallo, K., Szekely, A. D., Fazekas, A., Dobo-Nagy, C., Sikiric, P., \u0026amp; Varga, G. (2009). Antiinflammatory effect of BPC 157 on experimental periodontitis in rats. \u003ci\u003eJournal of physiology and pharmacology : an official journal of the Polish Physiological Society\u003c\/i\u003e, \u003ci\u003e60 Suppl 7\u003c\/i\u003e, 115–122.\u003c\/li\u003e\n\u003cli\u003eTudor, M., Jandric, I., Marovic, A., Gjurasin, M., Perovic, D., Radic, B., Blagaic, A. B., Kolenc, D., Brcic, L., Zarkovic, K., Seiwerth, S., \u0026amp; Sikiric, P. (2010). Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. \u003ci\u003eRegulatory peptides\u003c\/i\u003e, \u003ci\u003e160\u003c\/i\u003e(1-3), 26–32.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"5mg \/ 10 Vials","offer_id":51786430218557,"sku":"sku2194756131508","price":180.0,"currency_code":"USD","in_stock":true},{"title":"10mg \/ 10 Vials","offer_id":51786430251325,"sku":"sku2194756131507","price":250.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/BPC-157-1-1.webp?v=1780466175"},{"product_id":"semax-25mg","title":"（🧠Stress relief） Semax Peptide (25mg) -10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003ch2\u003e🧠 Cognitive enhancement\u003cbr\u003e🎯 Focus\u003cbr\u003e📚 Learning and memory\u003cbr\u003e🛡️ Neuroprotection\u003cbr\u003e😌 Stress relief\u003c\/h2\u003e\n\u003ch2\u003eSemax Peptide\u003c\/h2\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eSemax is a synthetic analog of adrenocorticotropic hormone (ACTH) comprising the amino acids 4 through 10 of ACTH. Semax has primarily been implicated in research on cognitive impairment and stroke. The peptide has also been studied closely within the context of dementia and certain inflammations of the optic nerve. Researchers posit that the peptide may exert neurotrophic action, suggesting that the peptide may act to increase the production of brain-derived neurotrophic factor (BDNF) in the central nervous system, with potential consequences in serotonin and dopamine release. Some researchers also suggest that Semax may interact with serotonin and enkephalin levels in the central nervous system.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e39\u003c\/sub\u003eH\u003csub\u003e54\u003c\/sub\u003eN\u003csub\u003e10\u003c\/sub\u003eO\u003csub\u003e10\u003c\/sub\u003eS\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 854.99 g\/mol\u003c\/p\u003e\n\u003cp class=\"grey-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-lle-GluLys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-LysThr-Glu-Thr-Gin-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-GluThy-lleGlu-Gin-Glu-Lys-Gin-Ala-Gly-Glu-Ser\u003c\/p\u003e\n\u003ch3\u003eSemax Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eSemax and the Blood-Brain Barrier\u003c\/strong\u003e\u003cbr\u003eSemax is a synthetic heptapeptide consisting of the amino acid sequence Met-Glu-His-Phe, a partial sequence derived from the naturally occurring adrenocorticotropic hormone (ACTH). This primary sequence is further augmented by appending a Pro-Gly-Pro (PGP) tripeptide at the C-terminal end, a modification hypothesized to potentially increase the molecule's lipophilicity. Enhanced lipophilicity might, in turn, improve the peptide’s capacity for passive diffusion or uptake through the brain's protective blood-brain barrier (BBB). Such facilitation might occur via lipid raft-mediated endocytosis mechanisms, potentially allowing the peptide to bypass the tight junctions that normally impede substances from entering the brain. Additionally, incorporating the PGP sequence at the C-terminus of the peptide is posited to influence its interaction with specific transporters or receptors located on the BBB, which might promote its entry into the brain through receptor-mediated transcytosis. Furthermore, acetylating Semax may confer increased molecular stability, potentially rendering the peptide more resistant to enzymatic degradation. This alteration might result in an extended half-life of Semax within biological systems, allowing for a prolonged period of activity before breakdown occurs.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eSemax and Stroke\u003c\/strong\u003e\u003cbr\u003eIn Russia, Semax has been researched in the context of acute cerebral hypoxia resulting from stroke or traumatic brain injury. As per studies in murine models, Semax appears to promote the expression of 24 genes in the brain and spinal cord through various molecular mechanisms. These genes are believed to modulate various functions, from smooth muscle cell migration to red blood cell formation and angiogenesis. The peptide has been suggested to promote the survival of neurons and potentially stabilize mitochondria.\u003csup\u003e[1]\u003c\/sup\u003e Scientists report that \u003cem\u003e“The immunomodulating effect of the peptide discovered in our research and its impact on the vascular system during ischemia is likely to be the key mechanisms underlying the neuroprotective effects of the peptide.”\u003c\/em\u003e \u003csup\u003e[2]\u003c\/sup\u003e Gusev et al. observed, \u003cem\u003e“early rehabilitation and [introduction] of Semax increased BDNF plasma levels, speed functional recovery, and improve motor performance.”\u003c\/em\u003e BDNF is a natural that some researchers believe may aid in cognitive development. There is data to suppose that BDNF stimulation may support neuroplasticity as well.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eSemax and Brain Structure\u003c\/strong\u003e\u003cbr\u003eSemax has been suggested by researchers via functional magnetic resonance imaging to trigger the function of what is known as \u003cem\u003ethe default mode network\u003c\/em\u003e.\u003csup\u003e[3]\u003c\/sup\u003e The default mode network includes areas of the brain that remain more active during rest than during conscious activity. It is considered a general-purpose system for monitoring the organism’s environment without focusing on specific elements. The network is an important aspect of an organism’s attention capacity as it is believed to support the change from a “resting” state to alertness.\u003csup\u003e[4]\u003c\/sup\u003e Researchers suggest that increased activity in the default mode network may correspond to improved neural connections within the brain. These connections may support cognitive processes. Through closer research into Semax, researchers speculate that the peptide may support global brain function through a domino chain of cognitive functioning.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eSemax and Gene Expression\u003c\/strong\u003e\u003cbr\u003eSemax appears to mediate changes in gene expression in the brain. Study findings indicate that introducing the peptide may trigger differential gene regulation in rats’ frontal cortex and hippocampus. This is relevant as the hippocampus regulates memory and learning, whereas the frontal cortex helps process and organize information. In both brain regions, scientists observed that gene expression spiked within 20 minutes of Semax exposure and specifically appeared to influence nerve growth factor (NGF) and BDNF.\u003csup\u003e[5]\u003c\/sup\u003e The researchers concluded that \u003cem\u003e“Semax … results in rapid, long-term, and specific activation of Bdnf and Ngf expression changes in different rat brain departments.”\u003c\/em\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eSemax and Cognitive Function\u003c\/strong\u003e\u003cbr\u003eACTH, the natural protein source of Semax, appears to preserve memory function and learning in murine models of epilepsy, as suggested in studies published in Canada, China, and the United States. It has also been an object of speculation for its potential in epileptic disorder research. According to Dr. Scantlebury, Semax is a potentially potent derivative of ACTH and may provide ancillary action that is absent in the natural peptide.\u003csup\u003e[6]\u003c\/sup\u003e Preliminary reports suggest that even low concentrations of ACTH may mitigate the risk of dysfunction following a seizure. This research indicates ACTH and Semax may possess nootropic characteristics. Research is ongoing.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eSemax and Serotonin Signaling\u003c\/strong\u003e\u003cbr\u003eSemax might potentially interact with and elevate serotonin levels, which may contribute to improved mood and reduced anxiety. The potential for Semax to affect neurotransmitter systems includes the possibility of restoring or stabilizing neural pathways. This action has the potential to balance the excitatory and inhibitory signals within the brain, fostering an environment more favorable to alleviating anxiety. This implies that the peptide's influence on neural circuits related to anxiety might be prolonged, thereby suggesting a lasting impact on these pathways.\u003csup\u003e[7]\u003c\/sup\u003e\u003cbr\u003e\u003cbr\u003eFurthermore, the sustained actions of Semax suggest it may play a role in either protecting or correcting neural circuits over an extended period beyond the initial exposure to the peptide. For example, in a series of murine model experiments, exposure to Semax was linked to altered levels of 5-hydroxyindoleacetic acid (5-HIAA), a major serotonin metabolite. This change suggests an enhancement of serotonergic activity, which is believed to be crucial for the neurotransmitter serotonin, which influences mood and cognitive functions. After exposure to Semax, a gradual increase in 5-HIAA levels was observed, rising to 180% over four hours.\u003csup\u003e[8]\u003c\/sup\u003e Additionally, it was observed that exposure to Semax 20 minutes prior to experimenting with D-amphetamine led to higher levels of 5-HIAA compared to when Semax was tested alone. Such findings indicate that Semax might play a role in modulating serotonin metabolism, potentially impacting serotonin-dependent pathways essential for regulating mood, cognitive processes, and overall brain function in test models.\u003c\/p\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSemax and Enkephalin Signaling\u003c\/strong\u003e\u003cbr\u003eRecent studies propose that specific enzymes, which may play a role in the breakdown of enkephalins, might be impeded by Semax, potentially leading to unique outcomes under laboratory conditions.\u003csup\u003e[9]\u003c\/sup\u003e Enkephalins are neurotransmitter substances produced in the brain that might play key roles in managing various biological processes. These neurotransmitters are thought to significantly impact nociception, which is the process by which pain is sensed by neurons and in stress response. Further, an increase in the levels of enkephalins may possibly influence the functioning of other neurotransmitter systems. This is due to the complex relationships between the opioid system, which includes enkephalins, and other neurotransmitter systems, such as those involving dopamine and serotonin. These relationships might manifest as changes in the release of neurotransmitters, variations in receptor activities, or alterations in signal transduction pathways.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e\u003cem\u003e Research chemicals are intended solely for laboratory experimentation and\/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and\/or qualified professionals. All information shared in this article is for educational purposes only.\u003c\/em\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"padding-bottom: 5px !important; margin-bottom: 25px !important;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eMedvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. Published 2014 Mar 24. .\u003c\/li\u003e\n\u003cli\u003eGusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN. Éffektivnost’ semaksa pri lechenii bol’nykh na raznykh stadiiakh ishemicheskogo insul’ta [The efficacy of semax in the treatment of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3. Vyp. 2):61-68. .\u003c\/li\u003e\n\u003cli\u003eLebedeva IS, Panikratova YR, Sokolov OY, et al. Effects of Semax on the Default Mode Network of the Brain. Bull Exp Biol Med. 2018;165(5):653-656. .\u003c\/li\u003e\n\u003cli\u003eMars RB, Neubert FX, Noonan MP, Sallet J, Toni I, Rushworth MF. On the relationship between the “default mode network” and the “social brain”. Front Hum Neurosci. 2012;6:189. Published 2012 Jun 21. .\u003c\/li\u003e\n\u003cli\u003eAgapova TIu, Agniullin IaV, Silachev DN, et al. Mol Gen Mikrobiol Virusol. 2008;(3):28-32.\u003c\/li\u003e\n\u003cli\u003eScantlebury MH, Chun KC, Ma SC, Rho JM, Kim DY. Adrenocorticotropic hormone protects learning and memory function in epileptic Kcna1-null mice. Neurosci Lett. 2017;645:14-18.\u003c\/li\u003e\n\u003cli\u003eNataliya Yu. Glazova, Daria M. Manchenko, Maria A. Volodina, Svetlana A. Merchieva, Ludmila A. Andreeva, Vladimir S. Kudrin, Nikolai F. Myasoedov, Natalia G. Levitskaya, Semax, synthetic ACTH(4–10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats, Neuropeptides, Volume 86, 2021, 102114, ISSN 0143-4179.\u003c\/li\u003e\n\u003cli\u003eEremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005 Dec;30(12):1493-500. . PMID: 16362768.\u003c\/li\u003e\n\u003cli\u003eKost NV, Sokolov OIu, Gabaeva MV, Grivennikov IA, Andreeva LA, Miasoedov NF, Zozulia AA. Ingibiruiushchee deĭstvie semaksa i selanka na énkefalindegradiruiushchie fermenty syvorotki krovi cheloveka [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]]. Bioorg Khim. 2001 May-Jun;27(3):180-3. Russian. doi: 10.1023\/a:1011373002885. PMID: 11443939.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786430316861,"sku":"sku2194756142613","price":150.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/SEMAX-25MG-2-1.webp?v=1780466177"}],"url":"https:\/\/carmonapettoys.shop\/collections\/best-sale.oembed?page=2","provider":"ISRAEL ISAIAH SCOTT","version":"1.0","type":"link"}